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Antibody-dependent  enhancement  (ADE)  is  the  process  by  which  virus-specific 
antibodies  enhance  entry  or  replication  of  a  virus,  leading  to  increased  infection  and  the 
potential to exacerbate disease progression or severity.  In terms of HIV infection, ADE could 
make the  difference  between  an  ineffective vaccine and  a dangerous  one.  There  is  also the 
possibility that ADE affects disease progression in natural infection.  Here, one aspect of ADE, 
complement-mediated ADE (C’-ADE), was investigated in detail.
An assay was developed to study C’-ADE in both R5- and X4-tropic HIV-1  strains in 
the context of early, primary infection and vaccination.  A CD4+ T cell line was used for these 
studies  which  expressed  the  complement  receptor  2  (CR2)  and  HIV-1  co-receptors  CXCR4 
and  CCR5.  C’-ADE  in  primary  infection  was  investigated  using  serum  samples  collected 
longitudinally  from  infected  individuals  from  as  early  as  12  days  post  onset  of  primary 
symptoms.  When tested against autologous viruses isolated early after infection, C’-ADE was 
detected in 9 out of 10 patients.  In some cases this was potent enough to produce increases in 
infection  greater  than  100-fold.  Later  virus  isolates  that  evolved  to  escape  antibody 
neutralisation were enhanced by sera that neutralised early virus.  Competition studies carried 
out  with  neutralising  and  enhancing  IgG  showed  neutralisation  to  be the  dominant  activity. 
Enhancing,  but  not  neutralising,  activity  of patient  sera  was  detected  against  heterologous 
primary isolates.
Post-vaccination C’-ADE was investigated using sera from volunteers vaccinated with 
a monomeric gpl20 vaccine from  a dual-tropic HIV-1  strain.  Sera from vaccinees enhanced 
infection of the vaccine virus strain but did not neutralise it.  Neutralisation was seen for an X4 
virus strain, MN, and individuals that produced the most potent neutralisation against MN also 
produced the most potent enhancement of the vaccine strain.
CR2-mediated increased attachment of opsonised viruses to the target cell was shown 
to be the principle mechanism of C’-ADE.  The use of a CR2 cytoplasmic tail mutant showed 
that receptor signalling was not necessary for C’-ADE.
Results  from these studies show that antibodies that appear to be non-neutralising in 
neutralisation assay systems can actually have dramatic effects on virus infection in a different 
context.  These new findings are considered in relation to existing knowledge on neutralisation 
and ADE of HIV.
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INTRODUCTION
1.1  HIV/AIDS IN CONTEXT
The human immunodeficiency virus (HIV) was first identified as the aetiological 
agent of acquired immunodeficiency syndrome (AIDS) in  1983 (Barre-Sinoussi et al., 
1983).  Now,  almost  a  quarter  of a  century  later,  an  estimated  40  million  people 
worldwide  are  living with HIV,  and 2.9 million people died of AIDS  in 2006 alone 
(UNAIDS,  2006).  Areas worst affected  are  mainly  in  sub-Saharan  Africa,  with this 
region accounting for two thirds of all adults and children living with HIV worldwide. 
Currently the outlook is bleak, with adult HIV prevalence as high as 30-40% in some 
countries  in  this  region  (UNAIDS,  2006).  A  cure  or  prophylactic  vaccine  remains 
elusive.
1.2  HIV PHYLOGENY AND EPIDEMIOLOGY
HIV-1  and  HIV-2  belong to the Lentivirus  genus of the  family Retroviridae, 
along with the simian, feline and bovine immunodeficiency viruses (SIV, FIV and BIV 
respectively),  Maedi/Visna virus (MW ),  caprine arthritis encephalitis virus (CAEV) 
and equine infectious anaemia virus (EIAV; Coffin et al.,  1997).
HIV-1  is most closely related to SIVcpz, which naturally infects chimpanzees, 
whilst  HIV-2  is  most  closely  related  to  SIVsm,  which  naturally  infects  sooty 
mangabeys.  The origin of the HIV epidemic in humans has been attributed to multiple 
cross-species transmissions of these SIVs during the early part of the 20th century.  In 
addition to chimpanzees  and  sooty mangabeys,  many other African  monkey  species 
are  natural  hosts  of SIVs,  including  baboons,  mandrills  and  African  green monkeys 
(Gordon  et al.,  2005).  Despite high plasma viraemia,  SIV  infections of natural  host 
animals are rarely pathogenic.  In contrast, HIV-1  and HIV-2 infections of humans and 
SIVmac  (experimentally derived from  SIVsm)  infection of rhesus macaques ultimately 
cause the chronic CD4+ cell depletion and immunodeficiency characteristic of AIDS 
(Heeney et al., 2006).  While a group of HIV-1  viruses have spread to cause the global
21pandemic,  HIV-2  is  largely  confined  to  West  Africa,  spreading  more  recently  to 
Europe, in particular Portugal, and India.
Within HIV-1  are three distantly related groups of viruses: M, the main group, 
responsible  for the  global  HIV  pandemic;  O,  found  in west central Africa; and N,  a 
very rare  group  found  in a small  number of individuals  in Cameroon.  The distance 
between  genome  sequences  of these  three  groups  is  large  enough  to  imply  three 
separate  introductions from  chimpanzees to  humans,  and the  precursors of group M 
and N viruses have been  identified  in wild chimpanzees (Hahn et al., 2000; Keele et 
al.,  2006).  The  earliest  human  sample  containing HIV-1,  dating back to  1959,  was 
found  in  Kinshasa in what is now the Democratic Republic of the Congo (Zhu et al., 
1998).  Using  sequences  obtained  post-1959,  and  assuming  consistent  evolutionary 
behaviour of the virus, the origin of the M group was extrapolated back to the  1930s 
(Korber et al., 2000).
The  M  group  has  been  further  subdivided  into  genetic  clades,  or  subtypes, 
labelled A to K with no subtypes E or I.  Due to rapid expansion of the pandemic, and 
evolution,  divergence and recombination of the circulating viruses, the nomenclature 
system  is  frequently  updated.  Several  of the  subtypes  have  been  divided  into  sub­
subtypes,  and  circulating  recombinant  forms  (CRFs)  containing  genome  sections 
derived  from different subtypes form part of the classification system (Leitner et al., 
2005).  Subtypes A  and C account for the majority of current infections worldwide. 
Subtype  C  is common  in  southern Africa and  India;  A  and  D  in central  and eastern 
Africa, and B in Europe, the Americas and Australia.
Hereafter the use ofHIV will refer specifically to HIV-1, unless making direct 
comparisons between HIV-1  and HIV-2.
1.3  HIV GENOME ORGANISATION AND PROTEIN PRODUCTS
The 9.2-kb HIV RNA genome contains the genes gag, pol and env, which are 
common to all retroviruses (Coffin et al.,  1997).  Processing of the Gag (group specific 
antigen)  polyprotein produces the matrix (MA,  pi7), capsid (CA, p24), nucleocapsid 
(NC,  p7),  and  p6  proteins and the  spacer peptides  SP1  (pi)  and  SP2  (p2).  The  Pol 
(polymerase)  polyprotein,  produced as a Gag-Pol  fusion polyprotein,  is processed to 
produce protease (PR, plO), reverse transcriptase (RT, p66 and p51) and integrase (IN, 
p32).  Processing of the Env (envelope) polyprotein produces the surface protein (SU, 
gpl20) and transmembrane protein (TM, gp41).  In addition, the HIV genome encodes
22the accessory proteins Vif, Vpr, Nef, Tat, Rev and Vpu.  The genome is flanked by two 
long terminal  repeats (LTR),  containing the regions R and U5  at the 5’  end,  and U3 
and R at the 3’ end.  A schematic diagram of the genome organisation of HIV is shown 
in Figure  1.1.
1.4  HIV REPLICATION CYCLE
The four Gag proteins MA, CA, NC and p6, along with the two Env proteins 
gpl20 and gp41, constitute the structural elements of the mature HIV virion (Coffin et 
al.,  1997).  Multiple hexameric CA proteins arranged in a lattice comprise the shell of 
the distinctive cone-shaped viral core, within which reside PR, RT, IN, p6,  Vif, Vpr, 
Nef and the two copies of the RNA genome complexed with NC.  MA forms a second, 
spherical  shell  immediately  beneath  the  host-cell  derived  lipid  bilayer,  embedded 
within which are the Env spikes.  A schematic diagram of the mature virion is shown 
in Figure  1.2.  An overview of the replication cycle of HIV, beginning with the entry 
of the virus into the host cell and ending with the formation of a mature virus particle, 
is described in sections 1.4.1 to 1.4.6 and shown schematically in Figure 1.3.
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Figure 1.1 Genome organisation of HIV-1
The 5’ and 3’  LTRs are shown in grey; the major genes encoding the polyproteins 
Gag, Pol and Env are shown in turquoise; accessory genes are shown in red.
IN
RNA genome
PR
NC
RT
Vpr
CA
Figure 1.2  Schematic diagram of an infectious HIV virion
An overview of a mature HIV virion is shown on the left, with an enlarged view of 
the  core  on the right.  Part of the  CA  shell  has been  cut away to  show the viral 
proteins  inside  the  core.  (Note  that  the  colours  of the  proteins  are  random  and 
unrelated to the colours of the genome in Figure 1.1).
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24HIV binds to the CD4 then chemokine co-receptor on the 
cell surface (step 1), inducing conformational changes in 
the envelope spike (step 2)  leading to viral and cellular 
membrane fusion (step  3).  The  viral  core  is  deposited 
into the cytoplasm and uncoating follows (step 4).  The 
resultant reverse transcription complex (RTC) is the site of reverse transcription in 
the cytoplasm (step 5), and the dsDNA formed is the central component of the pre­
integration complex (PIC; step 6).  The PIC  is imported into the nucleus and the 
viral DNA integrated into the host chromosomal DNA to form the provirus (step 7). 
Transcription and subsequent splicing results in the production of a variety of mRNA 
species (step 8) which are exported to the cytoplasm for translation into viral proteins 
(step  9).  Assembly  is  mediated  by  Gag  at  the  plasma  membrane  (step  10)  and 
immature particles bud from the cell (step  11).  Protease-mediated cleavage of the 
Gag  and  Gag-Pol  structural  components  results  in  the  formation  of  a  mature 
infectious virus particle (step 12).
Figure 1.3  Schematic diagram of the major stages 
the HIV replication cycle
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251.4.1  Entry and uncoating
HIV  entry,  as  discussed  in  detail  in  section  1.5,  is  initiated upon binding of 
gpl20  to  CD4  on  the  target  cell.  This  induces  conformational  changes  in  gpl20, 
facilitating  binding  to  the  HIV  co-receptor.  Further  conformational  changes  allow 
gp41-mediated fusion between the viral and target cell membranes and release of the 
viral  core  into the host cell  (Gomez and  Hope,  2005).  Following  fusion,  uncoating 
occurs:  a poorly understood process involving disassembly of the core, characterised 
by the dissociation of CA from the other core components and formation of the reverse 
transcription  complex  (RTC;  Bukrinskaya,  2007;  Narayan  and  Young,  2004).  The 
resultant RTC consists of the genomic viral RNA associated with NC, cellular tRNA, 
RT, IN, MA, Vpr and host proteins (Fassati, 2006; Fassati and Goff, 2001).  The RTC 
associates  with  cellular  actin  microfilaments  via  phosphorylated  MA,  a  process 
required for RTC function (Bukrinskaya et al., 1998), and subsequently associates with 
the  microtubule  network  for  transport  to  the  nucleus  (McDonald  et  al.,  2002). 
Efficient  reverse  transcription,  as  described  in  section  1.4.2,  proceeds  during  the 
journey through the cell.
Several  intrinsic cellular restriction factors are known to act at the post-entry 
stage  of HIV  replication.  Of these,  the  cellular polynucleotide  cytidine  deaminase 
APOBEC3G (apolipoprotein  B  mRNA-editing enzyme,  catalytic polypeptide-like)  is 
the  best  characterised  in  human  cells  (Sheehy  et  al.,  2002).  APOBEC3G  exerts 
antiviral  activity  through  incorporation  into  the  virion  during  assembly  and  later 
causing C-to-U hypermutation  in the minus-strand DNA during reverse transcription. 
This  is  manifest  as  excessive,  and  therefore  lethal,  G-to-A  substitutions  in the  plus 
strand of the viral DNA (Malim, 2006).  Vif protects wild-type HIV from the antiviral 
activity of APOBEC3G by targeting it for ubiquitination and proteasome degradation, 
hence reducing the level of virion-associated APOBEC3G.  Vif-defective viruses are 
therefore  unable  to  replicate  successfully  in  APOBEC3G-expressing  cells,  such  as 
macrophages and CD4+ T cells (Malim, 2006).
The  tripartite  interaction  motif (TRIM)  5a  protein  is  important  as  a  cross­
species  immunodeficiency virus  restriction  factor (Stremlau  et  al.,  2004).  TRIM5a 
proteins  from  rhesus  macaques,  owl  monkeys  and  African  green  monkeys,  for 
example,  block the ability of HIV-1  to replicate in these cells by targeting incoming 
capsid molecules through a mechanism that remains to be elucidated (Towers, 2005).
261.4.2  Reverse transcription
Initiation  of  reverse  transcription  appears  to  coincide  with  the  onset  of 
uncoating  (Nisole  and  Saib,  2004);  the  trigger  for  initiation  may  simply  be  the 
exposure of the  RTC to sufficient levels of deoxyribonucleotides (Freed and Martin, 
2001).  RT has three enzymatic activities: reverse transcription activity (production of 
DNA from an RNA template), ribonuclease H (RNase H) activity (degradation of the 
RNA  strand  of an  RNA:DNA hybrid)  and DNA  polymerase  activity  (production  of 
double-stranded DNA from a DNA template).  Reverse transcription is initiated by a 
cellular transfer RNA (tRNA) primer annealed to the primer-binding site (PBS) on the 
RNA.  The preferential tRNA for HIV is tRNALys3, and this is pre-packaged into the 
virion and associated with the RNA before entry to the cell.  A diagram and detailed 
description of the reverse transcription process is given in Figure  1.4.  Due to the lack 
of proofreading ability in RT, the process of reverse transcription is error-prone, with 
0.2-2 mutations per genome per cycle (Drake,  1993).
27Figure 1.4  Reverse transcription
RNA  is shown  in grey,  minus-strand DNA  in turquoise and plus-strand DNA in yellow.  (1) 
DNA synthesis initiates from the 3’-OH of the tRNA annealed to the PBS.  (2)  The plus-strand 
RNA  genome  serves  as  a template,  and  a short  section  of minus-strand DNA  is  synthesised 
towards the 5’  end of the RNA to generate U5  and R sequences.  (3) RNase H degrades the 
RNA duplexed with the newly-formed DNA, forming the minus-strand strong-stop DNA.  (4) 
The strong-stop DNA translocates from the 5’ to the 3’ end of the viral RNA.  Jumps can occur 
in cis or in trans.  (5) The minus-strand strong-stop DNA acts as a primer, and DNA synthesis 
proceeds to complete the minus strand.  RNA:DNA hybrids formed render the RNA template 
susceptible to RNase H digestion.  (6) A purine-rich region of the genome, the polypurine tract 
(ppt) is temporarily resistant to RNase H degradation and therefore serves as a primer for the 
initiation  of the plus-strand DNA  synthesis.  Only then  is the ppt  degraded.  (7)  Plus-strand 
DNA synthesis continues until the end of the bound region of the tRNA.  Part of the tRNA 
serves as a template for the production of a new PBS, and is then degraded by RNase H.  The 
resulting intermediate is called the plus-strand strong-stop DNA.  (8) The complementary plus- 
and  minus-strand  PBSs  anneal  to  each  other,  and  the  circular  intermediate  formed  allows 
completion  of  the  plus-  and  minus-strands.  (9)  Minus-strand  elongation  leads  to  the 
displacement of the plus-strand and a linear dsDNA is formed.©
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281.4.3 Nuclear import and integration
The  newly  produced  double-stranded  HIV  cDNA  associated with NC,  along 
with IN, MA, Vpr, RT and host proteins comprise the pre-integration complex (PIC). 
The PIC components MA, Vpr and IN possess nuclear localisation signals (NLSs) and 
are thought to participate in the active transport of the PIC into the nucleus (Fassati, 
2006).  Nuclear import enables HIV to infect non-dividing cells such as macrophages 
and  quiescent  T  cells  -  in  this  respect  lentiviruses  are  unique  among  retroviruses 
(Bukrinsky  et  al.,  1992;  Weinberg et al.,  1991).  Once  inside the  nucleus,  the viral 
DNA  must  be  integrated  into  the  host  chromosomal  DNA  before  transcription  can 
occur.  Integration  is  a  two-step  process  catalysed  by  IN,  aided  by  NC,  and  also 
thought to require a number of host cell proteins.  The first step, 3’ processing, occurs 
in the cytoplasm and involves the removal of a pGT dinucleotide from each 3’ end of 
the LTRs, adjacent to a conserved CA dinucleotide.  During the second step, known as 
strand transfer and occurring in the nucleus, IN catalyses the ligation of the CA-3’-OH 
viral DNA ends to newly created 5’-O-phosphate ends of the chromosomal DNA.  The 
unpaired  5’  dinucleotides  are  removed  from  the  viral  DNA  and  the  remaining  gaps 
repaired by host-cell DNA repair enzymes (Van Maele and Debyser, 2005).
Integrated viral DNA is known as the provirus, and most infected cells harbour 
more than one, located in various sites (Greene and Peterlin, 2002).  HIV integrase has 
a preference for transcriptionally active regions of DNA (Freed and Mouland, 2006), 
whilst integration into transcriptionally repressed regions of DNA may result in a form 
of post-integration latency.
1.4.4 Transcription and splicing
The  LTRs  in  integrated  viral  DNA  regulate  transcription  and  the  5’  LTR 
functions  as  a  eukaryotic  transcriptional  unit  (Greene  and  Peterlin,  2002). 
Transcription  is  carried  out  by  the  cellular  RNA  polymerase  II  (PolII;  Greene  and 
Peterlin,  2002)  in  coordination  with  Tat  and  cellular  transcriptional  transactivator 
proteins  (Freed  and  Martin,  2001).  A  PolII  TATA  box  and  three  consecutive  Spl 
transcription  factor-binding  sites  constitute  the  HIV  core  promoter.  Two  NF-kB 
binding  sites  act as  enhancer elements.  Quiescent T  lymphocytes  have  insufficient 
levels  of  nuclear  NF-kB  for  HIV  transcription  stimulation,  therefore  transcription 
proceeds at a basal level; activated T cells on the other hand, have increased levels of 
nuclear NF-kB  and  HIV transcription  is  upregulated  (Freed  and  Martin,  2001).  Tat
29functions to enhance the processivity of PolII by binding to the TAR (transactivation 
response)  element  at  the  5’  terminal  of  all  HIV  RNAs.  The  mRNA  transcripts 
produced  are  post-transcriptionally  processed  by  cellular  machinery.  Due  to  sub- 
optimal  splice  sites  in  the  9.2  kbp  primary  HIV  transcript,  a  variety  of unspliced, 
partially spliced and multiply spliced viral mRNAs are produced, which are essential 
for the production of the various viral proteins.  Completely spliced mRNAs, encoding 
Tat,  Rev  and  Nef,  are  exported  from  the  nucleus  by  the  default  cellular  pathway. 
Unspliced  and  partially  spliced viral  mRNAs  are escorted to the  cytoplasm  by Rev, 
which binds to the Rev response element (RRE) in these mRNAs and shuttles in and 
out  of  the  nucleus.  The  unspliced  viral  RNA  constitutes  the  genomic  RNA 
incorporated  into virions and the mRNA for Gag and Pol synthesis.  Partially spliced 
mRNAs are translated into Vif, Vpr, Vpu and Env proteins (Freed and Martin, 2001). 
Translation  and  processing  takes  place  in  various  locations  in  the  cytoplasm,  as 
described in the next two sections.
1.4.5  Protein production and assembly
The Gag and Gag-Pol polyproteins are translated from unspliced viral mRNA 
on cytoplasmic ribosomes (Freed and Martin, 2001).  The Gag-Pol fusion polyprotein 
is  produced  by  ribosomal  frameshifting  during  Gag  translation,  and  as  such  is 
produced at a rate of 5-10% that of Gag production.  The Env polyprotein, translated 
on  ribosomes of the ER and heavily glycosylated,  is cleaved by cellular proteases in 
the Golgi then transported as non-covalently associated trimers of gp41  and gpl20, to 
the plasma membrane for incorporation into virions.
The Gag polyprotein, hereafter referred to as Gag,  is the major orchestrator of 
viral  particle  formation:  Gag alone  is  sufficient for assembly and  formation of non- 
infectious  virus-like  particles  (Gheysen  et  al.,  1989).  Gag  contains  at  least  three 
functional  assembly  domains:  M,  the  membrane  binding  domain  (located  at the N- 
terminal of MA); I, the Gag-Gag interaction domain (located within NC, CA and p2); 
and  L,  the  late domain  (located near the C terminus,  within p6;  Bukrinskaya,  2007; 
Resh,  2005).  The M domain is comprised of an N-terminal cluster of basic residues 
and  a  co-translationally  added  myristyl  group:  together these  function  to target and 
bind  Gag to  lipid  rafts  in the  plasma membrane  (Ono  and  Freed,  2001;  Ono  et al., 
2000b; Saad et al., 2006).  This process requires the multimerisation of Gag, mediated 
by the I domain,  in order to maximise the exposure of the myristyl group (Ono et al.,
302000a; Resh, 2004; Resh, 2005; Tang et al., 2004).  An estimated  1500 to 5000 Gag 
molecules  are  required  for virus  assembly (Briggs  et al.,  2004).  The  multimerising 
Gag recruits viral RNA, Gag-Pol polyproteins, Env complexes, the tRNA primer and 
Vpr into the nascent virus particle.  These processes are generally conducted by the I 
domain, with MA interacting with the gp41 cytoplasmic tail to incorporate Env trimers 
(Dorfman et al.,  1994; Yu et al.,  1992).
As with the early journey of the virus through the cytoplasm, the stages of virus 
assembly  and  production  require  HIV  accessory  proteins  to  adapt  the  cellular 
environment to  the  advantage  of the  virus.  Vpr induces cell  cycle  arrest  in the  G2 
phase,  which  favours  efficient  HIV  transcription  (Le  Rouzic  and  Benichou,  2005). 
Vpu  and  Nef promote  CD4  degradation  and  down-regulation  in  order  to  prevent 
inappropriate  interaction  between gpl20  and  CD4  (Frankel  and Young,  1998).  Nef 
also  promotes  the  down-regulation  of MHC  class  I  on  the  cell  surface,  to  evade 
immune system detection of the infected cells.
1.4.6  Virus budding and particle maturation
The  late  domain  of  Gag  is  essential  for  virus  budding  by  virtue  of  the 
interaction of a PTAP motif in the L domain of p6 with components of the vacuolar 
protein  sorting  system  (VPS).  Binding  of p6 to TSG101  causes  recruitment of the 
ESCRT-1  complex (Gomez and Hope, 2005), which in turn is hijacked by the virus to 
mediate  budding.  Vpu  is  instrumental  in virus release due to  its promotion of CD4 
degradation (Frankel and Young,  1998), and its putative repression of a late infection 
block (Bieniasz, 2003).
During or shortly after virus budding, PR-mediated cleavage of Gag and Gag- 
Pol  takes  place  within  the  virion  to  precipitate  maturation  and  render  the  virus 
infectious.  Due to varying efficiencies among the PR target  site  sequences,  protein 
products are released in a determined order.  The products of Gag (in order of position 
from the N terminus) are MA, CA, NC, p6, and also two spacer peptides SP1, between 
CA and NC, and SP2, between NC and p6.  SP2 is involved in virus budding as part of 
Gag,  but the  function  of SP1  is unknown  (Bukrinskaya,  2007).  PR  is  first released 
from  Gag-Pol, with cleavage occurring in cis,  ending with the cleavage between CA 
and SP1,  liberating CA for the formation of the core.  In the immature virus particle, 
Gag  forms  a  spherical  shell  beneath  the  viral  membrane,  with  the  N-terminal  MA 
region interacting directly with the inner layer of the membrane (Fig 1.3 step 11).  PR
31processing of Gag causes a dramatic change in virion morphology, characterised by the 
rearrangement of CA proteins into the distinctive cone-shaped core of the  infectious 
virion.
1.5  HIV ENTRY
To  gain  entry  into cells HIV requires two receptors:  CD4 and a co-receptor. 
Details  of the  Env  proteins  that  mediate  these  interactions  (gpl20  and  gp41),  the 
cellular receptors, and the entry process, are given below.
1.5.1 Envelope structure
The env gene of HIV encodes a polyprotein precursor, gpl60, that is translated 
and glycosylated in the ER (Gomez and Hope, 2005), then transported to the Golgi for 
extensive glycosylation and cleavage into two proteins, gpl20 and gp41.  Cleavage is 
mediated by a cellular furin-like protease and is necessary for infectivity (McCune et 
al.,  1988).  gpl20  and  gp41  remain  non-covalently  associated.  The  mature  Env 
complex  -  the  native  spike  -  is  a  trimeric  structure  consisting  of three  gpl20/gp41 
heterodimers (Lu et al.,  1995).  gpl20 mediates sequential interactions with the target 
cell  receptors,  inducing  the  conformational  changes  necessary  to  produce  a  fusion- 
competent Env spike; gp41  anchors the Env spike to the viral membrane and mediates 
fusion of viral and cellular membranes.
1.5.1.1 gpl20
Sequence  analyses  from  different  HIV  isolates  have  shown  that  gpl20  is 
comprised  of five  conserved  (Cl  to C5)  and  five variable  (VI  to V5)  regions.  The 
conserved regions form the core of the molecule, with conserved Cys residues forming 
disulphide  bonds  linking  Cl,  C2,  C3  and  C4  and  forming  the  base  of the  surface- 
exposed  V1/V2,  V3  and  V4  loops  (Leonard  et  al.,  1990).  gpl20  is  heavily 
glycosylated,  with  N-linked  carbohydrates  accounting  for  approximately  half of its 
molecular weight (Poignard et al., 2001).
Important  information  regarding the  structure  of the  gpl20  molecule and the 
nature of its interactions with CD4, co-receptor and neutralising antibodies has been 
provided  by X-ray crystallography  studies (Huang et al.,  2005;  Kwong et al.,  1998; 
Rizzuto et al.,  1998; Wyatt et al.,  1998; Zhou et al., 2007), in agreement with previous 
predictions made from biochemical, mutagenic and immunochemical data (McCune et
32al.,  1988).  For stability reasons, the original crystal structure of the gpl20 core, shown 
in Figure 1.5, was derived from a modified HXBc2 gpl20 lacking the N and C termini, 
the V1/V2 and V3 loops, and stripped of over 90% of its carbohydrate content (Kwong 
et  al.,  1998;  Wyatt  et  al.,  1998).  This  version  of the  protein  was  crystallised  in 
complex with a two-domain fragment of CD4 and the Fab fragment of the monoclonal 
antibody 17b (Kwong et al.,  1998; Wyatt et al., 1998).  17b is representative of a group 
of antibodies that recognise an epitope  on gpl20 only revealed after conformational 
changes  induced  by CD4 binding -  the CD4  induced  (CD4i)  epitope.  It blocks co­
receptor  binding,  and  is  therefore  thought  to  recognise  regions  overlapping the  co­
receptor  binding  site.  Subsequent  X-ray  crystallography  reports  detailed  a  V3- 
containing gpl20 core  (Huang et al.,  2005) and a gpl20 core stabilised  in the CD4- 
bound state complexed with the neutralising antibody bl2 (Zhou et al., 2007).
The core of gpl20 is heart-shaped and comprised of two major domains:  the 
inner and outer domains, linked by a bridging sheet, as shown in Figure 1.5 (Kwong et 
al.,  1998; Wyatt et al.,  1998).  The inner domain is comprised of Cl and C5 and is the 
proposed gp41 contact interface (Kwong et al., 1998; Wyatt et al.,  1998).  The bridging 
sheet  consists  of four  antiparallel  p  strands  derived  from  the  V1/V2  stem  and  C4 
region. The outer domain is highly glycosylated and forms the putative exposed region 
of the trimeric envelope spike (Wyatt and Sodroski,  1998), with the bases of the V3, 
V4 and V5 loops anchored in this region (Kwong et al.,  1998).
Receptor binding sites are conserved but shielded by highly glycosylated and 
variable regions.  The CD4 binding site covers an extensive but recessed area located 
at the  interface of the  inner domain, bridging sheet and outer domain (Kwong et al., 
1998; Wyatt et al.,  1998).  Direct interactions are formed between 22 CD4 amino acid 
residues  and  26  gpl20  residues,  located  on  the  p  strands  of the  bridging  sheet,  p 
strands  of the  C3,  C4  and  C5  regions  and  a  loop  in  the  C3  region  (the  pi5-a3 
excursion or the CD4-binding loop).  Two large cavities are present at the gpl20-CD4 
interface.  The  larger  cavity  is  lined  with  hydrophilic  residues  that  can  tolerate 
considerable  sequence  variation  due to the  fact that many of them  contact CD4 via 
main-chain atoms.  The smaller cavity is highly conserved and known as the “Phe43” 
cavity,  as  into this deeply buried  hydrophobic  region extends the phenyl ring of the 
CD4  amino  acid  Phe43,  a  residue  vital  for  CD4-gpl20  interaction.  Phe43  alone 
accounts for 23% of the direct interactions between CD4 residues and gpl20 (Kwong 
et al.,  1998).
33The  CD4  binding  site  of gpl20  is  more  clearly defined  than that of the  co­
receptor due to the availability of crystallised gpl20-CD4 complexes.  In the absence 
of a gp 120-co-receptor complex, the nature of the interaction has been deduced from 
CD4i antibody binding sites and mutagenesis studies. The co-receptor binding site is 
highly conserved and consists of the bridging sheet and surrounding residues, and the 
V3  loop  (Huang et al.,  2005).  It has  been proposed,  through  analysis of the  CD4- 
bound gpl20 crystal structure containing the V3  loop, that the N terminus of the co­
receptor  binds  to  the  bridging  sheet  and  base  of the  V3  loop,  while  the  second 
extracellular  region  (E2)  of the  co-receptor engages  with  the  V3  tip  (Huang  et al.,
2005).  Despite  designation  as  a  variable  region,  the  V3  loop  is  in  fact  a  semi­
conserved structure.  Unlike the V2 region, for example, V3  is a constant 30-35 aa in 
length.  It has a conserved disulphide bond at its base and a conserved type II turn at its 
tip with the sequence GPXR in subtype B isolates (Zolla-Pazner, 2004).  The V3 loop 
also determines the co-receptor tropism of the virus: if the 11th and 25th amino acids of 
V3 are positively charged the virus will be X4 tropic; otherwise they will be R5 tropic 
(Resch et al., 2001).
gpl20 dominates the surface of the Env spike, almost completely shielding the 
gp41  portion of the trimer from immune attack.  The large surface of the inner domain 
faces the  trimer axis,  while the  heavily glycosylated  surface  of the  outer domain  is 
exposed on the surface. Regions in gpl20 responsible for gp41  interaction are located 
in the N and C termini of gpl20, in the Cl and C5 regions (Kwong et al.,  1998; Wyatt 
et al.,  1998).
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Figure 1.5  Crystal structure of the gpl20 core
Ribbon diagram of the HXBc2 gpl20 core structure.  The structure is derived from 
the gpl20 core in complex with a D1-D2 domain CD4 molecule, lacking the N and C 
termini,  the  V1/V2  and  V3  loops  and  stripped  of over  90%  of its  carbohydrate 
content.  The orientation of the structure is indicated relative to the viral and cellular 
membranes.  The bridging sheet, composed of four (3 strands, and the inner and outer 
domains are indicated.  From Kwong et al. 1998.
351.5.1.2 gp41
gp41  anchors  the  envelope  spike  to  the  surface  of  the  virion  by  its 
transmembrane  region,  and  possesses  a  long  cytoplasmic  tail  of approximately  150 
amino acids.  In  the  native  spike,  conserved regions of gp41  involved  in membrane 
fusion are largely shielded from the immune system by gpl20.  A highly hydrophobic 
region  at the N-terminus  of gp41  is thought,  by analogy to  a  similar domain  in the 
influenza HA protein, to constitute the fusion peptide of gp41  (Colman and Lawrence, 
2003).  This  is  followed  by  two  heptad  repeat  sequences,  the  N-terminal  and  C- 
terminal heptad repeat regions (N-HR and C-HR respectively) that are also central to 
the  fusion  process.  The  region  between  the  N-HR  and  C-HR  forms  a  conserved 
disulphide-bonded  loop,  which  is  critical  for  interaction  with  gpl20  (Maerz  et  al., 
2001).  The fusion peptide, N-HR and C-HR regions of gp41  are shown in Figure 1.6, 
and their role in virus-cell fusion is described in section 1.5.3.  The crystal structure of 
the fusion-active state of the gp41  core showed three parallel a-helices corresponding 
to the N-HR region forming a core, with three C-HR a-helices arranged antiparallel to 
the core.  This structure is known as the six-helix bundle (Chan et al.,  1997; Tan et al., 
1997; Weissenhom et al.,  1997).
1.5.1.3 Native Env spikes
Recent cryo-electron tomography studies of individual trimeric SIV Env spikes 
have produced two models of the 3-dimensional spike.  In the first (Zhu et al., 2006), 
the three gp41  molecules form a distinctive tripod structure, on top of which reside the 
three globular gpl20 subunits.  A cavity is evident between the legs of the spike, and 
each leg contacts the viral membrane and extends parallel to it for a short distance to 
form a “foot” structure (Zhu et al., 2006).  In the second (Zanetti et al., 2006), the Env 
spike  is  better compared  to  a  “mushroom”  structure,  with  the three  globular gpl20 
molecules  forming  a  three-lobed  structure  on  top  of  a  stem  formed  by  tightly- 
interacting  gp41  molecules.  A  cavity  exists  at the junction  between  the  gp41  and 
gpl20  trimers  (Zanetti  et al.,  2006).  It  is currently unclear whether methodological 
differences and limitations in the accuracy of the technique account for the two distinct 
structures presented, or whether the differences do in fact reflect variation of the spike 
structure (Subramaniam, 2006).
Use of the  same technique has produced  images of the surface of intact HIV 
virions, with interesting information about the distribution and number of trimeric Env
36spikes (Zhu et al., 2006).  In agreement with previous calculations (Zhu et al.,  2003) 
(Chertova et al., 2002) a surprisingly low number of Env spikes appear to be present 
on the viral surface, averaging 14 per particle (ranging from 4 to 35).  The Env spikes, 
occurring in clusters, were randomly dispersed rather than uniform, with closest spikes 
situated approximately 15nm from each other (Zhu et al., 2006).
The main limitation of the findings described above is the inability of electron 
microscopy  techniques  to  distinguish  between  functional  and  non-functional  Env 
spikes and,  likewise,  infectious and non-infectious viral particles.  It is possible that 
only the  virions  with the  highest number of spikes  (up to  35  per particle),  or those 
containing  regions with  particularly dense clusters  of spikes,  are  infectious  (Burton,
2006).  The spikes visualised, however, showed distinct trimeric conformations and are 
therefore unlikely to include the monomeric or disintegrated spike variants thought to 
constitute  the  non-functional  portion  (Moore  et  al.,  2006).  Disassembly  of  the 
envelope spike,  due to the weak non-covalent interactions between gp41  and gpl20, 
occurs  frequently  (McKeating  et  al.,  1991)  and  contributes  to  the  formation  of 
defective virions caused by the error-prone process of reverse transcription (Finzi  et 
al., 2006).
1.5.2  HIV cellular receptors
Sequential  interactions  between  HIV  envelope  and  cellular  receptors  lead to 
envelope rearrangements that induce fusion of the viral and cellular membranes.  CD4 
is the major HIV receptor, and the first to interact with envelope, followed by a seven 
transmembrane  (7TM)  chemokine  co-receptor,  as  described  below.  Additional  cell 
surface attachment receptors that may be exploited by HIV are also discussed.
1.5.2.1  CD4
The  role  of CD4  as  the  primary  HIV  receptor was  first  discovered  in  1984 
(Dalgleish  et  al.,  1984;  Klatzmann  et  al.,  1984).  CD4  is  a  55-kDa member of the 
immunoglobulin superfamily of proteins and is composed of four Ig-like extracellular 
domains, D1  to D4, a membrane spanning domain and a cytoplasmic tail (Maddon et 
al.,  1987).  The expression of CD4 defines a subset of T cells, the T-helper (TH ) cells 
or CD4+ T cells, which are the major targets for HIV infection in vivo, as described in 
section  1.6.  Its natural function is as a ligand for MHC class II molecules. CD4 can 
also be expressed independently of the TCR on cells such as monocytes, macrophages
37and DCs,  also targets for HIV infection in vivo.  The HIV binding sites on CD4 are 
located  in  the  Ig-like  domain  furthest from  the  cell  membrane,  Dl.  A  particularly 
protuberant Phe43 residue and an Arg59 residue of CD4 are critical for the CD4-gpl20 
interaction (Kwong et al.,  1998).
1.5.2.2  Co-receptors
Soon after the discovery of CD4 as the receptor for HIV,  it became apparent 
that CD4 alone was insufficient for virus entry (Maddon et al.,  1986); thus began the 
search for an HIV co-receptor.  Viruses had been classified into two groups according 
to their biological  properties:  the  non  syncytium-inducing (NSI),  macrophage tropic 
(M-tropic)  strains,  and  the  syncytium-inducing  (SI),  T-cell  tropic  (T-tropic)  strains. 
These differences were later reconciled with different co-receptor usage of the viruses. 
The first HIV co-receptors to be identified were CXCR4 (Bleul et al.,  1996; Feng et 
al.,  1996)  and CCR5  (Alkhatib et al.,  1996;  Deng et al.,  1996;  Dragic et al.,  1996). 
These  today  remain  the  most  relevant to  natural  HIV  infection.  The NSI/M-tropic 
viruses  were  re-classified  as  R5  viruses,  and  the  SI/T-tropic  viruses  as  X4  viruses 
(Berger et al.,  1998).  In addition, some viruses can use both CCR5 and CXCR4 and 
are termed dual tropic or R5X4 viruses.  The use of the original terms SI and NSI, or 
T-tropic and M-tropic, is now considered misleading, as R5 viruses can infect primary 
T  cells,  some  X4  viruses  can  infect  macrophages,  and  both  can  cause  syncitium 
induction depending on the cell type  infected.  In addition to CCR5  and CXCR4, at 
least a dozen other 7TM receptors can act as co-receptors for HIV, such as CCR3 and 
CCR8 (Clapham and McKnight, 2002), but whether these play a major role in vivo, for 
example in neuropathogenesis, remains to be conclusively shown.
The importance of CCR5 in natural HIV infection was highlighted by studies 
of individuals multiply exposed yet resistant to HIV infection.  A 32-bp deletion in the 
coding region of the CCR5 gene (CCR5-A32) introduces a premature stop codon and 
prevents cell-surface expression of CCR5 (Dean et al.,  1996; Liu et al.,  1996; Samson 
et  al.,  1996).  Individuals  homozygous  for  the  CCR5-A32  allele  have  a  complete 
absence of CCR5, and are highly resistant to HIV infection; a small number of infected 
homozygotes  identified  in  one  study  were  shown  to  harbour  X4  tropic  viruses 
(Sheppard  et  al.,  2002).  Individuals  heterozygous  for  the  CCR5-A32  allele,  when 
infected,  progressed  to  AIDS  more  slowly  than  wild-type  individuals  (Dean  et  al., 
1996;  Liu  et  al.,  1996;  Michael  et  al.,  1997).  CCR5-A32  is  at  an  average  allele
38frequency of approximately  10% across Europe, equating to a homozygote frequency 
of approximately 1% (Galvani and Novembre, 2005). It shows a distinct north-to-south 
gradient in Europe and western Asia and is virtually absent from Africans, East Asians 
and native Americans (Novembre et al., 2005).
The  HIV  co-receptors  are  7TM  G-protein  coupled  chemoattractant  cytokine 
(chemokine)  receptors.  These  consist  of  seven  transmembrane  domains  arranged 
around a central pore, with four extracellular domains (the N terminus, and three loops, 
El,  E2  and  E3)  exposed  on the  cell  surface  (Clapham  and  McKnight,  2002).  The 
natural ligands of CCR5 and CXCR4 are Mip-la, MIP-lp and RANTES, and SDF-1, 
respectively.
The  extracellular domains  of CCR5  and CXCR4 are modified by N- and O- 
linked glycosylation and tyrosine sulphation: CXCR4 has potential sites for N-linked 
glycosylation at the N terminus and E2; CCR5 has sites for O-linked glycosylation in 
the N terminus.  Tyrosine-rich regions are present at the N terminus of both CXCR4 
and  CCR5  and  may be  sites of tyrosine  sulphation  (Zaitseva et al.,  2003).  Regions 
involved  in  HIV  interaction  are  located  on  the  N  terminus  and  E2,  and  post- 
translational  modifications  at  these  regions  may  influence  interactions  with  gpl20 
(Clapham and McKnight,  2002).  Sulphated tyrosines at the N termini of CCR5  and 
CXCR4, along with acidic amino acids, would confer an overall negative charge on the 
co-receptor N terminus, which may facilitate interactions with positive amino acids in 
the  bridging  sheet  of gpl20.  Likewise,  negatively  charged  amino  acids  in  the  E2 
region  of CXCR4  may  play  an  important  role  in  interactions  with  the  positively 
charged V3 loops of X4 viruses (reviewed by Clapham and McKnight, 2002; Huang et 
al., 2005).
There  is  evidence  to  suggest  that  co-receptors  interact  with  CD4  in  the 
absence  of gpl20  binding,  probably  by  clustering  in  lipid  rafts,  with the  avidity of 
CCR5  interaction  with  CD4  apparently  higher  than  that  of CXCR4  (reviewed  by 
Zaitseva et al., 2003).
1.5.2.3  Additional attachment receptors
The initial step of the HIV entry process is the adsorption of HIV particles to 
the target cell surface.  While the first “official” HIV-target cell interaction is between 
gpl20 and CD4, it is thought that HIV exploits the presence of a variety of cell surface
39molecules to mediate additional cell surface contacts, serving to increase the efficiency 
of the CD4 binding step.
The  glycosphingolipid  galactosyl  ceramide  (GalC;  Kensinger  et  al.,  2004), 
heparan  sulphate  proteoglycans  (Mondor  et  al.,  1998)  and  C-type  lectin  receptors 
(CLRs)  such  as  DC-SIGN  have  been  shown  to  bind  directly  to  gpl20  on  HIV 
(Geijtenbeek  et  al.,  2000;  Lee  et  al.,  2001).  ICAM-1,  incorporated  into  the  virus 
membrane during budding from the host cell, can  interact with LFA-1  on target cell 
membranes to  enhance  infection  up to  10-fold  (Fortin  et al.,  1997).  None  of these 
molecules is considered a HIV receptor per se, as none is absolutely required for viral 
entry.  Furthermore, different attachment molecules are found on different cell types, 
and  it  is  unclear  which  are  important  in  vivo.  Antibody-dependent  enhancement 
(ADE)  of  HIV  infection  may  be  considered  an  extension  of this  scenario,  with 
antibodies  or  antibodies-plus-complement  bridging  the  viral  envelope  to  Fc  or 
complement receptors on the target cell.  The mechanism of ADE, however, may differ 
from the simple increase in attachment outlined above.  ADE is discussed in detail in 
section 1.11.
1.5.3  The entry process
The process of HIV entry into a target cell begins with gpl20 binding to CD4 
and  ends with the  fusion of viral  and cellular membranes,  resulting in a fusion pore 
large  enough  to  accommodate  the  viral  core.  Many  steps  of the  process  remain 
incompletely  resolved,  including  the  exact  conformational  changes  that  take  place 
within  the  Env  spike,  the  number  of Env  spikes  required  for  complete  fusion,  the 
fusion pore formation and widening process and the involvement of lipid rafts (Gallo 
et al., 2003).  Therefore, the model described below serves only as an outline of the 
process, based on information from structural studies of the Env proteins, studies with 
entry inhibitors and analogies with other viral entry systems (Gallo et al., 2003).
The first rate-limiting step of the entry process is the binding and engagement 
of CD4 by gpl20 (O'Doherty et al., 2000; Ugolini et al.,  1999).  A time lag of 10-15 
minutes has been observed during this step (Dimitrov et al.,  1992; Frey et al.,  1995; 
Weiss  et  al.,  1996),  but  pre-incubation  of virus  and  cells  at  25°C  (to  prevent  co­
receptor  binding  steps)  shortens  the  time  lag  (Melikyan  et  al.,  2000).  Resultant 
conformational changes occurring in gpl20 include structural changes in the V3  loop 
(Sattentau and Moore,  1991), and the exposure or creation of the co-receptor binding
40site,  as  determined  by  the  CD4-bound  gpl20  crystal  structure,  encompassing  the 
bridging sheet and surrounding regions (Kwong et al., 1998) and the base and tip of the 
V3 loop (Huang et al., 2005).  The second rate-limiting step of entry is the engagement 
of the co-receptor, which can occur tens of minutes after CD4 binding (Gallo et al., 
2003).  The density of CCR5 on the target cell has been shown to affect the kinetics of 
the fusion process (Reeves et al., 2002).
The  result  of co-receptor  binding  is the  formation  of a pre-hairpin  structural 
intermediate, during which conformational changes in gp41 trigger the insertion of the 
highly  hydrophobic  gp41  fusion  peptide  into  the  target  cell  membrane  (Dorns  and 
Moore,  2000;  Freed  et  al.,  1990).  The  entry-inhibitor  sensitive,  pre-hairpin 
intermediate is characterised by a triple-stranded coiled coil structure formed from the 
N-terminal helical regions (N-HRs) of each of the three gp41  molecules of the trimer 
(Moore  and  Dorns,  2003).  The  formation  of  this  structure  rapidly  leads  to  the 
formation  of the  six-helix  bundle,  during  which  the  gp41  molecules  fold  back  on 
themselves  and  the  more  C-terminal  helical  regions  (C-HR)  pack  into  the  outer 
grooves  of the triple-stranded N-HR coiled  coil  structure  in  an anti-parallel  manner 
(Gallo et al., 2003; Moore and Dorns, 2003).  The formation of the six-helix bundle is 
predicted to  bring the  viral  and  cellular membranes  into close proximity,  leading to 
membrane  curvature  then  mixing  of  the  outer  leaflets  of  the  membranes  and  a 
hemifusion state (Clapham and McKnight, 2002).  Hemifusion is rapidly followed by 
fusion  of the  inner  layers  of membrane,  creating a  fusion  pore that rapidly expands 
(Melikyan et al., 2000).  The fusion process is shown in Figure  1.6. The exact number 
of  CD4  molecules,  co-receptor  molecules  and  Env  spikes  required  for  successful 
fusion  is unclear, but is likely to be aided by co-localisation of CD4 and co-receptor 
clusters in  lipid rafts on the cellular membrane (Viard et al., 2002), and clustering of 
Env spikes on the viral membrane (Burton, 2006; Zhu et al., 2006).
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Figure 1.6  The process of gp41-mediated viral and cellular membrane fusion
Conformational changes resulting from gpl20 binding to CD4 and a co-receptor lead to the 
insertion of the gp41  fusion peptide into the target cell membrane and the subsequent events 
outlined above.
421.6  CELL TROPISM
In  vivo,  HIV  infects  cells  of  haematopoietic  origin,  with  CD4+  T  cells, 
macrophages and DCs the major cellular targets.  In theory, HIV can infect any cell 
expressing CD4 and one of the co-receptors mentioned in section  1.5.2.2.  In reality, 
although alternative co-receptor-using strains may contribute to pathogenesis, the only 
co-receptors  with  direct  proven  relevance  in  vivo  are,  to  date,  CCR5  and  CXCR4. 
Robust evidence for the importance of CCR5  in natural HIV infection is provided by 
the observations that individuals homozygous for the CCR5-A32 allele are resistant to 
infection  following  repeated  exposure to  virus  (Dean  et  al.,  1996;  Liu  et  al.,  1996; 
Samson et al.,  1996), and that R5 viruses predominate during early and asymptomatic 
stages of infection.  Therefore, cell tropism is described below within the confines of 
CD4+CCR5+  cellular  targets,  with  additional  attention  to  CD4+CXCR4+  cells. 
Likewise, the potential exists for HIV to infect cells by CD4-independent mechanisms, 
yet the defining feature of HIV pathogenesis is the infection and destruction of CD4+ 
cells  and  there  is  little  evidence  to  support  direct  infection  of CD4-  cells  in  vivo. 
Therefore, only CD4+ cellular targets will be discussed below in the context of direct 
infection.
1.6.1  CD4+ T cells
CD4+ T cells are the major targets of HIV infection.  Continuous CD4+ T cell 
lines used for in vitro studies of HIV, such as H9 and MT-2 cells, express high levels 
of CXCR4  and  little,  if any,  CCR5,  causing  the  emergence  of T  cell  line  adapted 
(TCLA)  HIV  strains  with  X4  tropism.  Primary  CD4+  T  cells,  however,  generally 
express either CXCR4 or CCR5, depending on their activation and maturation states. 
As a general rule, memory CD4+ T cells (CD45RO+) express CCR5, and naive CD4+ 
T cells (CD45RA+) express CXCR4 (Bleul et al.,  1997; Lee et al.,  1999).  Activated 
CD4+  memory  T  cells  are  the  principle  host cells  in  which  HIV  replicates to high 
levels (Schnittman et al.,  1990).  In addition, recently activated but apparently resting 
CD4+ memory T cells,  referred to hereafter as resting CD4+ T cells, are also major 
targets (Li et al., 2005; Zhang et al.,  1999; Zhang et al., 2004), and unlike truly resting 
cells  can  support  HIV  replication  (Haase,  2005).  HIV  preferentially  infects  HIV- 
specific CD4+ T cells in vivo, and throughout all  stages of infection higher levels of 
viral  DNA  were  found  in  HIV-specific memory CD4+ T cells  compared with  other 
memory CD4+ T cells (Douek et al., 2002).
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the majority of CD4+ T cells in the mucosal-associated lymphoid tissue (MALT) are 
CCR5+  (Douek  et  al.,  2003),  and  the  gut-associated  lymphoid  tissue  (GALT)  in 
particular is a focus for high-level HIV replication (Brenchley et al., 2006; Mehandru 
et al., 2004).  Local spread of HIV is therefore facilitated by the continuum of target 
cells in these tissues (Douek et al., 2003).  In addition to local spread of cell-free virus, 
direct  T  cell-to-T  cell  spread  of HIV  is  thought  to  be  an  important  mechanism  of 
propagation.  The term  “virological  synapse” (VS) has been adopted to describe the 
events that occur at the point of contact between the uninfected (target) and infected 
(effector)  cells,  by  analogy to  the  interactions  that take  place  at the  immunological 
synapse (Piguet and Sattentau, 2004).  A model of the VS depicts clustering of CD4 
and  co-receptors  on  the  target  cell  and  HIV  Env  proteins  on  the  effector  cells, 
stabilised by the  interactions of LFA-1  and ICAM-1  on the target and effector cells, 
respectively  (Piguet  and  Sattentau,  2004).  This  stable  site  of contact  facilitates 
transfer  of HIV  from  the  effector  cell,  through  budding,  to  the  target  cell,  through 
fusion.  The signalling pathways and molecular mechanisms that further define the VS 
await elucidation.
1.6.2  Dendritic cells
DCs,  including  Langerhans  cells  (LCs)  are  key  to  the  dissemination  and 
propagation of HIV infection.  DCs reside in the skin and mucosa as immature, resting 
cells equipped with  receptors  for recognition of pathogen-related antigens.  DCs are 
activated  upon  pathogen  recognition  and  uptake,  triggering  their  concomitant 
differentiation  into  mature  APCs  and  migration  to  local  lymph  nodes.  Here  they 
present antigen to T cells and stimulate the proliferation and activation of naive and 
memory  CD4+  T  cells  (Banchereau  et  al.,  2000).  For  this  reason,  DCs  play  an 
important role in HIV pathogenesis, as they are able to promote the direct infection and 
simultaneous  activation  of CD4+  T  cells,  providing  the  ideal  environment  for HIV 
replication.  Whilst DCs can be directly infected by HIV, they can also promote CD4+ 
T cell infection without being productively infected by a mechanism known as trans- 
infection.  The  most  thoroughly  investigated  mechanism  of /nms-infection  by  DCs 
involves the C-type  lectin receptor (CLR) DC-SIGN (DC-specific  IC AM-3-grabbing 
nonintegrin;  CD209).  DC-SIGN has been  detected  on  immature DCs  in the  lamina 
propria of mucosal tissues from the rectum, uterus and cervix (Jameson et al., 2002) as
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2003).  Uptake  of  HIV  into  early  endosomes  allows  maintenance  of  HIV  in  an 
infectious  form  (Geijtenbeek  et  al.,  2000;  Kwon  et  al.,  2002).  DC-SIGN  can  also 
promote the  infection  of DCs  in cis:  co-expression  of DC-SIGN with  CD4  and co­
receptor enhances HIV infection up to  100-fold (Lee et al., 2001).  Other CLRs have 
been  investigated  and shown to be potentially as  important for HIV capture as DC- 
SIGN.  Langerhans  cells,  for example,  bind  gpl20  via  langerin  (CD207),  while the 
mannose receptor (CD206) plays a similar role on dermal DCs (Turville et al., 2002). 
The VS has been observed in DC-T cell interactions, but in the case of trara-infection 
is referred to as the infectious synapse (McDonald et al., 2003; Turville et al., 2004). 
Upon  T  cell  contact  with  DCs,  virions  trapped  within  intracellular  vesicles  are 
recruited to the  site of contact, where they are transferred to clustered CD4 and co­
receptors on the T cell (McDonald et al., 2003; Turville et al., 2004).
The extent of direct DC  infection  in vivo remains unclear,  due to conflicting 
reports  regarding  productive  infection  of  DC  and  LC  in  vitro  (reviewed  by 
Wilflingseder et al., 2005).  This may reflect the diversity of DC subsets found in vivo, 
and  effects  of culture  conditions  on  susceptibility  to  infection.  Immature  DCs,  in 
particular LCs, are susceptible to direct infection by HIV (Kawamura et al., 2003).
1.6.3  Macrophages and monocytes
As  with  DCs,  the  migratory  potential  of monocytes  and  macrophages,  their 
interaction  with  CD4+ T cells  and  apparent  resistance  to  cytopathic  effects  of HIV 
infection  make  them  important reservoirs  and  disseminators  of virus  (Verani  et  al.,
2005).  Furthermore, in the same way that DC-SIGN and other CLRs are important in 
virus  binding to,  /ra/w-infection  by  and  cw-infection  of DCs,  macrophage  mannose 
receptor  (MMR)  may  play  a  similar  role  on  macrophages  (Nguyen  and  Hildreth, 
2003).
Original  classification  of HIV  strains  referred  to  R5  viruses  as  macrophage 
tropic and X4 viruses as T cell tropic.  However, X4 is expressed on macrophages and 
although  TCLA  viruses  do  not  efficiently  infect  macrophages,  X4-using  primary 
isolates may (Simmons et al.,  1998; Verani et al., 1998).
451.6.4  Other potential cellular targets for infection
Evidence  for  direct  infection  of  thymocytes  in  vivo  has  been  shown, 
particularly in later stages of disease.  As 90% of thymocytes express CD4 and 60-70% 
express CXCR4, X4 viruses are particularly destructive in the thymus (McCune, 1997; 
Moore et al., 2004).  Double positive (CD4+ CD8+) populations express both CXCR4 
and  CCR5,  while  CCR5  is  expressed  at  a  low  level  on  CD4  single  positive  cells 
(Moore  et  al.,  2004).  Intrathymic  macrophages  are  also  susceptible  to  infection 
(McCune,  1997).  CD4+ CCR5+ macrophages and microglial cells are targets for HIV 
infection in the brain.
1.7  THE COURSE OF HIV INFECTION AND PATHOGENESIS
The  definitive  feature  of HIV  pathogenesis  is  the  depletion  of CD4+  cells 
which,  over  a  prolonged  period,  leads  to  immunodeficiency  and  fatal  opportunistic 
infection  (Adler,  2001).  The  course  of disease,  from  initial  infection to the clinical 
manifestations of AIDS, can be split into distinct phases, described below.
1.7.1  Transmission and establishment of infection
HIV can be transmitted sexually,  vertically or intravenously.  In terms of the 
global  HIV  epidemic,  transmission  occurs  most  commonly  across  reproductive  or 
gastrointestinal  mucosal  surfaces.  As addressed  in  section  1.6,  R5  viruses are most 
important in natural transmission, despite the availability of CXCR4+ cellular targets. 
The reasons for this restriction are currently unclear, but are likely to be multiple and 
cumulative,  together  favouring  the  success  of R5  viruses  (Margolis  and  Shattock,
2006).  Factors  such  as  higher  levels of R5  viruses  in the transmitter at the time of 
transmission, unfavourable environment for X4 viruses in the genital tract, colon and 
rectum, the relative abundance of activated memory CD4+ CCR5+ T cells in mucosal 
tissue,  early infection events  involving macrophages, preferential early replication of 
R5 variants and a differentiating early immune response may all contribute (Margolis 
and Shattock, 2006).
The  rate  of successful  transmission  is  highest  during  the  peak  viral  load  of 
acute  infection;  this  has  been  estimated  to  be  at  least  10-fold  higher  than  during 
chronic  infection (Quinn et al., 2000; Wawer et al., 2005).  It is unclear whether the 
virus transmitted is in the form of infected cells or cell-free virus, as both are present in 
genital secretions.
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used to track early infection events (Miller et al.,  1989; Miller et al., 2005), and human 
cervical explant models have been used to identify early targets of infection (Collins et 
ah, 2000; Greenhead et ah, 2000; Miller and Shattock, 2003).  As most HIV infections 
occur  across  mucosal  surfaces,  these  are  considered  highly  relevant  models yet,  as 
information cannot be obtained directly from transmission in humans for practical and 
ethical reasons, knowledge of this is incomplete.  It is unclear whether the majority of 
successful  transmission  events  occur  across  intact  genital  or  gastrointestinal 
epithelium, or whether trauma or microtrauma are necessary, and this has bearings on 
the identity of the original target cells.
Trauma or microtrauma in the cervicovaginal epithelium allows direct access to 
underlying DCs,  macrophages and T cells  in the  lamina propria,  many of which are 
CD4+CCR5+.  In  sexual  transmission  across the  intact  genital  epithelium,  LCs  are 
considered an important primary target (Kawamura et ah, 2005) as they reside in the 
epithelium and extend dendritic processes into the lumen.  Immature LCs, expressing 
CD4 and CCR5,  are found  in vaginal,  ectocervical and foreskin mucosal epithelium. 
Indeed, the removal of these target cells through circumcision has been credited with 
the  high  success  rates  of recent clinical  trials  designed  to  assess the  effect of male 
circumcision on reduction of HIV acquisition rates (Weiss, 2007).  Immature LCs have 
been shown to be susceptible to infection ex-vivo (Kawamura et ah, 2000; Kawamura 
et ah,  2003;  Reece et ah,  1998) and  in vivo  (Bhoopat et ah,  2001; Zambruno et ah, 
1991).  Memory  CD4+  T  cells  have  also  been  identified  as  the  earliest  targets  of 
infection (Gupta et ah, 2002).
Initial seeding of CD4+CCR5+ founder populations in the lamina propria, be it 
through direct access to the cells or transport on or in LCs and DCs, is a critical step in 
determining infection outcome. Infection must spread to other susceptible target cells 
in the mucosa and become self-propagating with a basic reproductive rate (Ro) equal to 
or greater than  1, or it will be transient and abortive (Haase, 2005).  This may account 
for  the  relatively  low  transmission  rate  seen  for  vaginal  exposure,  with  estimates 
placed at approximately  1   in 200 (Piot et ah,  2001) to  1   in  1000  (Gray et ah, 2001) 
exposure events resulting in productive infection.  In the macaque model, small foci of 
infected  cells are detectable  in  cervicovaginal tissues within  3-4  days post exposure 
(Hu et ah, 2000; Miller et ah, 2005; Zhang et ah,  1999).  These foci expand to infect 
more cells in the lamina propria, probably through unbroken chains of resting CD4+ T
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Infection of activated CD4+ T cells, which produce larger numbers of progeny virus 
than resting CD4+ T cells but are fewer in number in mucosal tissue, serves to amplify 
virus production and transmit virus over greater distances (Haase, 2005).
The  risk  of  transmission  increases  if  the  recipient  or  transmitter  has  a 
concomitant  sexually transmitted disease  (STD).  Genital  ulceration  in the recipient 
greatly compromises the mucosal epithelial barrier and increases the chances of direct 
access  to  target  cells.  In  addition,  local  immune  activation  results  in  an  influx  of 
immune cells, many of which are targets for HIV.
In the  next stage  of infection the virus disseminates to the  lymphoid tissues. 
Local  draining  lymph  nodes  are  the  first target,  progressing  via the  bloodstream  to 
peripheral lymph nodes, the GALT and the spleen.  This has been estimated to occur 
within approximately two weeks of vaginal exposure (Miller et al., 2005; Zhang et al., 
1999),  although  low-level  dissemination,  not  considered  to  constitute  established 
systemic  infection,  may  begin  as  early as  24  hours  after exposure  (Hu  et al.,  2000; 
Miller  et al.,  2005).  DCs  are the  obvious candidates  as vehicles  for dissemination, 
given their role as sentinel cells: sampling and trafficking antigen to lymph nodes.  In 
this way,  DCs transport virus  from  entry  sites to  lymphoid tissues,  and promote the 
infection of CD4+ T cells, as described in section 1.6.2.
1.7.2  Acute infection
The  beginning of the  acute phase  is  signalled  by established  infection  in the 
lymphoid  tissue,  where  CD4+  CCR5+  T  cell  targets  are  plentiful  and  in  close 
proximity,  favouring intensive viral  replication.  This  is reflected  in blood viral load 
measurements,  which  can  peak  at  levels  as  high  as  108  RNA  copies  per  ml 
approximately 2 weeks post exposure, with levels of viral production detected in the 
order  of  1012  virions  per  day  (Little  et  al.,  1999);  viral  production  during  chronic 
infection was measured  as  1010 virions per day (Perelson et al.,  1997).  The GALT, 
containing  at  least  60%  of total  bodily T  cells,  is  a major  site  of virus  production. 
Recently it has been appreciated that a dramatic loss of CD4+ T cells from the GALT 
is a major feature of acute infection (Brenchley et al., 2004; Li et al., 2005; Mattapallil 
et  al.,  2005;  Mehandru  et  al.,  2004;  Veazey  et  al.,  1998).  These  CD4+  CCR5+ 
memory  T  cells  are  underrepresented  in  the  peripheral  blood  and  lymph  nodes, 
therefore  this  decimation  has  gone  largely unnoticed through conventional  sampling
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this time,  and when  individual populations of CD4+ T cells are examined,  selective 
depletion of the CCR5+ memory subset can be seen in peripheral blood (Douek et al., 
2003).
Peak viral  load coincides with or precedes the emergence of a CTL response 
and seroconversion.  Prior to this,  infection cannot be detected by routine testing for 
antibody, despite high levels of replicating virus and high infectivity of the individual 
(Kahn  and  Walker,  1998);  therefore,  diagnosis  of  acute  HIV  infection  relies  on 
detection  of  RNA  by  PCR  or  p24  antigen  by  ELISA  (Adler,  2001).  Clinical 
manifestations  often  occur  at this  stage,  known  as  primary  HIV  illness  or  infection 
(PHI),  seroconversion  illness,  or acute HIV  infection.  Symptoms can  include fever, 
headache,  diarrhoea,  fatigue  and  myalgia,  probably  resulting  from  the  immune 
response  to  infection,  and  can  last  from  several  days  to  a  few  weeks  (Kahn  and 
Walker,  1998).  Viral  reservoirs  are  established,  predominantly  in  the  lymphoid 
tissues.  The  largest of these, the FDC-trapped viral  reservoir (Pantaleo et al.,  1993; 
Schacker et al., 2000),  is established alongside the appearance of a humoral immune 
response  to  infection  as  a  consequence  of  antibody  and/or  complement-mediated 
binding of virus to Fc and complement receptors.  This causes a shift in focus, from T 
cell-associated  virus  being  the  major  viral  population,  to  FDC-associated  virus 
dominating  throughout  infection  (Haase,  1999;  Haase  et  al.,  1996).  Other  virus 
reservoirs are established in the form of latently infected cells.
Peak  viral  load  is  followed  by a  100-  to  1000-fold  drop  in  RNA  copies/ml, 
leading  to  the  chronic  stage  of  infection  approximately  1   month  after  exposure, 
throughout which  viraemia and  the  CD4  cell  count remain  relatively stable  and the 
infection is largely asymptomatic.  The reason for the precipitous drop in viral load is 
thought to be the emergence of a robust T cell response, as inferred by the temporal 
proximity of viral load decline and detection of a CTL response (Borrow et al.,  1994; 
Borrow et al.,  1997;  Koup et al.,  1994),  although exhaustion of T cell targets  in the 
GALT  may  also  be  a  key  contributing  factor  (Derdeyn  and  Silvestri,  2005;  Haase, 
2005).
1.7.3  Chronic infection
The extent of damage inflicted on the CD4+ T cell population during the acute 
phase of infection has its consequences during chronic infection.  Throughout chronic
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addition to this, chronic immune activation as a response to the constantly replicating 
virus  has  further  detrimental  effects  on  the  immune  system  whilst  providing  more 
CD4+ cellular targets  for HIV  infection  (Derdeyn and  Silvestri,  2005).  Generalised 
immune  activation  can  impair the  function  of many  parts  of the  immune  system  - 
CD4+  and  CD8+ T  cells  in  particular.  This  may  contribute to  an  eventual  lack of 
control of HIV replication, consequential increases in viral loads and further death of 
CD4+ cells.
At late stages of infection in some individuals, X4 virus strains start to emerge. 
This is known as the co-receptor switch and occurs alongside a sharp decline in CD4+ 
cell numbers and a rise in viral load.  The use of the CXCR4 co-receptor broadens the 
tropism of HIV to  include naive T cells and thymocytes.  It is uncertain whether the 
emergence of X4 strains precipitates the drop in CD4+ cells due to more aggressive 
replication  or whether the  deterioration  of the  immune  system  allows X4  strains to 
emerge (Weiss, 2003).
The chronic, asymptomatic stage of HIV infection lasts for several years before 
the CD4+ cell decline signalling the onset of AIDS.  Infected individuals are classified 
as rapid, moderate, slow progressors, or long-term non-progressors (LNTP) according 
to the duration of the asymptomatic period.  Factors proposed to influence the delay to 
onset  of AIDS  in  LTNP  are  multiple,  including  more  potent  cellular  or  humoral 
immune responses, co-receptor polymorphisms and other genetic predispositions, and 
replication defects of the infecting virus, such as mutations in Nef (Crotti et al., 2006). 
The  viral  set-point,  the  steady  state  viral  load  as  measured  at  the  onset  of chronic 
infection, is predictive of the rate of progression to AIDS: individuals with lowest set- 
points generally progress more slowly (Helbert and Breuer, 2000; Kahn and Walker, 
1998).
1.7.4  AIDS
Prior to the onset of AIDS, individuals may present with persistent generalised 
lymphadenopathy,  lasting several months (Adler, 2001).  Symptoms of AIDS usually 
start to appear when the CD4+ cell count falls below 200 cells per pi.  AIDS-defining 
illnesses cover a wide spectrum of manifestations, but many are due to opportunistic 
infection  and  malignancies  resulting  from  immunosuppression,  such  as  candidiasis, 
Pneumocystis carinii pneumonia and Kaposi’s sarcoma (Adler, 2001).
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pathogenic effects on other organ systems such as the central nervous system (CNS), 
lymph nodes and thymus.  HIV can directly infect macrophages and microglial cells in 
the CNS.  The virus enters the brain soon after systemic establishment of infection and 
is thought to  replicate  there  at  low  levels throughout the  course  of infection.  CNS 
disease  is  generally  a  late  feature  of  infection.  Clinical  disorders  include  HIV- 
associated  dementia  (HAD),  which  is  correlated  with  high  plasma  viral  loads. 
Syncytia  of microglia  are  an  important  component  of CNS  infection,  especially  in 
children.
Lymph node architecture deteriorates throughout infection,  leading to atrophy 
by the end-stages of disease.  This could be due to direct viral infection of cells in the 
lymph node or to cytokines produced in response to infection.  The production of new 
T  cells  by  the  thymus  is  impaired  early  in  infection  and  thymic  function  is 
progressively  lost.  X4 viruses are particularly aggressive  in the thymus as they can 
infect the majority of developing T cell subtypes; therefore the co-receptor switch is 
likely to contribute to thymic damage (Moore et al., 2004).
1.8  THE ANTIBODY RESPONSE TO HIV
As  this  thesis  is  primarily  concerned  with  the  effect  of  antibodies  and 
complement on HIV infection, only these two aspects of the immune response to HIV 
will  be  described  here.  The  complement  system  and  the  interactions  of HIV  and 
complement are addressed in section 1.9.
1.8.1  The antigenic nature of the Env spike
Only  antibodies  that  recognise  intact  virus  particles  have  the  potential  to 
neutralise HIV, yet not all antibodies that bind to the infectious virion are neutralising. 
The prevailing model of HIV neutralisation depicts steric hindrance of envelope spikes 
through high-level antibody occupancy (Burton et al., 2001; Parren et al., 1998).  In the 
case of HIV, the only two viral protein targets available for neutralising antibodies are 
gpl20  and  gp41.  Neutralising  antibodies  are thought to  recognise the native  spike, 
whereas non-neutralising antibodies are elicited to envelope monomers or other non­
functional  forms of the  envelope  (Poignard et al.,  2003)  such as monomeric gpl20- 
gp41  complexes and gp41  “stumps” (Moore et al., 2006).
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neutralising faces (Moore and Sodroski,  1996; Wyatt and Sodroski,  1998).  The silent 
face,  located  on  the  outer  domain  of  gpl20,  is  so-called  because  of  its  poor 
immunogenicity  resulting  from  clustering  of carbohydrate  side  chains  in this region 
(Poignard  et  al.,  2001).  The  non-neutralising  face,  located  on  the  inner domain  of 
gpl20,  is  highly  immunogenic  and  elicits  a  strong  antibody  response  in  infected 
individuals.  However,  due  to  its  positioning  within  the  trimeric  envelope  spike, 
antibodies to this region are thought to be incapable of binding to the native spike, and 
therefore  do  not  neutralise  functional  virus  (Wyatt  and  Sodroski,  1998).  The 
abundance of antibodies to this region  in  infected  individuals  is probably due to the 
presence  of shed  monomeric  gpl20,  or  non-functional  envelope  monomers  on  the 
virus  surface  (Moore  et  al.,  2006;  Poignard  et  al.,  2001).  The  neutralising  face  of 
gpl20  incorporates regions from the outer and  inner domains and the bridging sheet 
(Wyatt and Sodroski,  1998) and includes the receptor binding sites.  Structures within 
this  region  important  for  functional  activity  of gpl20  are  conserved  among  diverse 
HIV  strains,  and  as  such  are  poorly  available  for  antibody  recognition  (Wyatt  and 
Sodroski,  1998).  There are three immunodominant regions on gp41: cluster I (aa 579- 
604),  II  (aa 644-663) and III  (aa 619-648; Gorny and Zolla-Pazner, 2003).  As these 
regions  are  thought  only  to  be  exposed  in  the  post-fusion  or  disassembled  spike, 
antibodies to these regions are non-neutralising.  A transitional epitope, the membrane- 
proximal external region (MPER), that is poorly exposed on the Env spike but thought 
to be accessible during the entry process, has given rise to neutralising antibodies, as 
described in section  1.8.2.
Multiple  features  of the  envelope  spike  confer  protection  from  neutralising 
antibodies:
•  The sequential receptor binding process ensures that critical, conserved regions of 
the envelope, such as the co-receptor binding site and gp41  fusion protein, are not 
revealed  until  the  moment  of  target  cell  receptor  interaction.  At  this  point 
proximity  to  the  target  membrane  may  sterically  hinder  antibody  binding,  and 
shield these regions from antibody attack.  Some naturally occurring SIV strains, 
and  HIV-2,  along  with  some  tissue-culture-adapted  HIV-1  strains,  are  CD4- 
independent  and  can  fuse  with  the  target  cell  membrane  following  co-receptor 
interaction  alone.  It  is therefore thought that early primate  lentiviruses engaged 
directly  with  co-receptors,  and  that the  CD4  binding  step  evolved  later  in  HIV
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are more sensitive to neutralisation, probably due to increased exposure of the co­
receptor binding site (Bhattacharya et al., 2003).
•  Receptor  binding  sites  are  shielded  from  antibody  attack  by  the  positioning  of 
variable loops.  The CD4 binding site is recessed and masked by the V1V2 loops; 
the co-receptor binding site is masked by V3.  The variable loops are a major target 
for  neutralising  antibodies,  but  sequence  variability  and  functional  plasticity  in 
these regions allows for rapid immune escape.
•  The majority of the exposed face of gpl20 in the Env spike is glycosylated. As the 
glycans  are  added  to  the  protein  during  post-translational  processing  in the  host 
cell, these carbohydrates are seen as “self’ by the immune system, thus this face of 
gpl20 is known as the silent face.
•  Most of the surface region of gp41  is covered by gpl20 or carbohydrate moieties 
(Sattentau et al.,  1999).
Primary isolates (Pis) are often resistant to neutralisation. The native spike of 
Pis  is  thought to take  on  an energetically  favourable  “closed”  conformation:  tightly 
packed trimers with heavily glycosylated and variable exposed regions and occluded 
conserved  neutralisation  epitopes  (Klasse  and  Moore,  1996;  Sattentau  et  al.,  1999). 
During the  course  of adaptation to growth  in  culture,  TCLA  strains take  on a more 
“open”  and  fusogenic  conformation,  with  the  inner  face  of gpl20  monomers  more 
exposed within the trimers.  This increases their efficiency of entry, but at the cost of 
increased sensitivity to neutralisation.
1.8.2  Neutralising antibodies
A  handful  of monoclonal  antibodies  with  broad  neutralising  activity  against 
HIV  have  been  described  (reviewed  by Burton  et al.,  2005;  Pantophlet and Burton, 
2006;  Poignard  et al.,  2001;  Zolla-Pazner,  2004).  Any hint of vulnerability of HIV 
Env  spike  to  neutralisation  can  be  mapped  to  the  epitopes  for  these  monoclonal 
neutralising  antibodies:  the  CD4-induced  (CD4i),  CD4  binding  site,  gp41  MPER, 
2G12,  and  V3  loop  epitopes.  Several  of these  antibodies  have  unusual  structural 
features, as described below.
The  CD4i  epitope  overlaps  with  the  gpl20  co-receptor  binding  site  and  is 
exposed upon CD4 binding (Kwong et al.,  1998) or in CD4 independent virus strains
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basic,  and part of the region of CCR5 responsible for interaction with gpl20, the N- 
terminal  peptide,  is  postulated  to  interact  with  the  co-receptor  binding  site  via 
negatively-charged  sulphated  tyrosines  (Farzan  et  al.,  1999).  Several  characterised 
CD4i antibodies were found to have sulphated tyrosines in their long heavy chain third 
complementarity detemining regions (CDR H3); others had a high proportion of acidic 
residues  (Choe  et  al.,  2003;  Kwong  et  al.,  1998).  CD4i  antibodies  are  broadly 
neutralising, with the MAb 17b showing activity against HIV-1  subtypes A, B, C, D, E 
and F (Salzwedel et al., 2000), and CD4i antibodies from HIV-1  infected individuals 
capable  of neutralising  HIV-2  strains  (Decker  et  al.,  2005).  This  cross-reactivity 
reflects  the  conserved  nature  of the  CCR5  binding  site  and  the  gpl20  residues that 
contact the CD4i antibodies (Wyatt et al.,  1998).  However, neutralisation is dependent 
upon  pre-treatment  of the  viruses  with  sCD4;  the  antibodies  alone  are  not  potent 
inhibitors  of  infection  due  to  the  inaccessibility  of  the  co-receptor  binding  site 
following cell-surface CD4-induced exposure.  Potency is greatly increased when Fab 
or single-chain fragments are used (Labrijn et al., 2003; Moulard et al., 2002).  It has 
been  proposed  that  CD4i  antibodies,  which  are  produced  to  high  titres  in  infected 
individuals,  play  a  role  in  natural  HIV  infection  by  neutralising  spontaneously 
generated  CD4  independent  variants  and  thus  providing  a  selective  pressure  for 
continued CD4 tropism (Decker et al., 2005).
The  prototype  neutralising  antibody  to  the  CD4  binding  site  is  IgG 1  b 12 
(Barbas et al.,  1992), hereafter referred to as b 12.  bl2 has been crystallised in complex 
with gpl20 molecules constrained to remain in a CD4-bound conformation, revealing 
information about its interaction with gpl20 (Zhou et al., 2007).  Unusually, only the 
heavy chain of bl2 interacts with gpl20, with each of the three CDR Hs contributing 
to the interaction and providing a contact surface equivalent in size to typical antibody- 
protein  interfaces (Zhou et al., 2007).  Previously it had been predicted that the long 
(18  aa)  CDR H3  region  of bl2  extended  into the Phe43  binding pocket of the CD4 
binding site, and this was the primary reason for the broad neutralising activity of bl2 
(Burton et al., 2005; Saphire et al., 2001).  However, recent crystal structure analysis 
shows that this feature is not central to the gpl20 binding properties of bl2, and that in 
fact the CDR H3  binds peripherally to the Phe43  pocket (Zhou et al., 2007).  Many 
other  CD4  binding  site  antibodies  are  non-neutralising,  but  bl2  has  broadly 
neutralising activity against a range of primary isolates. This is thought to be because
54bl2  can  bind  to  the  CD4  binding  site  in  both  native  spike  and  monomeric  gpl20 
structures, whereas the non-neutralising antibodies only bind to the monomeric gpl20 
CD4bs (Burton et al., 2005).
A  unique  monoclonal  antibody,  2G12,  has  been  characterised  as  a  glycan- 
binding  antibody  that  recognises  clustered  al->2-linked  mannose  residues  on  the 
gpl20  silent  face  (Hansen  et al.,  1990; Trkola et al.,  1996).  As most carbohydrate 
moieties appear as “self’ to the immune system, and most of the gpl20 silent face is 
covered with N-linked glycans, antibodies directed to this region are rarely identified. 
Structural analysis of this antibody revealed a domain-swapped configuration, in which 
the  variable  heavy  chains  (V h)  from  each  Fab  have  exchanged  places  within  the 
molecule, providing a novel interface between the two Vh chains in addition to the two 
VH /VL   interfaces.  This  allows  the  antibody  to  interact  with  the  specific  cluster  of 
oligomannose sugars over an extended contact region (Pantophlet and Burton, 2006).
The anti-V3  loop antibody 447-52D neutralises a range of isolates bearing the 
sequence GPGR on the tip of the V3 loop (Gomy et al.,  1992).  The importance of the 
GPGR  region  as a neutralising epitope  is  unequivocally more  pronounced  in TCLA 
strains and subtype B Pis, but as viruses from other subtypes do not possess the GPGR 
sequence  on  their  V3  loops  447-52D  has  a  limited  breadth  of  neutralisation. 
Interestingly, main-chain atoms mediate most of the interactions between 447-52D and 
the GPGR sequence, with side-chain residues from the Pro and Arg contributing to the 
interaction.  This  allows  for a degree  of sequence variability  in the epitope  for this 
antibody.
Whilst  the  majority  of antibodies  to  gp41  are  non-neutralising,  two  broadly 
neutralising anti-gp41  monoclonal antibodies have been characterised -  2F5 and 4E10 
(Purtscher et al.,  1994; Trkola et al., 1995; Zwick et al., 2001b).  The epitopes for these 
antibodies are located close to the transmembrane region of gp41; both are adjacent to 
the  immunodominant  cluster  II,  with the  2F5  epitope  spanning aa  662-667  and  the 
4E10 epitope aa 671-677 (Zwick et al., 2001b). The region is exposed for only a brief 
period during the conformational changes involved in receptor binding.  As peptides 
corresponding to these regions failed to elicit antibodies similar to 2F5 and 4E10, it is 
thought  that  the  molecular  context  within  which  these  epitopes  are  presented  is 
important, probably requiring the presence of the viral membrane.
551.8.3  Non-neutralising antibodies
Immunodominant  epitopes  such  as  cluster  I  in  the  ectodomain  of gp41,  and 
regions  in  C5  of  gpl20  that  interact  with  gp41,  give  rise  to  high  titres  of non­
neutralising  antibodies  in  infected  individuals.  Monoclonal  antibodies  to  these 
regions, and many others that are not accessible on the functional spikes, are also non­
neutralising.  However, apart from neutralisation, antibodies may have other functional 
activities when acting  in cooperation with other components of the  immune system. 
These  include  complement-mediated  inhibitory  or  enhancing  activity  and  FcyR- 
mediated effector activities.
Virus-inhibitory activity of antibodies may be increased when assayed on or in 
the presence of different cell types.  Antibody-mediated inhibition of primary isolates 
was increased when PBMCs were used as target cells compared to purified CD4+ T 
cells from the same donor.  This was attributed to the presence of FcyR-bearing NK 
cells, triggered to produce an antiviral response, partially mediated by (3-chemokines, 
by antibody-opsonised virus engagement with FcyRs (Forthal et al., 2005).
A role for the in cis involvement of FcyRs on macrophages and immature DCs 
(iDCs) in increasing inhibitory activity of monoclonal antibodies was proposed by Holl 
and colleagues (Holl et al.,  2006).  Neutralising activities of several Nabs,  including 
bl2  and  2G12,  against two  subtype  B  Pis  were  increased  16- to  12,000-fold when 
assayed on macrophages or iDC target cells compared to PBMCs.  In addition, MAbs 
that  had  no  neutralising  activity  against  BaL  on  PBMCs  became  neutralising when 
assayed  on  macrophages  and  iDCs.  Similarly,  several  MAbs  that  had  weak 
neutralising  activity  against  a  subtype  C  PI  on  PBMCs,  showed  an  8- to  2000-fold 
increase in activity on macrophages and iDCs.  Furthermore, the inhibitory activity of 
sCD4 and the fusion inhibitor T20 were similar on the different target cells, suggesting 
that levels of CD4 or different efficiencies of fusion on the different target cells did not 
account  for  the  results  seen.  Removal  of  antibody  Fc  portions,  and  subsequent 
antibody blocking of FcyRs, showed that increased inhibitory activity of the MAbs was 
FcyR-mediated,  and  possibly  as  a  result  of  endocytosis  and  degradation  of  the 
opsonised  virus  (Holl  et  al.,  2006).  Another  study  showed  that,  when  using 
macrophages  as target cells,  autologous  neutralising antibodies  could  be  detected  in 
infected  individuals as early as 2 months after infection.  In contrast,  using the same 
sera on lymphocytes, neutralising activity was not detected until  10 to  14 months after
56infection (Ruppach et al., 2000).  Other studies have reported ADCC activity of both 
polyclonal  non-neutralising  antibodies  from  infected  individuals  and  monoclonal 
antibodies (Forthal et al.,  1995; McDougall et al.,  1997; Subbramanian et al., 2002).
Complement-mediated mechanisms of virus  inactivation  in concert with non­
neutralising antibodies have also been reported (Aasa-Chapman et al., 2005; Huber et 
al.,  2006) and these are discussed  in more detail  in section  1.9.2.2.  In  contrast, the 
presence  of non-neutralising  antibodies  may  assist  the  virus,  not  only  due  to  the 
direction of immune resources towards an ineffective response, but also through active 
subversion  by HIV.  The  subject of this thesis,  antibody-dependent enhancement of 
HIV infection, is an example of this situation and is discussed in detail in section 1.10, 
while other complement-mediated mechanisms that assist viral infection are described 
in section  1.9.2.3.
1.8.4  The antibody response during the course of HIV infection
The role of antibodies in controlling HIV infection is unclear.  The drop in viral 
load  during  acute  infection  has  been  attributed  to  CD8+ T  cell-mediated  control  of 
infection (Borrow et al.,  1994; Borrow et al.,  1997; Koup et al.,  1994) the exhaustion 
of large pools of cellular substrates, or certain activities of non-neutralising antibodies 
(see section  1.8.3) but not to viral neutralisation by antibody as this response is delayed 
relative to the decline in viral load.
Virus present during early stages of replication and acute infection is relatively 
homogeneous  (Derdeyn et al.,  2004; Zhu et al.,  1993;  Zhu et al.,  1996), with gpl20 
sequence  homogeneity  approximating  >99%  in  seroconvertors  compared  with 
approximately  90%  in  chronically  infected  individuals  (Zhu  et  al.,  1993).  A  study 
examining  heterosexual  subtype  C  virus  transmission  in  HIV-discordant  couples  in 
Zambia  found  consistent differences  in the  viral  sequences  detected  in the recipient 
compared  with  those  in  the  donor.  A  bottleneck  effect  was  observed  upon 
transmission,  wherein  the  viral  sequences  from  the  recipient  formed  a  distinct 
subcluster within the viral sequences from the donor (Derdeyn et al., 2004).  Likewise, 
other studies with subtype B viruses showed that the transmitted virus represented only 
a minor variant in the blood, and even semen, of the transmitter,  indicating selective 
transmission or amplification (Zhu et al.,  1993; Zhu et al.,  1996). Observations that V3 
sequences of virus in newly infected recipients remained predominantly homogeneous 
for at least 6 months favours the former explanation (Zhu et al.,  1996).  Interestingly,
57phenotypic  analysis  of transmitted  clade  C  viruses  showed  them  to  be  particularly 
susceptible to neutralisation by plasma from the donor and also from unrelated clade C 
antibodies (Derdeyn et al., 2004).  This was attributed to significantly shorter variable 
regions (V)  1-4.  Increased exposure of the CD4 binding site through loss of N-linked 
glycosylation and modulation of the positioning of the variable loops was proposed as 
the mechanism for increased neutralisation sensitivity (Derdeyn et al., 2004).  Shorter 
VI-4 regions in transmitted viruses were also observed for subtype A viruses, but not 
subtype B  (Li et al., 2006).  Thus, there is evidence to suggest some vulnerability of 
early viruses to  neutralisation,  yet uncertainty as to the  potency of early autologous 
neutralising antibody responses.
Envelope-specific  antibodies  can  be  detected  in  the  blood  of  infected 
individuals as early as 6 days after onset of symptoms of PHI (Aasa-Chapman et al., 
2005), but neutralising antibodies are not thought to arise for one to several months; a 
figure that varies from report to report (Aasa-Chapman et al., 2004; Aasa-Chapman et 
al., 2005; Moog et al.,  1997; Richman et al., 2003; Wei et al., 2003). Methodological 
differences  between  studies  and the  lack  of a  standard  neutralisation  assay make  it 
difficult to amalgamate or even compare results from different laboratories (Moore and 
Burton, 2004).  Likewise, the issue of whether a 50% or 90% reduction in infectivity 
constitutes  neutralisation,  and  whether  it  is  more  accurate  to  present  IC50  or  IC90 
titres, has bearings on the timing of an emerging neutralising response (Aasa-Chapman 
et al., 2004; Richman et al., 2003; Wei et al., 2003).  Furthermore, even within studies, 
autologous neutralising responses vary enormously between individuals.  For example, 
in  a  study  by  Richman  and  colleagues,  in  one  group  of individuals  an  autologous 
neutralising response was detected as early as 4-8 weeks post onset of PHI symptoms, 
in  a  second  group  3-6  months,  and  in  a  third  only  negligible  titres  of autologous 
neutralising antibodies were detected throughout the 36 months of follow-up (Richman 
et al., 2003).
Thus, the earliest detection of autologous neutralising antibodies occurs at  1-2 
months post onset of symptoms, and only in recent reports using the most sensitive of 
assays (Richman et al., 2003; Wei et al., 2003).  Other reports generally quote a time 
frame of 3  months to a year, but always with some study subjects failing to produce 
detectable  neutralising  antibodies  in  this  period  (Aasa-Chapman  et  al.,  2004;  Aasa- 
Chapman et al., 2005; Li et al., 2006; Moog et al.,  1997; Pilgrim et al.,  1997).
58Ongoing high-level replication throughout infection and in the face of immune 
pressure  from neutralising antibody and CTL responses leads to the accumulation of 
genetic mutations, the production of viral quasispecies and rapid immune escape by the 
virus.  Viral  sequence variation within one chronically infected individual at a given 
time point is roughly equivalent to the global sequence variation of influenza virus for 
any  given  year  (antigenic  shift  excluded;  Korber  et  al.,  2001).  The  situation  of 
immune control of HIV infection is further frustrated by the pool of proviral DNA in 
latently  infected  cells,  acting  as  a  viral  “archive”  (Korber  et  al.,  2001),  and  FDC- 
associated  virus  that  is  rendered  apparently  unaffected  by  otherwise  neutralising 
antibodies (Burton et al., 2002; Heath et al.,  1995).
Studies of HIV neutralisation escape have been made using sequential paired 
virus  isolates  and  plasma  samples  from  infected  individuals.  Successive  antibody 
samples  tested  against  a  previous  autologous  virus  isolate  generally  increase  in 
neutralisation potency; successive virus isolates against a given autologous plasma or 
serum sample decrease in susceptibility to neutralisation.  The rate at which these two 
processes occur is  indicative of the rate at which neutralising antibody responses are 
mounted and the rate of phenotypic immune escape, respectively, and were shown to 
significantly correlate (Frost et al., 2005).  Rates of neutralising antibody response and 
phenotypic escape were shown to vary between individuals, but this did not correlate 
with  viral  load  set  points  (Frost  et  al.,  2005).  Most  studies  show  weak  or  no 
neutralisation  of autologous  virus  by  contemporaneous  plasma  (Frost  et  al.,  2005; 
Mascola, 2003; Moog et al.,  1997; Richman et al., 2003; Wei et al., 2003), indicating 
that  the  neutralising  antibody  response  remains  a  step  behind  the  rapidly  evolving 
virus.  Either a pre-existing neutralisation-resistant minor viral  variant  is  selected  for 
dominance,  or  de  novo  mutations  create  a  variant that  is  poorly  recognised  by  the 
existing  antibody  response.  A  moving  glycan  “shield”  has  been  proposed  as  one 
mechanism  of immune escape by HIV,  during which changes in the positions of N- 
linked  glycosylation  contributed  to  antibody  escape  but  without  compromising  the 
protein structure of the underlying Env spike (Wei et al., 2003).  Another study showed 
the  continuous,  ongoing  accumulation  of amino  acid  mutations  spread  across  the 
gpl20 sequence rather than focused on regions of N-linked glycosylation (Frost et al., 
2005).  Viruses  that  evolve  to  evade  neutralisation  in  the  host  are  not  abnormally 
resistant to  heterologous  sera or neutralising monoclonal  antibodies (Mascola,  2003; 
Richman et al., 2003).
59The early neutralising response to infection is specific for the infecting strain; 
over time,  the  neutralising response  broadens  and  becomes  capable  of heterologous 
neutralisation (Aasa-Chapman et al., 2004; McKnight et al.,  1992; Moog et al.,  1997; 
Richman et al.,  2003).  This was shown to be  independent of rates of viral  immune 
escape  (Frost  et  al.,  2005).  The  isolate-specific  neutralising  antibodies  produced 
during the early neutralising response to HIV infection are commonly directed to the 
V3  loop,  and  less  frequently the  V2  loop (Wyatt and  Sodroski,  1998;  Zolla-Pazner,
2004).  Rapid immune escape renders the efficacy of these antibodies short-lived.  V3- 
specific neutralising antibodies with broad specificity may arise later in infection and 
these  recognise  conformational  structures  rather than  linear  epitopes  (Zolla-Pazner,
2004).  CD4 binding site antibodies are also credited with broad neutralisation later in 
the  neutralising  response  (Wyatt  and  Sodroski,  1998).  One  study  found  CD4i 
antibodies in 178 out of 189 HIV-1  infected patients investigated, but these are thought 
mainly to  contribute  to the  restriction  of evolving  virus to  CD4 tropism  rather than 
broad  neutralising  activity.  The  study  of  LTNPs  and  highly-exposed  protected 
individuals  (HEPS)  has  attributed  a neutralising antibody  response to the  control  or 
prevention of infection (Zhang et al.,  1997), with CD4 binding site antibodies among 
those  found  in  LTNPs  and  neutralising  IgA  found  in  HEPS  (Devito  et  al.,  2002; 
Humbert and Dietrich, 2006).
1.9  HIV AND COMPLEMENT
1.9.1  The complement system
The  complement  system  consists  of over 30  serum  and  cell-surface  proteins 
involved  in  host  defence  against  infection.  Upon  activation  an  enzyme  cascade  is 
generated,  driven  by the sequential proteolytic cleavage of complement components, 
under tight regulation by complement control proteins. This process culminates in the 
opsonisation and  lysis of pathogens and the generation of an inflammatory response. 
Hepatocytes  in the  liver are the primary,  but not sole,  site of complement synthesis 
(Alper et al.,  1969).  Monocytes, macrophages, fibroblasts, epithelial cells, adipocytes, 
astrocytes and microglia are among the many cell types also capable of complement 
production  (reviewed  by  Morgan  and  Gasque,  1997),  either  constitutively  or  under 
cytokine drive.
60Here, the complement system is described within the framework of activation 
by, and consequences for, viral infection.
1.9.1.1 Complement activation pathways
There  are three  pathways of complement activation:  the classical,  alternative 
and  mannose-binding  lectin  (MBL) pathways.  All three  converge to cleave C3, the 
central  component  of complement,  and  ultimately  trigger  the  terminal  complement 
pathway if unimpeded.
1.9.1.1.1 The classical complement activation pathway
The classical pathway is primarily activated by immune complexes, consisting 
of multiple IgG or single IgM molecules bound to antigen.  IgM is the most powerful 
immunoglobulin  activator of complement,  followed by IgG.  Of the IgG subclasses, 
IgGl  and  IgG3  are the most potent activators of complement, followed by IgG2 and 
IgG4  (Spiegelberg,  1974).  While  IgA  activates  complement via the  MBL pathway 
(Roos et al.,  2001) and the alternative pathway (Hiemstra et al.,  1987),  complement 
activation is not as potent as that seen by IgM and IgG isotypes. An important feature 
of the classical pathway is that, by virtue of Clq activation by antibody, it forms a link 
between  innate and adaptive  immunity (reviewed by Barrington et al., 2001; Carroll, 
2004; Ochsenbein and Zinkemagel, 2000).
Figure  1.7  shows  the  initial  events  of the  classical  complement  activation 
pathway.  Cl,  a  multimolecular  enzyme  complex,  is  the  first  component  of the 
classical  complement pathway.  It consists of one molecule of Clq,  a collectin,  and 
two molecules each of Clr and Cls, both serine proteases.  The distinctive globular 
heads of Clq contain pathogen and Ig recognition motifs (reviewed by Kishore et al., 
2002;  Thielens et al.,  2002).  Activation by binding to  immune complexes via Ig Fc 
regions, or directly to the pathogen, induces a conformational change in Clq, leading 
to the autoactivation of Clr and subsequent activation of Cls, reviewed by (Gal and 
Ambrus, 2001).  Activated Cls then cleaves C4 into C4a and C4b, the latter of which 
covalently binds to the pathogen surface via an exposed thioester group.  Covalently 
bound C4b, in turn, recruits C2, facilitating Cls-mediated cleavage of C2 into C2a and 
C2b*.  C2a remains bound to C4b in an active form, constituting the C3 convertase of 
the classical pathway, C4b2a.
61* A general rule in complement nomenclature is that larger products of a cleavage event are assigned the 
suffix “b”, and smaller ones “a” e.g. C4a and C4b.  C2 is the exception to this rule, with C2a referring to 
the larger, active fragment of C2.
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Figure 1.7  Schematic diagram of early events in the classical complement pathway
For each stage of the diagram, regions in red indicate the “active” components referred to in 
the text boxes immediately below.  Inactive thioester bonds are shown as white discs; activated 
thioester bonds forming covalent bonds are shown as white stars.  Note that the concept is the 
same for the MBL activation pathway, with the exception that Clq, r and s are substituted for 
MBL, MASP-1   and MASP-2 respectively.
1.9.1.1.2 The MBL complement activation pathway
The activation of the  MBL  pathway results  in the  formation of the  same  C3 
convertase  as  the  classical  pathway,  yet  the  initial  proteins  of the  pathway  differ 
(Matsushita and Fujita,  1992).  The MBL pathway is initiated upon binding of MBL, a 
collectin  and  structural  homologue  of Clq,  to  mannose  and  other  residues  on  the 
pathogen surface  (Stahl  and  Ezekowitz,  1998;  Turner,  1996).  This  is  turn activates 
MBL-associated serine protease (MASP) -1, a homologue of Clr, and then MASP-2, a 
homologue of Cls, with MASP-2 proceeding to cleave C4 and C2 (Matsushita et al., 
2000; Thiel et al., 1997) to produce the C3 convertase C4b2a.
1.9.1.1.3 The alternative complement activation pathway
The C3 convertase formed via the alternative pathway, C3bBb, differs from the 
classical and lectin pathway C3 convertase. The alternative pathway is activated by the 
spontaneous hydrolysis of C3.  This induces a conformation change in C3, permitting
62the binding of factor B, a homologue of C2.  Factor B is then cleaved into Ba and Bb 
by  factor D,  and  this  forms  a fluid-phase  C3  convertase,  C3(H20)Bb.  C3(H20)Bb 
cleaves more molecules of C3 to C3a and C3b, and some of the C3b fragments may 
attach to a complement-activating surface, as described in section 1.9.1.2.  Some may 
also  attach  to  host  cell  surfaces,  but  control  measures  are  in  place  to  prevent 
continuation of the cascade, as described in section  1.9.1.4.  C3b covalently bound to 
the pathogen surface allows the binding of factor B, followed by factor D cleavage of 
factor B and the production of the membrane bound alternative pathway C3 convertase 
C3bBb.  Properdin,  also  known  as  factor P,  binds to  C3bBb and  stabilises  it.  The 
nature of the alternative pathway allows it to activate the complement cascade alone, 
or serves to amplify ongoing cascades triggered by the other pathways.
1.9.1.1.4  Convergence of the activation pathways and consequences of C3 cleavage
At  the  point  of  C3  convertase  formation,  the  three  activation  pathways 
converge.  The next step of the complement cascade is driven by C3 and the generation 
of  its  breakdown  products.  C3a  is  an  anaphylotoxin  and  acts  as  a  powerful 
inflammatory  mediator,  recruiting  phagocytic  cells  and  antibody  to  the  site  of 
infection.  The formation of C3b has several consequences:
1.  It acts as an opsonin, with the large quantities of C3b generated by C3 convertase 
activity  coating  the  surface  of the  pathogen,  signalling  it  for  destruction  via 
complement receptors on effector cells.  This is discussed in more detail in section 
1.9.1.2.
2.  It binds to other complement components to form new multimolecular complexes 
that initiate the subsequent phase of the cascade, the terminal pathway.  Binding of 
C3b  to  the  classical  and  MBL  pathway C3  convertase  forms the C5  convertase 
C4b2a3b.  Similarly,  binding  of C3b  to  the  alternative  pathway  C3  convertase 
forms the C5 convertase C3bBbC3b.
3.  The  generation  of C3b  can  further  activate  the  alternative  pathway,  leading to 
amplification  of complement  activation  and  C3b  production,  and  consequently 
increasing the occurrence of points one and two.
1.9.1.2  Deposition of complement  fragments on the surface of  pathogens
The cleavage of C3 to C3b, via any of the three activation pathways, induces a 
conformational change that reveals an active thioester group (Abdul Ajees et al., 2006;
63Janssen  et  al.,  2006;  Wiesmann  et  al.,  2006).  This  thioester reacts  non-specifically 
with hydroxyl or amine groups to form a covalent bond between C3b and the pathogen 
surface  (Law  and  Levine,  1977;  Tack et al.,  1980),  or else  is  rapidly  inactivated  by 
hydrolysis.  As many as  1000 C3b fragments can be generated in the vicinity of a C3 
convertase, and these act as ligands for the complement receptor CR1.  Furthermore, 
degradation products of C3b remain bound to the pathogen and also act as complement 
receptor ligands, as shown in Figure 1.8.
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Figure 1.8 Schematic diagram of C3 degradation products and their receptors
C3, upon contact with a C3 convertase on a pathogen surface, is cleaved to C3a and C3b, the 
latter becoming covalently attached to the pathogen surface.  It is subsequently sequentially 
degraded  into  fragments,  with  each  covalently  bound  fragment  a  ligand  for  complement 
receptors, shown in blue text boxes above their ligands.  C3 structure is adapted from Janssen 
2006 (Janssen et al., 2006).
Unless  involved  in  the  formation  of other  complement  complexes,  C3b  is 
rapidly  converted to  its  inactive  form  iC3b.  This  is  mediated  by  factor  I,  and  only 
occurs  when  C3b  is  associated  with  factor  H,  CR1  or  membrane-cofactor  protein 
(MCP  or CD46).  Factor H,  a fluid phase protein,  interacts with molecules,  such  as 
sialic  acid, that are most commonly  found on host cells,  and in this way marks  C3b 
molecules  attached  to  self for  inactivation.  CR1  and  CD46  are  membrane-bound 
receptors found on host cells.  iC3b is a ligand for CR3, CR4 and CR2.  Factor I, again 
with CR1,  CD46 or factor H acting as cofactors,  further cleaves iC3b to produce the
64soluble  fragment  C3c  and  membrane-bound  C3dg.  C3c  has  no  known  biological 
function.  C3dg  is  a  ligand  for  CR2,  and  can be  further  degraded  to  C3g  and  C3d 
(Lachmann et al., 1982), the latter of which is also a ligand for CR2.
1.9.1.3  The terminal complement pathway
The endpoint of the complement cascade is the formation of a lytic pore in the 
pathogen  membrane.  This  occurs  via the  terminal  complement  pathway,  shown  in 
Figure  1.9,  which  is  triggered  by  the  formation  of a  C5  convertase,  C4b2a3b  or 
C3bBbC3b.  C5  specifically  binds  to  the  C3b  component  of the  C5  convertase, 
enabling the cleavage of C5 to C5a and C5b by the C2a or Bb serine protease activity 
of the  complex.  C5a is an anaphylotoxin.  C5b binds C6 then C7.  Conformational 
changes  in  the  molecules  of this  complex  allow the  insertion  of C7  into  the  target 
membrane via a hydrophobic domain.  C8, also containing hydrophobic regions, then 
binds  to  C5b,6,7  and  is  also  inserted  into  the  membrane.  Bound  C8  induces  the 
formation  of a  membrane  pore  through  the  polymerisation  of C9  molecules.  This 
constitutes  the  membrane  attack  complex  (MAC),  leading  to  lysis  of the  pathogen 
(reviewed by Cole and Morgan, 2003).
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Figure 1.9  Schematic diagram of the terminal complement pathway
Active components, as referred to in the text boxes below each stage, are shown in red.
1.9.1.4  Complement system regulation
Given that the uncontrolled activation of the  complement cascade could have 
catastrophic  effects  on  the  host,  a  number  of regulatory  measures  exist  to  prevent
65damage to self.  Localised activation is an important control feature of the complement 
system:  active  proteases  are  retained  on  the  surface  of the  pathogen  to  focus  the 
cascade and prevent uncontrolled inflammation and tissue damage.  For example, C4b 
is only able to bind C2 when it is covalently bound to the pathogen surface, and C2 is 
only susceptible to cleavage by Cls when it is bound to C4b.  Accordingly, as Cls is 
bound to Clq, these reactions all occur in the vicinity of the Clq binding site.  Rapid 
inactivation  ensues  if the  activated  fragments  are  not  bound  to  the  site  of initial 
complement activation (Janeway, 2001).  In addition,  a number of membrane-bound 
and soluble factors act to contain and control the complement cascade, by dissociating 
complexes or catalysing the breakdown of active complement components (reviewed 
by Blue et al., 2004; Janeway, 2001; Morgan,  1999).  These are described below in the 
order in which they intervene in the complement cascade:
1.  Inhibition of Cls protease activity:
The Cl  inhibitor,  Cl-inh,  binds to the Clr-Cls complex and forces its displacement 
from Clq.  It also prevents the spontaneous activation of Cl  in solution.
2.  C4b breakdown.
C4b can be inactivated by the protease factor I.  This can occur before the formation of 
the C3 convertase, or after its dissociation.  Factor I requires a cofactor to function, and 
this can take the form of C4 binding protein (C4bp), CR1 or CD46.  C4bp is present in 
solution.  CR1  and CD46 are found on certain host cell surfaces, therefore promoting 
factor I-mediated inactivation of an inappropriate complement response.
3.  C3b breakdown
As with C4b, C3b can be inactivated by factor I.  The cofactor for this process is either 
factor  H,  CR1  or  CD46.  Factor  H  is  a  soluble  protein,  and  binds  to  C3b  in  the 
presence  of sialic  acids  present  on  host  cells  (and  generally  absent  from  pathogen 
surfaces).
4.  Prevention offormation or accelerated decay of  the C3 convertase
CR1, decay accelerating factor (DAF or CD55) and factor H compete with factor B for 
binding  to  C3b  to  prevent  C3  convertase  formation,  or  displace  factor  B  from  the 
formed alternative pathway C3 convertase.  CR1 and CD55 have the same effect on C2 
binding to C4b in the classical or lectin pathway C3  convertase.  CR1  and CD55 are 
found on host cell surfaces, and factor H has a higher affinity for C3b when it is bound 
to host cells.
665.  Inhibition of the MAC formation
CD59, or protectin, is widely distributed on host cells and prevents the binding of C9 
to the C5b,6,7,8 complex.
1.9.1.5 Complement receptors
There  are  five  known  receptors  for fragments of the complement component 
C3 (Holers et al.,  1992; Leslie, 2001; Roozendaal and Carroll, 2006): CR1, CR2, CR3, 
CR4 and the newly discovered CRIg (Helmy et al., 2006).  The major characteristics of 
CRM ,  the  best  studied  of the  complement receptors,  are  shown  in  Table  1.1.  An 
overview of the characteristics and function of CRM  is given below.
RECEPTOR SIZE
(kDa)
PROTEIN
FAMILY
LIGANDS CELLULAR
EXPRESSION
CR1  (CD35) 290, 
250 or 
210
Regulators
of
complement
activation
C3b, C4b, iC3b Erythrocytes, 
monocytes/macrophages, 
neutrophils, eosinophils, 
basophils, NK cells, B cells, 
T cells, dendritic cells, 
FDCs, astrocytes, epithelial 
cells.
CR2 (CD21) 145 Regulators
of
complement
activation
iC3b, C3dg,
C3d
EBV gp3 50/220
CD23
IFN-a
B cells, FDCs, astrocytes, T 
cell subsets, epithelial cells.
CR3
(CD 1  lb/CD 18)
165/95 (32 integrin iC3b, C3b, 
C3dg
Monocytes/macrophages, 
dendritic cells, neutrophils, 
eosinophils, basophils, NK 
cells, microglial cells, 
platelets, FDCs.
CR4
(CD 11 c/CD 18)
150/95 (32 integrin iC3b Monocytes/macrophages, 
neutrophils, eosinophils, 
basophils, NK cells, 
microglial cells, platelets.
Table 1.1  Major characteristics of the four C3 fragment receptors
671.9.1.5.1 Complement receptor 1
CR1  is  a  type  I  transmembrane  protein  from  the  regulators  of complement 
activation (RCA) protein family.  It occurs in several allelic forms of 210, 250 and 290 
kDa.  The largest isoform of CR1  consists of 30 short consensus repeats (SCRs), each 
of 60-65 aa, a transmembrane region and a short cytoplasmic tail.  CR1 is expressed on 
most  blood  cells,  including  erythrocytes,  monocytes/macrophages,  neutrophils, 
eosinophils, basophils, NK cells, B cells and some T cells (Stoiber et al., 2005).  The 
highest affinity ligands for CR1 are C3b and C4b, with lower affinity binding of iC3b. 
CR1 can act as a receptor for antigen bound by these fragments, and through the action 
of CR1  erythrocytes play a major role in clearance of soluble immune complexes from 
the  circulation.  Furthermore,  CR1  has  cofactor  activity  for  factor  I-mediated 
degradation of C3b to iC3b, iC3b to C3c and C3dg, and C4b to C4c and C4d (Leslie, 
2001;  Speth  et  al.,  1997)  as  described  in  section  1.9.1.4.  CR1  also  has  decay- 
accelerating activity for the C3 convertases.  It prevents the binding of factor B to, or 
accelerates  the  removal  of Bb  from,  C3b  in  the  alternative  pathway;  likewise,  it 
prevents the binding of C2 to, or accelerates the removal of C2a from, C4b.
1.9.1.5.2 Complement receptor 2
Like  CR1,  CR2  is  a  type  I  transmembrane  protein  from  the  RCA  protein 
family.  Two  isoforms  of the  protein  exist,  consisting  of  15  or  16  short  consensus 
repeats (SCRs) or complement control protein modules, a transmembrane domain and 
a  short  cytoplasmic  tail.  The  SCRs  are  each  60-70  aa  long  and  arranged  as  four 
homology groups of four, designated I-IV, ordered from the membrane distal end.  In 
humans,  CR2  is expressed mainly on mature B  cells,  but also on FDCs, thymocytes 
(Tsoukas and Lambris,  1988),  subsets of CD4 and CD8 T cells (Fischer et al.,  1991; 
Fischer et al.,  1999; June et al., 1992; Masilamani et al., 2002; Sauvageau et al., 1990), 
basophils, mast cells, astrocytes (Gasque et al., 1996), keratinocytes and epithelial cells 
(Holers, 2005; Speth et al.,  1997).  The long (16 SCRs) and short (15 SCRs) isoforms 
of CR2 are selectively expressed on FDCs and B cells, respectively (Liu et al.,  1997). 
The  biological  ligands  of CR2  are  C3dg,  C3d,  iC3b,  CD23,  IFN-a  and  the  EBV 
envelope proteins gp350/220 (Holers, 2005).  The binding site for iC3b, C3dg and C3d 
and gp350/220 of EBV is located in the most amino terminal two SCRs, in homology 
region I (Lowell et al.,  1989).  On B cells CR2 forms a co-receptor complex along with 
CD19 and CD81.  When the B cell receptor (BCR) is co-ligated with the co-receptor,
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augmented  by  1000-  to  10,000-fold  and  lowers  the  B  cell  activation  threshold. 
(Dempsey et al.,  1996).  On other cell types CR2 is expressed independently from the 
complex.
1.9.1.5.3 Complement receptor 3
The  p2  integrin CR3  (CD1 lb/CD 18,  Mac-1)  is a heterodimeric adhesion and 
recognition receptor.  It consists of two glycoprotein subunits:  the  165 kDa a chain, 
CD1 lb, and the 95 kDa p chain, CD 18, also shared by CR4 (CD11  c/CD 18) and LFA-1 
(CDlla/CD18;  Leslie,  2001;  Speth et al.,  1997).  CR3  recognises a wide variety of 
ligands  including LPS and ICAM-1, but in the context of the complement system its 
most important interaction is with iC3b (Ehlers, 2000).  It also has low affinity for C3b 
and C3dg (Stoiber et al.,  2005).  Activation of CR3  on monocytes/macrophages and 
neutrophils  results  in  phagocytosis  and therefore  clearance  of iC3b-bound  antigens. 
CR3  is the  primary complement receptor on neutrophils and monocytes,  and  is also 
expressed on eosinophils, basophils, NK cells, platelets and FDCs.
1.9.1.5.4 Complement receptor 4
CR4,  also a  P2  integrin,  is  similar  in  structure  and  function to CR3.  The  P 
subunit of CR4, CD18, is shared with CR3, and its 150 kDa a subunit, CD1 lc, shares 
63%  sequence  homology  with  the  a subunit of CR3,  CDllb.  CR4  is  found  on the 
same cell types are CR3, with the exception of FDCs and DCs.
1.9.2  Interaction of HIV and complement
Many  viruses  have  evolved  mechanisms  to  evade  the  deleterious  effects  of 
complement, and in some cases to further subvert the complement system to their own 
advantage  (Blue  et  al.,  2004).  The  mechanisms  of  interaction  of  HIV  with 
complement and consequences thereof are described below.
1.9.2.1  Complement activation by HIV
HIV  activates  the  complement  cascade  by  both  antibody-dependent  and  - 
independent  pathways  (Gregersen  et  al.,  1990;  Robinson  et  al.,  1991;  Spear  et  al., 
1990;  Spear et al.,  1993).  The antibody-independent pathway involves direct binding 
of Clq to several regions on gp41  (Ebenbichler et al.,  1991; Marschang et al.,  1997;
69Stoiber et al.,  1994; Thielens et al.,  1993) and gpl20 (Prohaszka et al.,  1995; Susal et 
al.,  1994;  Susal  et  al.,  1996),  triggering the classical  complement pathway,  and the 
binding of MBL to carbohydrate moieties on gpl20 (Haurum et al.,  1993; Susal et al., 
1994),  triggering  the  MBL  complement  activation  pathway.  Direct  activation  of 
complement is important in early stages of infection prior to the generation of HIV- 
specific antibodies (Stoiber et al., 2005).  During and following seroconversion, HIV- 
specific  complement-activating antibodies  are  generated.  Bound  antibodies amplify 
the activation of complement and the deposition of complement fragments on the viral 
surface (Hidvegi et al.,  1993;  Saarloos et al.,  1995;  Spear et al.,  1993;  Stoiber et al., 
2001;  Thieblemont  et  al.,  1993b).  Antibody-dependent  complement  activation  was 
shown  to  be  significantly  more  efficacious  than  antibody-independent  complement 
activation,  as determined by a  10-20-fold increase in C3  deposition on HIV-infected 
cells (Saarloos et al.,  1995).  Specificities of anti-HIV antibodies capable of activating 
complement include the V3  loop of gpl20 (Spear et al.,  1994) and gp41  (Robinson et 
al.,  1991).
1.9.2.2  Lysis of HIV by complement
Several  papers  have  documented  the  inactivation  of HIV  by  antibodies  and 
complement.  Whether this leads to direct lysis of the virions remains to be definitively 
shown.  A recent paper by Huber and colleagues, detailing a freeze-thaw assay for the 
measurement of complement-mediated lysis,  showed that antibodies in the plasma of 
infected  individuals  could  mediate  lysis  of  autologous  virus  in  concert  with 
complement  (Huber  et  al.,  2006).  Sullivan  et  al  also  showed  direct  complement- 
mediated lysis of 14-86% of HIV isolated from patient plasma (Sullivan et al.,  1996). 
However, neither of these studies demonstrated a direct relationship between lysis of 
virions and a subsequent decrease in infectivity of these virus preparations, so it cannot 
be  ruled  out  that  lysed  virions  form  part  of the  uninfectious  portion  of HIV  virus 
preparations.  Aasa-Chapman et al addressed both issues: complement-mediated HIV 
inactivation and lysis, and subsequent infectivity, and found that, although complement 
increased the  inactivation  of patient-derived  viruses  by  early  autologous  antibodies, 
lysis accounted for only a small proportion of this inactivation (Aasa-Chapman et al.,
2005).
701.9.2.3 HIV complement evasion strategies
The cell type used to produce HIV has bearings on susceptibility of the virus to 
lysis.  A large body of evidence suggests that primary isolates of HIV are intrinsically 
resistant to complement-mediated lysis through a variety of mechanisms (Gregersen et 
al.,  1990; Saifuddin et al.,  1997; Saifuddin et al.,  1995; Stoiber et al.,  1996; Stoiber et 
al.,  2005).  As the virus buds from the cell surface, host cell membrane proteins are 
incorporated  into  the  viral  membrane.  Complement  regulatory  proteins  are  among 
these  proteins,  with  CD55,  CD59  and  CD46  well  characterised  in  their association 
with  HIV  virions  (Marschang  et  al.,  1995;  Saifuddin  et  al.,  1997;  Saifuddin  et  al., 
1995;  Stoiber et al.,  1996).  Blocking CD55  and CD59 on HIV virions with specific 
antibodies increased the sensivity of virions to complement-mediated lysis (Marschang 
et al.,  1995; Saifuddin et al., 1995).  In addition to this, the soluble protein factor H can 
bind directly to gp41  and gpl20 (Pinter et al.,  1995; Stoiber et al.,  1995) and has been 
suggested to play a role in HIV resistance to C’-ML (Stoiber et al.,  1996).  This would 
also promote the degradation of C3b deposited on HIV to the inactive form iC3b via 
factor I, and likewise from iC3b to C3dg.  MCP incorporated into the viral membrane 
can  also  act as  a cofactor for factor I.  These  strategies mean that the terminal  lysis 
activity of complement is for the most part inhibited, yet opsonisation still occurs -  a 
process that many researchers have proposed may have benefits for HIV, as described 
in 1.9.2.4.
1.9.2.4 Outcomes of HIV opsonisation by complement
In the absence of lysis, the opsonisation of HIV and subsequent binding of HIV 
immune  complexes  to  complement  receptors  can  have  several  possible  outcomes 
(Speth  et  al.,  1997).  It  may  be  of benefit to  the  immune  system  by  assisting viral 
clearance through phagocytosis and destruction of immune complexes.  Alternatively, 
it could benefit the virus and facilitate infection,  dissemination and establishment of 
viral  reservoirs (reviewed by Banki et al.,  2005b;  Stoiber et al.,  2001;  Stoiber et al.,
2005).  Of particular importance is the role of complement in the trapping of viruses on 
the FDC network in lymph node germinal centres (GC; Banki et al., 2005a; Burton et 
al., 2002; Kacani et al., 2000).  Binding of antibody and complement-opsonised HIV to 
CR2 is considered the major mechanism of FDC trapping (Joling et al.,  1993; Kacani 
et al., 2000).  Virus retained in this way, rather than being neutralised and subsequently 
destroyed, remains infectious for months and provides an infectious reservoir for GC-
71resident  T  cells  and  other  target  cells  passing  through  the  GC.  Complement  and 
antibody-mediated binding of HIV to FDCs also appears to confer a significant degree 
of neutralisation resistance on the virus (Heath et al.,  1995).
An extension to the scenario of CR-mediated trapping of HIV is CR-mediated 
trans-infection.  Complement-opsonised HIV bound to cells such as DCs and B cells 
may promote the infection of susceptible target cells through cell-cell interactions.  In 
this way, productive infection may be more efficient than cell-free virus alone.  DCs 
express CR3 and CR4 (De Panfilis et al., 1989), and CR3 has been shown to contribute 
to the DC-SIGN-mediated mechanism of trans-infection (Bouhlal et al., 2007).  B cells 
express  CR1  and  CR2  and  have  been  shown  to  mediate  /ram-infection  of T  cells 
(Doepper et al., 2000; Dopper et al., 2003; Jakubik et al.,  1999; Moir et al., 2000).  In 
addition,  erythrocytes  express  CR1  and  tightly  bind  HIV  via  complement  in  the 
presence and absence of antibody (Montefiori et al.,  1994).  They transport immune 
complexes to the liver and spleen for destruction by phagocytic cells, and may promote 
the infection of susceptible cells in these organs (Stoiber et al., 2005).  B cells are also 
vulnerable to CR-mediated infection (Boyer et al.,  1992; Gras et al., 1993; Legendre et 
al.,  1996),  a  process  that  has  been  classified  as  a  form  of ADE,  but  it  is  unclear 
whether this makes a major contribution to pathogenesis in vivo.
In  tissues,  such  as  the  brain,  positive  feedback  loops  drive  complement 
production.  Activation of complement and the binding of immune complexes to cells 
with complement receptors can lead to activation of these cells, and a further increase 
in  local  complement  synthesis  (Morgan  and  Gasque,  1997).  This  allows  for 
complement-mediated  entry of HIV  into, or binding of HIV onto,  cell  types such as 
astrocytes in the brain, and also contributes to neurological damage (Depboylu et al., 
2005;  Speth  et  al.,  2002;  Speth et al.,  2001).  Microglial  cells are the main cellular 
target for HIV infection in the brain and have been shown to express CR3 (Hassan et 
al.,  1991) whereas astrocytes express CR1 and CR2 (Gasque et al.,  1996).
Of all the forms of subversion of the complement system by HIV, C’-ADE of 
HIV infection is perhaps the most extreme.  The presence of complement and antibody 
promote  levels  of  infection  higher  than  in  the  absence  of opsonisation.  This  is 
discussed in detail in the next section.
721.10  ANTIBODY-DEPENDENT ENHANCEMENT OF VIRAL 
INFECTION
1.10.1  History and significance
Antibody-dependent  enhancement  (ADE)  of  virus  infection  (reviewed  by 
Morens,  1994; Sullivan, 2001; Takada and Kawaoka, 2003; Tirado and Yoon, 2003) is 
a phenomenon in which virus-specific antibodies enhance the entry or replication of a 
virus, leading to increased infection and the potential to exacerbate disease progression 
or severity.  It was first described in the  1960s (Hawkes,  1964), and was later given 
clinical  relevance  through  epidemiological  studies  of dengue  disease  enhancement 
(Halstead  et  al.,  1970;  Halstead  and  O'Rourke,  1977a).  Severe  manifestations  of 
dengue  disease  take  the  form  of  dengue  haemorrhagic  fever  and  dengue  shock 
syndrome  (DHF/DSS).  Immune  enhancement  was  investigated  as  a  contributory 
factor to DHF/DSS as a result of two epidemiological observations.  It was noted that 
DHF/DSS  occurred  mostly  upon  secondary  infection  with  a  viral  serotype  distinct 
from that of the  primary  infection (Russell  et al.,  1967), with the biggest risk factor 
being  secondary  infection  with  dengue  serotype  2  (DEN-2;  Halstead  et  al.,  1970; 
Russell  et  al.,  1967;  Sangkawibha  et  al.,  1984).  More  striking  was  the  bimodal 
incidence curve  in children.  Peak incidences for DHF/DSS occurred first between 5 
and  10 months and later between 3 and 5 years.  Severe disease in the first age group 
coincides with the decline of maternally-acquired antibody titre (Halstead et al.,  1969). 
Severe  disease  in  the  second  age  group  coincides  with  the  earliest  age  at  which 
secondary infection can occur.  Both situations pointed towards a role for low levels of 
anti-dengue  antibodies  in  pathogenesis,  and  lead  to  the  development  of the  ADE 
hypothesis (Halstead and O'Rourke,  1977a; Halstead and O'Rourke, 1977b; Halstead et 
al.,  1977).
Aside from disease enhancement in natural  infection, ADE can also be a risk 
factor  for  disease  exacerbation  and/or  increased  chance  of  infection  following 
vaccination.  ADE has been retrospectively implicated in vaccinations that resulted in 
enhanced disease severity (Morens,  1994), such as RSV (Chin et al.,  1969; Kim et al., 
1969;  Prince  et  al.,  1986),  measles  and  even  rabies  (Morens,  1994),  although 
experimental  data  directly  supporting  these  claims  is  lacking.  ADE  has  also  been 
implicated in the enhanced disease states observed after lentiviral vaccine trials carried 
out on equine infectious anaemia virus (EIAV; Raabe et al.,  1999; Wang et al.,  1994), 
caprine  arthritis  encephalitis virus  (Jolly et al.,  1989;  Jolly and Narayan,  1989) and
73feline  immunodeficiency  virus  (FIV;  Siebelink  et  al.,  1995);  therefore  it  will  be 
important  to  ascertain  whether  enveloped-based  vaccines  against  HIV,  also  a 
lentivirus, might have a similar effect.
However,  even  when  substantial  evidence  points  towards  ADE  as  a  major 
factor  in  exacerbated  disease in vivo  (Halstead et al.,  1970;  Montefiori  et al.,  1990; 
Ponnuraj et al., 2003; Siebelink et al.,  1995; Wang et al.,  1994), it cannot be ruled out 
that other immunopathogenic phenomena are playing a role, such as profound T cell 
activation and death (Mongkolsapaya et al.,  2003) or a bias towards a TH 2 response 
(Openshaw et al.,  2001).  Clearly, enhanced disease is often a multifactorial process. 
Consequently,  corroborating  in vivo effect with evidence of in vitro enhancement is 
difficult.  Reports have shown in vitro ADE of a wide variety of viruses; Ross River 
virus (RRV), Rift Valley fever virus (RVFV), simian immunodeficiency virus (SIV), 
ebola virus, feline infectious peritonitis virus (FIPV), rabies and coxsackie virus being 
but a few examples (reviewed by Morens, 1994; Sullivan, 2001; Takada and Kawaoka, 
2003;  Tirado  and  Yoon,  2003).  ADE  of HIV  has  been  studied  extensively  but 
somewhat inconclusively due to conflicting observations in the literature, as discussed 
below.
1.10.2  Mechanisms of enhancement
In terms of virus-cell interactions, there are several ways in which enhancement 
could occur.  The simplest model is the binding of enhancing antibody-opsonised, or 
enhancing  antibody  and  complement-opsonised,  virus  to  FcRs  or  CRs,  increasing 
virus-cell  contact  and  facilitating  the  engagement  of  envelope  proteins  with  the 
primary  virus  receptors.  With  regards  to  HIV,  as  the  CD4-gpl20  interaction  is 
considered the rate-limiting step of HIV entry (O'Doherty et al., 2000; Ugolini et al., 
1999),  it is thought that the virus makes use of a range of attachment receptors on the 
cell  surface to  increase concentrations of cell-associated virus and therefore  increase 
the probability of CD4 engagement.  ADE of HIV can achieve this aim, but may also 
have  other effects on HIV entry and replication.  Ligation of receptors by enhancing 
antibody could trigger endocytosis of the virus, or signal through the receptor to alter 
cellular  conditions  in  favour  of virus  replication.  In  some  cases  ADE  may  occur 
independently  of cellular  receptors  by  altering  the  conformation  of the  viral  entry 
proteins.  The  main  mechanisms  of  ADE  are  described  below,  with  additional 
information  regarding  the  specifics  of these  mechanisms  for  HIV  where  relevant.
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and 6.
1.10.2.1 FcR-ADE
FcR-mediated  ADE  (FcR-ADE)  was  the  first  mechanism  of  ADE  to  be 
elucidated  (Halstead  and  O'Rourke,  1977a;  Halstead  and  O'Rourke,  1977b)  and 
remains  the  most  commonly observed  form  of ADE,  having been  demonstrated  for 
dengue virus, West Nile virus (Peiris et al.,  1981; Peiris and Porterfield,  1979), yellow 
fever virus (Schlesinger and Brandriss,  1981a; Schlesinger and Brandriss,  1981b) and 
measles virus (Iankov et al., 2006) among others.  Involvement of FcR-ADE might be 
also  inferred by observations of enhanced infection in the absence of complement in 
monocytes/macrophages,  without directly showing the  involvement of FcRs.  Studies 
of flavivirus FcR-ADE represent the classic model of FcR-ADE and are performed on 
macrophages, monocytes or macrophage-like cell lines, such as human U937 cells and 
mouse P388D1  cells.  Enhancement levels in these systems are generally in the range 
of 5- to 200-fold increases in infection compared to infection in the absence of virus- 
specific  antibody  (Halstead  and  O'Rourke,  1977a;  Peiris  et  al.,  1981;  Peiris  and 
Porterfield,  1979; Schlesinger and Brandriss,  1981a).
Receptor-blocking  experiments  have  demonstrated the  involvement of FcyRI 
(Homsy  et  al.,  1989;  Jouault et al.,  1991;  Laurence et al.,  1990;  Pemo et al.,  1990; 
Takeda et al.,  1990), FcyRII (Laurence et al.,  1990), and FcyRIII (Homsy et al., 1989), 
and also the IgA receptor FcaR (Kozlowski et al.,  1995) in ADE of HIV infection.
1.10.2.2 C’-ADE
Complement-mediated ADE  (C’-ADE) is mediated by CRs on the target cell. 
As with FcR-ADE,  it was first observed for a flavivirus, being described by Cardosa 
in  1983,  who  showed  CR3-mediated  C’-ADE  of  West  Nile  virus  by  IgM  and 
complement  (Cardosa  et  al.,  1983).  C’-ADE  is  usually  characterised  by  the 
requirement  of fresh,  non-heat-inactivated  supplementary  serum  in  the  assay,  with 
generally lower levels of enhancement than those seen for classic FcR-ADE.
Most  information  regarding  C’-ADE  has  come  from  studies  of  HIV,  first 
observed  by  Robinson  and  colleagues  (Robinson  et  al.,  1988a)  and  subsequently 
investigated in detail by the same group (Robinson et al.,  1991; Robinson et al., 1990a; 
Robinson  et  al.,  1990b;  Robinson  and  Mitchell,  1990;  Robinson  et  al.,  1989a;
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others  (Delibrias et al.,  1993;  June et al.,  1991;  Lund  et al.,  1995;  Prohaszka et al., 
1997; Reisinger et al.,  1990; Szabo et al.,  1999).  It was found that cells with a high 
level  of CD4 and CR2 (MT-2 cells) supported C’-ADE, whereas cells with CD4 but 
low  or undetectable  CRs  (H9,  CEM,  C3  and  U937  cells)  did  not  (Robinson  et  al., 
1989a).  The dependence of C’-ADE on CD4 and CR2 was subsequently confirmed 
with  blocking antibodies to these  receptors  on  MT-2  cells  (Robinson et al.,  1990c). 
CR1  (Delibrias et al.,  1993; Delibrias et al.,  1994; Gras and Dormont,  1991) and CR3 
(Reisinger et al.,  1990)  have also been  implicated  in C’-ADE of HIV infection, and 
more recently ClqRs have been shown to play a role in C’-ADE of HIV (Prohaszka et 
al.,  1997) and Ebola virus infection (Takada et al., 2003).
Besides T cells, C’-ADE has also been shown to occur in syncytiotrophoblasts 
(Toth et al.,  1994), B cells (Boyer et al.,  1992; Gras et al.,  1993; Gras and Dormont, 
1991; Legendre et al.,  1996; Tremblay et al., 1990), thymocytes (Delibrias et al., 1994) 
and  epithelial  cells  (Bouhlal  et  al.,  2002).  Importantly,  C’-ADE  of  infection  of 
primary cells has been demonstrated, with CR1  and CR3 mediating CD4-independent 
C’-ADE  of monocytes  (Thieblemont  et  al.,  1993a)  and  CR3  mediating  C’-ADE  of 
DCs (Bajtay et al., 2004).
Existing  evidence  suggests  that  increased  adhesion  to  the  target  cell  is  the 
principal mechanism of C’-ADE (June et al.,  1991; Lund et al.,  1995; Robinson, 2006) 
but  this  has  not  been  exclusively  proven  and  other  mechanisms  involving  receptor 
signalling may play a role.
Enhancement  of  HIV  can  also  be  mediated  by  complement  alone,  in  the 
absence  of antibodies,  although this  is weaker than  enhancement  in the presence of 
antibodies  (Sullivan,  2001).  It  is  also  possible  that  unopsonised  HIV  can  interact 
directly with complement receptors as interactions between gp41  and CR3 have been 
demonstrated in vitro (Stoiber et al.,  1997).
1.10.2.3  ADE through alteration of cellular processes
The alteration of cellular processes through ADE could be considered a subset 
of C’-ADE  or  FcR-ADE,  as  the  same  receptors  are  involved  but  the  downstream 
mechanisms differ.  Studies of enhanced RRV infection in macrophages delineated a 
novel ADE mechanism: FcR-mediated suppression of intracellular antiviral responses. 
Instead of the  inhibition of RRV production  in macrophages caused by LPS-induced
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specific antibodies.  This was shown to be due ADE-infection specific suppression of 
tumour  necrosis  factor  (TNF)  a  and  inducible  nitric  oxide  synthase  (NOS2)  genes 
(Lidbury and Mahalingam, 2000).
In HIV infection there is evidence to suggest that CR-mediated cell activation 
provides  a  favourable  environment  for  HIV  replication  (Speth  et  al.,  1997). 
Engagement of CRs on infected cells, or during the process of enhanced infection, may 
increase viral replication.  This was shown for infected CD4+ T cells by CR1  ligation 
(Mouhoub et al.,  1996) and monocytic cells via CR1 and CR3 ligation (Thieblemont et 
al.,  1995).  In the  latter study,  enhanced p24 antigen production was associated with 
NF-kB  nuclear  translocation,  triggered  by  the  activation  of  CR1  and  CR3 
(Thieblemont et al.,  1995).
While these experiments used CR-specific monoclonal antibodies to stimulate 
the  receptors,  it  is  conceivable that antibody and  complement-opsonised virus could 
mediate the same effect, either by signalling in cis during entry or signalling by cell- 
free virus in  infected cells in trans.  In vivo, a state of generalised immune activation 
characterises  chronic  HIV  infection  and  this  is  thought  to  favour  virus  production 
through providing more activated target cells for infection.  Ligation of CRs by HIV 
immune complexes may contribute to this, either directly via CRs on T cells, DCs and 
macrophages  (Delibrias  et  al.,  1992),  or  indirectly  through  cytokine  production  by 
activated B cells (Arvieux et al.,  1988).
1.10.2.4  Receptor-independent ADE
More recent studies of ADE of HIV have focused on enhanced infection via 
antibody-mediated modulation of the viral envelope conformation (non-FcR, non-C’- 
ADE)  as  determined  by  studies  on  cell  lines  lacking  FcRs,  in  the  absence  of 
complement and also using Fab antibody fragments (Guillon et al., 2002; Schutten et 
al.,  1997; Sullivan et al.,  1995). This appears to be more dependent on viral strain than 
on  specific  antibody  epitopes,  and  it  is  thought  that  the  antibodies  mediating  the 
enhancement  mimic  the  viral  receptors,  precipitating  conformational  changes  and 
thereby increasing entry efficiency.
771.10.2.5  Characteristics of enhancing antibodies
The original model of ADE, developed for dengue virus enhancement, involves 
neutralising antibodies at sub-neutralising concentrations.  This model applies to many 
examples  of  ADE,  with  neutralising  antibody  titration  experiments  showing  the 
biphasic  curves  that have  come  to  characterise classical  dengue  virus enhancement: 
neutralisation  occurring at high  concentrations  of antibody and  enhancement at  low 
concentrations.  Studies of monoclonal neutralising antibodies to WNV showed that 
neutralisation and ADE were functions of antibody occupancy; infection enhancement 
occurred  when  the  virus  was  bound  by  antibody  with  a  stoichiometry that was  no 
longer sufficient for neutralisation (Oliphant et al., 2006; Pierson et al., 2007).
An  alternative  to  sub-neutralising  concentrations  of  neutralising  antibodies 
involves  high  concentrations  of  antibodies  that  bind  to  non-neutralising  epitopes. 
Again,  with  reference  to  dengue  virus,  this  may  apply to  ADE  by heterotypic  non­
neutralising  serum,  and  in  this  case  ADE  can  occur  at  high  serum  concentrations 
(Halstead and O'Rourke,  1977a; Halstead and O'Rourke,  1977b).  This scenario could 
also  lead to  a biphasic titration curve when serum  is used,  reflecting the balance of 
neutralising  and  enhancing  antibodies:  neutralising  antibodies  dominate  at  high 
concentrations, but as these are diluted out, enhancing antibodies dominate.
Evidence  exists  to  suggest  that  HIV-enhancing  antibodies  differ  from 
neutralising antibodies.  First indications of this were shown in  1988, when Robinson 
and  colleagues  showed that when HIV  seropositive  sera were  applied to  an affinity 
column containing a recombinant fragment of Env (the 20 C-terminal aa from gpl20 
and the N-terminal two thirds of gp41, produced in E.  coli) the fraction that bound to 
the  column  was  enhancing,  while  the  flow-through  neutralised  (Robinson  et  al., 
1988a).  Subsequent  experiments  defined  an  antibody-enhancing  epitope  on  gp41, 
located at aa579-613 of the immunodominant cluster I (Mitchell et al., 1998; Robinson 
et  al.,  1991;  Robinson  et  al.,  1990a;  Robinson  et  al.,  1990b).  A  second,  minor 
antibody-enhancing  epitope  was  mapped  to  aa  644-663  on  gp41  (Robinson  et  al., 
1991).
Other  studies  suggested  that  certain  virus  strains  are  more  susceptible  to 
enhancement than others.  One  study mapped the ability of V3-specific monoclonal 
antibodies to enhance infection of three strains of HIV: a difference of one amino acid 
in  the  antibody-binding  epitope  was  sufficient  to  determine  whether  the  virus  was 
enhanced,  neutralised  or unaffected  (Kliks  et  al.,  1993).  In  a  study  investigating a
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infected  individuals,  the  significant  proportion  of  combinations  resulting  in 
enhancement of infection rather than neutralisation (28%) was associated more with 
certain viral isolates rather than certain sera (Kostrikis et al.,  1996).
1.10.3  Measuring ADE
The choice of how to study ADE is more complicated than for neutralisation, 
as in addition to the virus-antibody interactions, the interaction of the immune complex 
with the target cell is a key determinant of assay outcome and adds a further layer of 
complexity.  The  issues  associated  with  development  of an  enhancement assay  are 
highlighted by Raabe and colleagues (Raabe et al.,  1999).  The target cell type, virus 
strain,  antibody  source  and  concentration,  MOI,  method  of measuring  infectivity 
levels, and the method of presenting enhancement data may all influence the outcome 
of the assay, and possibly account for differences seen between research groups (Raabe 
et al.,  1999).
There  are  several  ways  in  which  results  from  enhancement  assays  may  be 
presented:
1.  Fold enhancement: the ratio of infection in the presence of virus-specific antibody 
to infection in the absence of virus-specific antibody.
2.  Endpoint titre:  the highest dilution of antibody at which enhancement is seen.
3.  Peak titre:  the dilution of antibody at which enhancement is greatest.
For  most  studies  of classic  flavivirus  enhancement,  the  standard  format  for 
reporting  results  of enhancement  experiments  is  fold  enhancement,  with  additional 
information about antibody titres provided, as initiated by Halstead in  1977 (Halstead 
and  O'Rourke,  1977a).  For  studies  of  HIV  enhancement,  the  methodology  of 
measuring enhancement of infection and presenting data varies between reports.  For 
example, some measure CPE and define enhancement as anything greater than a 1   SD 
increase  (Robinson  et  al.,  1988a),  or  50%  increase,  in  CPE  relative  to  the  control 
culture and present results as endpoint titres (McDougall et al.,  1997; Robinson et al., 
1990c);  others  measure  viral  production,  usually  by  RT ELISA,  and  present results 
either as fold enhancement (Banhegyi et al., 2003; Kozlowski et al.,  1995; Lund et al., 
1995; Montefiori et al.,  1995; Prohaszka et al.,  1997; Szabo et al., 1999) or as endpoint 
titres  derived  from  a  cut-off value  of at  least  2-  or  3-fold  increases  in  infection 
(Homsy,  1988;  Homsy et al.,  1990).  Given that antibody titrations  in enhancement
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and enhancement occurring at high dilutions, and that increases in infection could be 
anything  between  1.5-  and  1000-fold,  it  seems  logical  to  present  both  the  fold 
enhancement and dilution of antibody at which this occurs (Montefiori et al., 1995).  In 
addition,  it  may  be  more  physiologically  relevant to  assay  sera  at  low,  rather than 
excessive, dilutions in order to determine the dominant antibody activity.
The most reproducible data to emerge on ADE of HIV has been carried out on 
cell lines such as MT-2, MT-4 and U937 cells.  However, in the past this has restricted 
researchers to the study of X4-tropic TCLA strains of HIV, which are now known to 
bear less relevance to primary isolates than was previously thought.  Several important 
studies  have  shown the  capacity of primary cells to  support enhanced  infection,  yet 
donor  variability  is  a  recognised  complication  associated  with  macrophage 
experiments, and the methods necessary for preparation of primary target cells do not 
make for a quick, reproducible assay for ADE.
801.11 Scope of this thesis
The drawback of the enhancement assays currently or previously used to study 
ADE  of HIV  is  either that T cell  lines  are used,  limiting  study to  TCLA  X4  virus 
strains, or that primary cells are used, often incurring problems due to donor variability 
or  time-consuming  methods  of primary  cell  preparation.  This  thesis  describes  the 
development  of a  reproducible,  inexpensive  and  modem  enhancement assay for the 
study of both R5 and X4 virus strains (Chapter 3).
The majority of studies investigating ADE of HIV  infection have focused on 
sera from  individuals at chronic or AIDS stages of disease.  Few have addressed the 
potential for antibodies produced soon after infection with HIV to enhance infection, 
during  which  time  the  antibodies  are  non-neutralising.  None  have  addressed  the 
possibility that these early antibodies may enhance early autologous vims.  In Chapter 
4 of this thesis, the enhancement assay developed in Chapter 3 was used to investigate 
C’-ADE of early primary virus isolates by autologous sera.  Sequential serum samples 
from  individuals  recently  infected  with  HIV  were tested  against autologous  viruses 
isolated  at  early  and  late  time  points  after  infection.  The  relationship  between 
neutralisation  and  C’-ADE  was  investigated,  with  competition  studies  showing 
neutralisation to be the dominant response.
In  Chapter  5,  the  enhancement  assay  was  used  to  investigate  C’-ADE  in 
individuals  vaccinated  with  an  experimental  gpl20  subunit  vaccine.  C’-ADE, 
complement-mediated  inactivation  (C’-MI)  and  complement-mediated  rescue  from 
neutralisation (C’-RN) were also investigated, and it was shown that, depending on the 
assay and virus strain used, different antibody activities could be observed in the same 
vaccinee serum sample.
In Chapter 6 the mechanism of the C’-ADE and C’-RN shown in Chapters 3, 4 
and 5 was investigated.  CR2 was cloned from SupTl/R5 cells and stably expressed on 
NP2 cells, and conferred the capacity to support enhanced infection onto these cells.  A 
CR2  cytoplasmic tail  mutant tested  in parallel showed that signalling ability of CR2 
was not essential for enhanced infection, suggesting that the major mechanism of CR2- 
mediated C’-ADE is increased attachment to the target cell.
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Materials and Methods
2.1  BUFFERS AND SOLUTIONS
FACS  1% FCS (v/v); 0.1% azide in PBS
Formol saline  3.8% formaldehyde in PBS
LB broth  1%  tryptone; 0.5% yeast extract; 0.5% NaCl
PBS  137 mM NaCl; 3 mM KC1; 10 mM Na2HP04;  2mM K2HP04
pH 7.4
PERM  1% saponin (w/v) in FACS buffer
SOC medium  2% tryptone; 0.5% yeast extract; 10 mM NaCl; 2.5  mM KC1;
10 mM MgCl2; 10 mM MgS04; 20 mM glucose 
TAE  40 mM Tris-HCl pH 7.8; 20mM sodium acetate;  1  mM EDTA
TBS  20 mM Tris-HCl pH 7.6; 120 mM NaCl
TBS-T  TBS containing 0.05% Tween 20
T/V  0.5% trypsin and 0.02% versene (v/v) in PBS
2.2  CELL CULTURE
2.2.1  Human cell lines
The cell lines used in this study are detailed in Table 2.1.
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ADHERENT
or
SUSPENSION
CELL TYPE REFERENCE
H9 S
Human cutaneous T cell 
lymphoma
(Mann et al.,  1989)
MT-2 S
Human T cell leukaemia 
(transformed with HTLV)
(Harada et al., 
1985; Miyoshi et 
al.,  1981)
MT-4 S
Human T cell leukaemia 
(transformed with HTLV)
(Harada et al., 
1985; Miyoshi et 
al.,  1981)
Molt-4 S Human T cell leukaemia
(Kikukawa et al., 
1986)
C8166 S
Human T cell leukaemia 
(transformed with HTLV)
(Salahuddin et al., 
1983)
SupTl S
Human T cell lymphoma 
(non-Hodgkin’s)
(Smith et al., 1984)
SupTl/R5 s
As with SupTl but 
transduced to express 
CCR5
From Dr James 
Hoxie
NP2/CD4/R5
NP2/CD4/X4
A
Human glioma 
(transduced to express 
CD4, CCR5 and/or 
CXCR5
(Soda et al.,  1999)
293T A
Human embryonic kidney 
(expressing the SV40 T 
Ag)
(Graham et al., 
1977)
Table 2.1 Cell lines
2.2.2  Maintenance of cell lines
Adherent cell lines were maintained in Dulbecco’s modified Eagle medium (D- 
MEM;  Invitrogen,  UK)  supplemented  with  5%  heat  inactivated  (56°C  for  1   hour) 
foetal calf serum (FCS; Helena Biosciences).  Suspension cell lines were maintained in
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supplemented  with  1   pg/ml  puromycin  (Sigma  Biochemicals).  All  cells  were 
incubated at 37°C in a humidified atmosphere with 5% CO2.  Cell lines were split once 
every 3-5 days at ratios of 1:3 to  1:20 as required.  For adherent cell lines, media was 
removed by aspiration and cells were washed once with 5 ml PBS before adding  1-2 
ml  of T/V and  incubating at 37°C  for 5  minutes or until the cells detached from the 
flask.  5  ml  of fresh culture medium was added to  inactivate the T/V,  and the cells 
were diluted as necessary and replenished with fresh culture medium.  Suspension cells 
were split as required, centrifuged at 325 g for 5 minutes to pellet, and resuspended in 
fresh culture medium.
2.2.3 Freezing cells
Cells  were  pelleted  by centrifugation  for 5  min at 325 g and resuspended  in 
FCS containing 10% dimethyl sulphoxide (DMSO; v/v; Sigma, UK) at a density of 107 
cells/ml.  1   ml aliquots were immediately dispensed into cryotubes (Nunc), wrapped 
individually  in  paper,  placed  in  a  polystyrene  box  and  slowly  frozen  at  -80°C 
overnight  before  transferring  to  the  vapour  phase  of liquid  nitrogen  for  long-term 
storage.
2.2.4 Thawing cells
Cryotubes containing cells were removed from liquid nitrogen and thawed in a 
37°C water bath before adding  10 ml of fresh culture medium and pelleting at 325 g 
for 5 minutes.  Cells were resuspended in 10 ml fresh culture medium, transferred to a 
25  cm2 tissue  culture  flask (Helena Biosciences) and maintained as  in  section 2.2.2 
until required.
2.2.5 Transfection of 293T cells
293T cells were used for the production of lentiviral vectors via three-plasmid 
transfections  (section  2.11.1),  and  to  ensure  correct  expression  of CR2  and  KHR 
constructs  using single  plasmid transfections using FuGENE 6  (Roche Diagnostics), 
according to the manufacturer’s instructions.  Cells were plated in a 6-well plate one 
day  prior  to  transfection  at  a  density  of  4  x  105  cells  per  well,  resulting  in 
approximately  70-80%  confluence  on  the  day  of transfection.  Culture  medium  was 
changed before transfection.  For each well of the 6-well plate,  6 pi FuGENE 6 was
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mixed before adding 1   pg total DNA.  The transfection mixture was then incubated at 
room  temperature  for  15  minutes,  with  occasional  gentle  mixing,  before  adding  it 
dropwise to cells.  Medium was replaced after overnight incubation, and supernatant 
was harvested, or cells analysed by flow cytometry for receptor expression, 24 or 36 
hours later.
2.2.6 Preparation of peripheral blood mononuclear cells
PBMCs  were  prepared  from  fresh  blood,  processed  within  2  hours  of 
phlebotomy.  Blood  was  drawn  by  myself or  another  qualified  phlebotomist  from 
healthy  volunteers  using  S-Monovette  collection  tubes  containing  EDTA  (Sarstedt, 
Germany).  Anonymity  of  donors  was  maintained,  according  to  ethical  approval 
obtained from UCL Committee for the Ethics of non-NHS Human Research (project 
number 0335/001).
35 ml of blood, diluted  1:1  with PBS, was layered onto  15 ml of Lymphoprep 
(ficoll; Nycomed, Norway) in a 50 ml Falcon tube and centrifuged at 700 g (with the 
brake off) for 30 minutes at room temperature.  The PBMCs formed a white layer at 
the  interface  between  the  Lymphoprep  and  plasma/PBS,  and  this  was  carefully 
harvested  and  washed  once  with  PBS  and  once  with  RPMI  1640  at  325  g  for  10 
minutes.  The pelleted cells were resuspended at a density of approximately  1   x  106 
cells/ml  in  RPMI  containing  10%  FCS  and  0.5  pg/ml  phytohaemagglutinin  (PHA; 
Biostat,  UK)  and  grown  for 3  days.  Cells were then  pelleted  and  resuspended at a 
density of approximately  1   x  106 cells/ml in RPMI containing  10% FCS and 20 U/ml 
interleukin-2  (IL-2;  Roche,  Germany),  and  cultured  for  a  further  2-3  days  prior to 
infection.
2.2.7 Flow cytometry analysis of cell surface receptor expression
For analysis of cell surface receptor expression,  2 x  105 cells were tested per 
sample in 5-ml round-bottomed polystyrene tubes if analysing fewer than  10 samples; 
otherwise 96-well U-bottomed plates were used.  Wash steps were carried out in 500 
and  200  pi  volumes  in  the  5-ml  tubes  and  96-well  plates  respectively,  with 
centrifugation at 325 g for 5 minutes.  Antibodies were used at dilutions recommended 
by the manufacturers.  All were specified as being suitable for flow cytometry. When 
primary  antibodies  directly  conjugated  to  a  fluorophore  were  used  (see  Table  2.2),
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directly  conjugated  to  a  fluorophore,  polyclonal  goat  anti-mouse  conjugated  to 
phycoerythrin (PE; Dako, Denmark) IgG was used as a secondary antibody.
Adherent cells were detached  from  culture  flasks  by treatment with versene. 
Cells were washed once in PBS and once in FACS buffer, followed by incubation with 
50 pi  of  10%  goat  serum  in  FACS  buffer  for  30  min  at  4°C.  100  pi  of primary 
antibody was  added to the  cells and  incubated  for 30 min at 4°C.  Cells were then 
washed three times in FACS buffer and incubated with 50 pi of secondary antibody for 
30 min at 4°C, before washing cells twice with FACS buffer, once with PBS and fixing 
in  formol  saline  for  10  min  at  4°C.  Cells  were  washed  with  PBS  and  receptor 
expression  analysed  on  a  Becton  Dickinson  FACScan  using  Cellquest  software 
(Beckton Dickinson, UK).  10,000 events were acquired per sample.
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ANTIBODY
TYPE
ISOTYPE CLONE MANUFACTURER
CR1  (CD35)
Monoclonal 
mouse anti-human
IgGl To5 Dako, Denmark
CR2 (CD21)
Monoclonal 
mouse anti-human
IgGl 1F8 Dako, Denmark
CR3 (CDllb)
Monoclonal 
mouse anti-human
IgGl 2LPM19C Dako, Denmark
FcyRI (CD64)
Monoclonal 
mouse anti-human
IgGl 10.1 Dako, Denmark
FcyRII
(CD32)
Monoclonal 
mouse anti-human
IgGl KB61 Dako, Denmark
FcyRIII 
(CD 16)
Monoclonal 
mouse anti-human
IgGl DJ130c Dako, Denmark
Isotype
control
Mouse IgGl Dako, Denmark
CD4
PE-conjugated 
anti-human 
monoclonal
IgG2a
BD Biosciences 
PharMingen
CCR5
PE-conjugated
anti-human
monoclonal
IgG2a 2D7
BD Biosciences 
PharMingen
CXCR4
PE-conjugated
anti-human
monoclonal
IgG2a
BD Biosciences 
PharMingen
Isotype
control
Mouse IgG2a G155-178
BD Biosciences 
PharMingen
Isotype
control
Mouse anti-rat-PE IgGl W3/25 Dako, Denmark
Table 2.2  Antibodies used for cell surface receptor expression analysis by flow cytometry
872.3  SOURCES OF CONTROL SERA AND PLASMA
2.3.1 Complement source
Fresh sera from 4 healthy, HIV-negative individuals were pooled and divided 
into  1-ml aliquots.  Half of the aliquots were heat inactivated at 56°C for  1   hour and 
then  stored  at -80°C  for use  as the  complement  inactivated  control  (HIC’)  and  the 
remaining aliquots were stored immediately at -80°C for use as a complement source 
(C’).  Samples  were  stored  for  no  longer  than  3  months  and  freshly  thawed 
immediately before use in each assay.
2.3.2 Seronegative control serum (NHS) and plasma (NHP)
The  same  batch  of seronegative  control  serum,  also  referred  to  as  normal 
human  serum  (NHS;  PAA Laboratories, Austria) was divided into  1-ml aliquots and 
stored at -80°C for use in all enhancement and neutralisation assays.  Individual NHS 
samples, used for assessment of variation in enhancement assays, and individual NHP 
samples, used for the purification of control IgG and IgM, were collected from healthy 
individuals, heat inactivated for 1  hour at 56°C, divided into 1-ml aliquots in cryotubes 
colour-coded to denote separate donors, and stored at -80°C.
2.4  THE JENNER COHORT
Blood  samples  were  obtained  from  a cohort  of individuals  recently  infected 
with HIV, the Jenner cohort, as previously reported (Aasa-Chapman et al., 2004; Aasa- 
Chapman et al., 2005).  The subjects studied in this thesis were all men who have sex 
with  men  (MSM)  presenting  with  primary  HIV  illness  (PHI)  following  sexual 
exposure to HIV.  All were found to be  infected with HIV-1  subtype B.  The study 
protocol was approved by the Camden and Islington NHS Trust Ethics Committee and 
written consent was obtained from all subjects.  All samples used in this thesis were 
from treatment-naive individuals.
Blood samples were obtained weekly for the first month, monthly for 3 months 
and subsequently every 3 months.  Plasma, serum, and whole blood were divided into 
aliquots and stored at -80°C.  PBMCs were were isolated and stored in liquid nitrogen.2.5  HIV
2.5.1 Propagation of TCLA virus strains
The TCLA virus isolates IIIB and MN were propagated in the T cell line H9. 
Cells were counted and approximately 1  x 106 cells pelleted by centrifugation at 325 g 
for  10 minutes before resuspending in 0.5-1  ml of virus stock and incubating at 37°C 
for 3 hours.  5 ml of culture medium was added and cells were incubated in an upright 
25  cm2  flask  for  3-4  days  until  syncytia were  observed  under the  light microscope. 
Cells  were then  pelleted and  co-cultivated with  5  x  106 uninfected cells  in  1   ml  of 
culture medium for 3  hours at 37°C.  15 ml of fresh culture medium was added, and 
cells were incubated in an upright 75 cm2 tissue culture flask for a futher 3-4 days until 
large  syncytia  were  observed  under the  light  microscope.  At  this  point  virus  was 
harvested  by  centrifuging  the  cells  and  aliquoting  1-ml  volumes  into  cryovials  for 
storage in vapour-phase liquid nitrogen.
2.5.2 Isolation and propagation of primary isolates
All patient primary isolates and the vaccine virus strain W61D were propagated 
in PBMCs.  1-2 x 107 PBMCs (prepared according to section 2.2.6) from two different 
donors were  used  for co-culture with patient PBMCs  (prepared according to  section 
2.4)  or  inoculation  with  W61D  virus  (kindly  provided  by  Anna  Helander).  Donor 
PBMCs were pelleted at 325 g for 10 minutes and resuspended in 1  ml of fresh culture 
medium (containing 5 U/ml IL-2).  Patient PBMCs were thawed and washed in 5 ml of 
fresh  culture  medium  and  resuspended  in  1   ml  of fresh  culture  medium.  Patient 
PBMCs or  1-ml of W61D virus stock were added to the donor PBMCs and incubated 
for 2 hrs at 37°C.  8 ml of fresh growth medium was added and the cells transferred to 
a 25 cm2 flask and incubated for 7 days at 37°C.  On day 8 post-inoculation, cultures 
were  replenished with  fresh PBMCs  (prepared  according to section 2.2.6)  from two 
new donors.  Infected PBMCs were pelleted and 8 ml of the supernatant stored in 500- 
pl  aliquots  in  liquid  nitrogen  for  subsequent  determination  of virus  content.  The 
PBMCs  were  resuspended  in  the  remaining  2  ml  of supernatant  and  split  into  two 
separate  tubes.  3  x  106  PBMCs  from  the  two  new  donors  in  10  ml  fresh  culture 
medium were added to each tube, transferred to a 25 cm2 culture flash and incubated 
for  a  further  7  days.  This  procedure  was  repeated  on  days  15,  22  and  29.  Viral 
production was monitored using a commercial p24 ELISA (Biomerieux, France), and
89virus  titres  from  peak  days  of p24  production  were  determined  on  NP2  cells  (see 
section 2.7.1.1).
2.6  VIRUS DETECTION ASSAYS
2.6.1 In situ intracellular p24 staining
In situ p24 staining was used to detect infection following NP2-based assays. 
Fixed cells were washed once with PBS containing 1% FCS, then incubated for 1  hour 
at room temperature with 200 pi per well of primary antibody: an equal mixture of 2 
mouse  anti-p24 monoclonal  antibodies (ADP 365  and  366,  AIDS  Reagent Program, 
NIBSC, UK) diluted  1:40 in PBS containing  1% FCS.  Cells were washed twice with 
PBS containing  1% FCS, then  incubated for  1   hour at room temperature with 200 pi 
per  well  of  secondary  antibody:  goat  anti-mouse  polyclonal  Ig  conjugated  to  p- 
galactosidase  (Southern  Biotechnology  Associates  Inc,  USA)  diluted  1:400  in  PBS 
containing  1% FCS.  Cells were then washed twice with PBS containing 1% FCS and 
once  with  PBS,  and  incubated  at  37°C  with  200 pi  per  well  of  P-galactosidase 
substrate  (0.5  mg/ml  5-bromo-4-chloro-3-indolyl-p-galactopyranoside  (X-gal; 
Invitrogen,  UK)  in  PBS  containing  3  mM  potassium  ferrocyanide,  3mM  potassium 
ferricyanide and  ImM MgCh) overnight.  Cells infected with HIV developed a blue 
colour.  Foci of infection were counted by light microscopy.
2.6.2 RT ELISA
A  commercial  lentivirus  RT ELISA  (Lenti-RT Activity Assay;  Cavidi  Tech, 
Sweden)  was  used  to  determine  RT  activity  in  cell-free  supernatants  in  order  to 
quantify HIV in viral stocks or cell supernatant from T cell-based assays, according to 
the manufacturer’s instructions.  The RT in the sample synthesises a DNA strand from 
an  immobilised  template/primer  construct,  incorporating  bromo-deoxyuridine 
triphosphate  (BrdUTP),  which  is  later  quantified  by  a  BrdUTP  binding  antibody 
conjugated to  alkaline phosphatase  (AP).  The  level  of RT activity in the  sample  is 
proportional to the colour change of the AP substrate, measured by absorbance at 405 
nm  in  a  Lucy  1   luminometer  (Anthos-Labtech,  UK)  and  analysed  using  Stingray 
software (Dazdaq, East Sussex, UK).
902.6.3 Intracellular p24 stain and flow cytometry
2.6.3.1 Intracellular p24 staining of T cell lines
Intracellular  p24  staining  of T  cell  lines  and  subsequent  analysis  by  flow 
cytometry was used to determine the percentage of infected cells following T cell line- 
based enhancement and neutralisation assays. Intracellular staining of T cell lines was 
carried out in 96-well U bottomed tissue culture plates.  Wash steps were carried out in 
200 pi volumes, with centrifugation at 325 g for 4 minutes. All steps were carried out 
on ice and all centrifugation steps at 4°C.  All buffers were pre-cooled to 4°C before 
use.  Cells  were  washed  once  with  FACS  buffer then  fixed  with  100 pi  of formol 
saline for lOminutes at 4°C.  Cells were then washed once with FACS buffer and once 
with  PERM  buffer  (1%  saponin  in  FACS  buffer)  to  permeabilise.  Blocking  was 
carried out with 50 pi of 10% goat serum in PERM buffer for 30 minutes at 4°C.  50 pi 
of primary  antibody,  diluted  1:20  in  PERM  containing  10%  goat  serum,  was  then 
added to each well and incubated for 1  hour at 4°C.  Primary antibody was the same as 
that  used  for  the  NP2  cell  assays:  an  equal  mixture  of  two  mouse  monoclonal 
antibodies  to  two  separate  epitopes  on  p24  (ADP  365  and  366).  Cells  were  then 
washed  three  times  in  PERM  buffer  then  incubated  for  1   hour  at  4°C  with  50 pi 
secondary antibody:  goat anti-mouse polyclonal antibody conjugated to FITC (Dako, 
Denmark).  Cells were washed twice with PERM buffer and once with FACS buffer, 
then  fixed  again  with  formol  saline  for  10 min at 4°C,  then washed once with PBS 
before  transferring  to  2  ml  polystyrene  tubes  for  analysis  on  a  FACScan  flow 
cytometer  (Beckton  Dickinson,  UK)  using  Cellquest  software  (Beckton  Dickinson, 
UK).
2.6.3.2 Determination ofpercent infected cells by flow cytometry
Using  uninfected,  stained  cells  as  a  control,  cells  were  gated  on  the  major 
(healthy) lymphocyte-like population on forward scatter (FSC) / side scatter (SSC) dot 
plots.  Samples  were  analysed  on  SSC/FL-1  dot plots,  and  a  second  gate  set  up to 
count  infected  cells  (represented  by the  level  of p24  expression,  as  represented  by 
FITC  fluorescence measured on FL-1).  10,000  events were acquired  in the healthy 
population per sample, in triplicate.  Samples were “blanked” by averaging the number 
of events  occurring  in the  infected gate for 6 uninfected samples  (usually averaging 
<0.01%) and removing this from each test sample.
912.7  INFECTION ASSAYS
2.7.1 NP2 cell-based assays
2.7.1.1 Titration of virus stocks
NP2/CD4/R5  and NP2/CD4/X4  cells were  seeded  in  48-well  plates one  day 
prior to  infection at a density of 2 x  104 cells/well.  Ten-fold serial dilutions of viral 
stocks were made in fresh culture medium, and 100 pi of each dilution were added to 
the cells in triplicate and incubated for 2 hours at 37°C.  Cells were then gently washed 
with culture medium, overlaid with 500 pi fresh culture medium and incubated for 72 
hrs  at 37°C.  After 72  hours  incubation,  culture medium was removed and the cells 
fixed  for  10 min at room temperature with 200 pi per well of methanol/acetone (1:1 
v/v), pre-cooled at -40°C.  Cells were washed once with PBS then overlaid with PBS 
and stored at 4°C until in situ  p24 staining, detailed in section 2.6.1.
2.7.1.2 Neutralisation assay
Patient sera or plasma, or monoclonal antibodies, were two-fold serially diluted 
in NHS.  Alternatively, longitudinal studies of neutralisation in sequentially collected 
autologous samples were performed on undiluted serum or plasma, resulting in a final 
concentration of 10% in the assay.
The  prepared  sera,  plasma,  monoclonal  antibody,  or NHS  as  a  control,  was 
incubated at a final concentration of 10% with 100 ffu of virus in  100 pi fresh culture 
medium.  This was incubated for 1  hour at 37°C before adding to the cells (prepared as 
in section 2.7.1.1) and incubating for 2 hours at 37°C.  Cells were then gently washed 
with culture medium, overlaid with 500 pi fresh culture medium and incubated for 48 
or 72 hrs at 37°C.  Cells were fixed as in section 2.7.1.1.
2.7.1.3 C’-MI assay
C’-MI  assays  (Aasa-Chapman  et  al.,  2005)  were  performed  as  per  the 
neutralisation assays, with the following modifications:
C’-MI  assays  were  performed  with  sera  as  an  antibody  source.  Heat 
inactivated  (HIC’)  or  active  (C’)  complement  (see  section  2.3.1)  was  added  to  the
92virus/serum mix before the 1-hour incubation at 37°C.  The final concentration of HIC’ 
or C’ was 10%; likewise, the final concentration of patient serum or NHS was 10%.
2.7.1.4  Assays on NP2 cells transduced to express CR2, KHR or FcyRIIa
Assays  were  performed  as  per  the  CMI  assays,  with  the  exception  that 
NP2/CD4/R5/CR2 or -KHR cells were used in parallel with NP2/CD4/R5  cells as a 
control,  or  NP2/CD4/X4/CR2,  -KHR  or  -FcyRIIa  cells  were  used  in  parallel  with 
NP2/CD4/X4 cells as a control.  Two viral inputs of 10 and 100 ffu were used.
2.7.2  T cell line-based assays
2.7.2.1  SupTl/R5 enhancement assay
The  standard  SupTl/R5  enhancement  assay,  developed  in  Chapter  3  of this 
thesis and used throughout Chapters 4, 5 and 6, is described below.  Variations on the 
assay are given in section 2.7.2.2.
Virus (for virus quantity see section 2.7.2.2 below) was added to HIC’  or C’ 
and  patient or vaccinee  serum,  or NHS  as a control,  in a total  volume of 100  pi  in 
serum-free culture medium and incubated for 1  hour at 37°C.  Patient serum, vaccinee 
serum or NHS, and HIC’ or C’ as appropriate, were each used at a final concentration 
of 10% at the time of incubation.
Meanwhile,  SupTl/R5 cells were seeded in U-bottomed 96-well tissue culture 
plates  at  105   cells  per  well  in  100  pi  of fresh  culture  medium.  After  the  1-hour 
incubation, virus-serum mixtures were transferred to the cells, giving a final volume of 
200 pi per well.  Plates were incubated at 37°C.  In order to monitor the RT output of 
the assay (section 2.6.2), and to provide fresh medium for the cells, on days  1   and 3 
100 pi  of cell  supernatant was removed from each well and  immediately stored at -  
40°C.  Cell supernatant was replaced with 100 pi per well of fresh culture medium.  On 
day 5 or 6 of the assay the entire 200 pi of cell supernatant was removed and stored at 
-40°C  and the cells were stained for intracellular p24 expression (section 2.6.3).  In 
some cases assays were stopped on day 5 rather than day 6 as cytopathic effect in the 
enhanced cultures was so advanced that it was feared the cells would not withstand 
intracellular staining.
932.7.2.2  Enhancement assay variations
All viruses were titrated onto the relevant cell type in the presence of HIC’ and 
NHS  to  determine  their  final  output  in  the  enhancement  assay.  For  the  standard 
enhancement assay on SupTl/R5 cells used in Chapter 4 onwards, an input that gave 
0.1%  infected  cells  in  the  presence  of  HIC’  was  used.  In  terms  of  ffu/ml,  as 
determined by titration on NP2/CD4/R5 cells, this ranged from 100 to 500 ffu per well 
depending on the virus.
For the IIIB enhancement assays used in Chapter 3, on MT-2 and MT-4 cells, 
IIIB was used at an input of 100-300 ffu per well, that resulted in  1-2% infected cells 
in the presence of HIC’ and NHS, which is equivalent to an output of 400-1000 pg/ml 
RT.  RT output was determined by RT ELISA from culture supernatant obtained on 
day 5 for the MT2 cells and day 3 for the MT4 cells.
For the IIIB neutralisation assays used in Chapter 3  on H9,  MT-2, MT-4 and 
SupTl/R5 cells, IIIB was used at an input that resulted in 2-10% infected cells in the 
presence of HIC’.
2.8  ANTIBODY PURIFICATION
IgG  and  IgM were  purified  from  patient plasma using a MabTrap protein  G 
column  (Amersham  Biosciences,  UK)  and  HiTrap  IgM  Purification  (Amersham 
Biosciences, UK) kits, respectively, according to the manufacturer’s instructions.  1  ml 
of plasma was used per purification, in parallel with control HIV seronegative plasma 
(NHP; see section 2.3.2).  500-pl fractions were collected throughout the purification. 
All  fractions collected were assayed for protein content using BioRad Protein Assay 
solution (BioRad, Germany).  10 pi of each of the collected fractions were diluted 1:10 
in PBS.  Standards were prepared with known concentrations of human IgG.  10 pi of 
each  diluted  fraction  or  standard  was  added to  70  pi  of PBS  and  20  pi  of BioRad 
Protein Assay solution and mixed thoroughly.  Absorbance was read in a microplate 
reader  at  570  nm.  Eluent  fractions  containing  protein  were  pooled.  If the  pooled 
volume was greater than the original plasma input volume, samples were concentrated 
using Vivaspin protein concentrators (Vivascience, Germany).
942.9 ANTI-gpl20 ANTIBODY ELISA
96 well Maxisorb plates (Nalgene, NUNC International, Hereford) were coated 
with  a  sheep  polyclonal  anti-gpl20  antibody  (D7324;  Aalto  Bio  Reagents,  Dublin, 
Ireland) at  10 pg/ml PBS overnight at 4°C.  Plates were washed 4 times with TBS-T 
and  blocked with TBS  containing 4% milk powder for  1   hour at room temperature. 
After one wash with TBS-T,  plates were incubated with  50  pi per well of HIV IIIB 
gpl20 (MRC AIDS Directive; product number EVA657) at a saturating concentration 
(0.2 ng/pl) in TBS containing  1% milk powder for 2 hours at room temperature.  For 
each serum sample to be tested, a blank well excluding the gpl20 was included.  Plates 
were then washed 4 times with TBS-T then incubated with patient sera,  serially ten­
fold diluted in TBS-T containing 4% milk powder and 10% goat serum.  An equal mix 
of QC sera 1, 2 and 4 (from individuals chronically infected with HIV (Aasa-Chapman 
et al., 2004)) was used as a positive control.  Diluted patient sera and positive control 
sera were added to the plates in duplicate as well as to blank (no gpl20) wells.  After 1  
hr of incubation at room temperature the plates were washed 4 times in TBS-T.  100 pi 
of alkaline phosphatase (AP)-conjugated goat anti-human Ig (Harlan SeraLab, Crawley 
Down,  UK),  diluted  1   in  2000  in TBS-T containing 4% milk powder and  10% goat 
serum,  was  added to each well  and  incubated  for  1   hr at room temperature.  Plates 
were washed 6 times in TBS-T before adding  100 pi per well of AP substrate (Lumi- 
Phos  Plus,  Aureon Biosystems,  Vienna, Austria) and  incubating  in the dark at room 
temperature for 1   hr.  Relative light units (RLU) were determined at 405 nm in a Lucy 
1   luminometer (Anthos-Labtech, UK) and analysed using Stingray software (Dazdaq, 
East Sussex, UK).
2.10 NUCLEIC ACID PRODUCTION AND MANIPULATION
The following procedures were used to clone CR2 (and produce a cytoplasmic 
tail mutant, KHR) from SupTl/R5 cells, for subsequent expression in NP2 cells.
2.10.1  Isolation of total cellular RNA
5  x  106  SupTl/R5  cells  were  pelleted  by  centrifugation  at 325  g for  5  min. 
Culture medium was removed by aspiration,  and the cell pellet resuspended in  1   ml 
TRIzol (Invitrogen, UK) and incubated at room temperature for 10 min before adding 
200  pi  of  chloroform.  After  thorough  mixing  and  a  further  incubation  at  room
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min  at  4°C,  and  the top,  clear  layer transferred to  an  RNAse-free tube.  500  pi  of 
isopropanol  was  added,  mixed,  incubated  at  room  temperature  for  10  min  then 
centrifuged at 4°C  for  10 min at  17,000 g to pellet RNA.  The RNA pellet was then 
washed with  100 pi of 75% ethanol and left to air dry before resuspension in RNAse- 
free  water  and  treatment  with  DNAse.  Impurities  were  removed  using the  Qiagen 
PCR purification kit, according to the manufacturer’s instructions.
2.10.2  cDNA synthesis
First-strand  cDNA  was  synthesised  from  total  cellular  RNA  using  an 
Invitrogen  Superscript  III  kit  (Invitrogen,  UK),  according  to  the  manufacturer’s 
instructions.  Briefly, RNA was mixed with oligo(dT)2o primers (specific for mRNA) 
and dNTPs at 65°C  for 5  min, then cooled on ice  for  1   min.  cDNA synthesis mix, 
containing a version of M-MLV (Moloney murine leukaemia virus) RT,  was added to 
the  RNA/primer/dNTP mix and incubated at 50°C  for 50 min for first-strand cDNA 
synthesis.  The reaction was terminated by incubation at 85°C for 5 min, cooled and 
treated with RNAse H to remove the RNA from the DNA:RNA hybrid.  The resultant 
cDNA was stored at -20°C until use as a template for PCR.
2.10.3  PCR amplification of specific DNA
Primers to the coding sequence of CR2 were designed using the CR2 sequence 
available  on  Genbank,  accession  number  NM_001877  {Homo  sapiens  complement 
component  (3d/Epstein  Barr  virus)  receptor  2,  transcript  variant  2,  mRNA)  and 
publications  detailing  cytoplasmic  tail  mutants  of CR2  (Barrault  and  Knight,  2004; 
Carel et al.,  1990).  The forward primer, containing the ATG start codon of CR2 (in 
bold  type)  was  used  for the  amplification  of both  full-length  and  truncated  (KHR) 
sequences,  and  had  the  sequence  5’-GCG  CTG  ATC  AGC  CAC  CAT  GGG  CGC 
CGC GGG CC-3’.  The reverse primer used to amplify the 3102-bp full-length CR2 
contained the CR2 TGA stop codon (in bold type), and had the sequence 5’-GCG CTT 
CGA ATC AGC TGG CTG GGT TGT AT-3’.  The cytoplasmic tail mutant KHR was 
constructed by  inserting a stop codon  after the  first three  amino acids,  KHR,  of the 
cytoplasmic tail sequence, resulting in a 21-aa truncation.  The reverse primer used to 
produce the 3006-bp KHR CR2 sequence contained a TGA stop codon (in bold type),
96and had the sequence 5’-GCG CTT CGA ATC ATC TGT GTT TTG ATA TCA CGT 
AT-3\
PCR was performed using the AccuPrime Taq DNA Polymerase High Fidelity 
kit (Invitrogen, UK), which contains taq DNA polymerase and GB-D polymerase with 
proofreading  activity.  Reactions  were  set  up  containing  5  pi  lOx AccuPrime  PCR 
Buffer I (including dNTPs), 5 pmol each of the relevant forward and reverse primers, 1  
pi of cDNA template (see section 2.10.2) and 0.2 pi AccuPrime Taq High Fidelity, and 
made up to 50 pi with autoclaved, distilled water.  Reaction mixtures were incubated at 
94°C  for  3  minutes  to  activate  the  enzyme,  followed  by  30  cycles  of 94°C  for  30 
seconds, 62°C for 30 seconds and 68°C for 3 min.
2.10.4  Agarose gel electrophoresis of DNA
Agarose  gel  electrophoresis  was  used  to  separate  DNA  fragments  by  size 
following  restriction  enzyme  digestion  (section  2.10.6),  and to  purify  specific DNA 
products produced by PCR (2.10.3).  Gels consisted of 0.8% agarose (w/v; Roche, UK) 
in 0.5x TAE buffer with 0.5 pg/ml ethidium bromide.  A 1-kb GeneRuler DNA ladder 
(Fermentas Life Sciences, UK) was used as a molecular weight marker.  DNA bands 
of specific size were excised from the agarose gel and purified using the QIAquick Gel 
Extraction Kit (Qiagen, UK) according to the manufacturer’s instructions.
2.10.5  Restriction enzyme digestion of DNA
Restriction enzymes were obtained from Promega Life Sciences and used in the 
buffers  provided  according  to  manufacturer’s  instructions.  Partial  digests  were 
performed  by  ten-fold  serially  diluting  the  restriction  enzyme  in  appropriate  buffer 
before adding to the restriction reaction mixture.
2.10.6 Ligation of DNA fragments
2.10.6.1  Ligation of  purified PCR products into pCR2.1 TOPO
Agarose gel-purified PCR products were ligated into the cloning vector pCR2.1 
TOPO  (Invitrogen,  UK)  according  to  the  manufacturer’s  instructions.  Ligation 
reactions were transformed directly into competent bacteria (section 2.10.7).
972.10.6.2  Sub-cloning of  DNA fragments in pCSGW
The restriction enzymes Not I and Bam HI were used to remove the CR2 and 
KHR  coding  fragments  from  pCR2.1-TOPO  for  ligation  into  CSGW.  A  partial 
restriction digest was performed with Bam HI due to an additional Bam HI recognition 
site within the CR2 coding sequence.  The resultant 3-kb gel-purified fragments (see 
section 2.10.4) were  ligated into Bam El/Not I cut CSGW (with the eGFP-encoding 
gene  removed)  using  Promega  T4  DNA  Ligase,  according  to  the  manufacturer’s 
instructions, before transforming directly into competent bacteria (section 2.10.7).
2.10.6  Transformation of competent bacteria
1   jlxI  of ligation  mix  was  added  to  80  pi  Dh5a or  Stbl  2  competent  bacteria 
(Invitrogen, UK) and incubated on ice for 30 min, followed by heat-shock at 42°C for 
45  seconds and a further 2 min incubation on ice.  250 pi of SOC medium (supplied 
with the bacteria) was added and the bacteria were incubated at 30°C for 1   hour with 
shaking at 200 rpm.  Cultures were then plated on L-agar plates containing 50 pg/ml 
ampicillin and incubated for 24 hrs at 30°C.
2.10.7  Plasmid purification
A single bacterial colony from an agar plate was inoculated into 3  ml of LB- 
broth containing 50 pg/ml ampicillin and grown for 24 hrs at 30°C with shaking at 200 
rpm.  Bacteria  were  pelleted  by  centrifugation  at  17,000  g  for  5  min  and  used  to 
prepare plasmid DNA using the QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer’s instructions.
2.10.8  Screening plasmids for correct inserts
Initial screening of pCR2.1-TOPO plasmids for correct CR2 and KHR inserts 
was  carried  out  by  restriction  digestion.  Plasmids  showing  the  correct  predicted 
digestion pattern were then sequenced (section 2.10.10).
2.10.9  DNA sequencing
CR2 and KHR constructs in the cloning vector pCR2.1-TOPO were sequenced 
using the vector sequencing primers M l3 reverse and M13(-20) forward, and internal 
sequencing  primers  designed  using  the  NM_001877  CR2  coding  sequence.  All 
sequencing was carried out by the DNA Sequencing Service at the Wolfson Institute
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coding sequence, plasmids containing the correct inserts were selected, and full-length 
CR2 and KHR fragments were sub-cloned into CSGW.
2.11  STABLE EXPRESSION OF CR2 AND KHR IN NP2 CELLS
2.11.1 Lentiviral vector production
CSGW-CR2  and  -KHR  constructs  were  initially  screened  for  expression  of 
CR2  and  KHR  by  single-plasmid  transfection  into  293T  cells  and  staining  for  cell 
surface expression of CR2, as detailed in section 2.2.5 and 2.2.7.  Lentiviral vectors for 
the  stable  expression  of CR2,  KHR,  and  GFP  were  produced  in  293T  cells  by  co­
transfection  of three  plasmids  (shown  in  Figure  2.1).  The transfection procedure  is 
described in section 2.5.5.
The  packaging  construct  used  was  pCMVAR8.2  (Naldini  et  al.,  1996), 
containing the genes gag, pol,  tat, rev, vif, vpr, vpu and nef (see Figure 2.1).  A CMV 
promoter  drives  the  expression  of the  viral  genes.  The  reporter  construct,  CSGW, 
encodes an eGFP reporter gene driven by a SFFV promoter,  located in between two 
LTRs (Demaison et al., 2002).  This allows for the integration of the construct into the 
cellular genome, resulting in stable and permanent expression of eGFP.  CSGW-CR2 
and  CSGW-KHR  are  CSGW  plasmids  with  CR2  or  KHR  in  the  place  of eGFP, 
respectively. The envelope construct encodes VSV-G virus envelope, under control of 
a CMV promoter.  All three constructs were within a pUC19 plasmid backbone. The 
three  plasmids  were  transfected  into 293T cells  at an  envelope:  packaging:  reporter 
(CSGW,  CSGW-CR2  or CSGW-KHR) ratio of 3:2:1.  The transfection procedure  is 
described in section 2.2.5.
2.11.2 Stable expression of CR2 and KHR on NP2 cells
GFP,  CR2  and  KHR  lentivirus vectors  produced  according to  section  2.11.1 
were used to transduce NP2/CD4/X4 and NP2/CD4/R5.  GFP lentiviral vectors were 
used  in parallel with the CR2 and KHR lentiviral vectors in order to monitor protein 
expression  by  GFP  intensity.  1   x  104  NP2/CD4/R5  and  NP2/CD4/X4  cells  were 
seeded into each well of a 48-well plate.  On day 1   following seeding, culture medium 
was  removed,  and  200  pi  of lentiviral  vector  incubated  per well  for  1   hour  before 
removing and overlaying cells with 500 pi fresh culture medium.  This was repeated
99on  days  3  and  5.  Cells  were  then  grown  up  and  analysed  for cell  surface  receptor 
expression by flow cytometry (2.2.7).
Lentiviral vector plasmid components
1)  HIV-1 packaging construct (pCMVAR8.2)
nef
CMV LTR vpu
RRE tat
vpr
rev
2)  Reporter construct (CSGW) or CR2-expression construct
LTR  ¥ RRE cPPT SFF\) |eGFP ]WPRE  LTR
LTR  ¥ RRE cPPT SFFV>| CR2  |WPRE  LTR
3)  Envelope construct (VSV-G)
vsv
Figure 2.1 Schematic diagram of the constructs used to produce lentiviral vectors
The constructs were contained within a pUC19 backbone, and used to produce lentiviral 
vectors via 3-plasmid transfections, as detailed in section 2.2.5.
cmv;
100CHAPTER 3 
Studies of antibody-dependent enhancement of HIV IIIB 
infection and enhancement assay development
This  chapter  investigates  ADE  of a  TCLA  HIV  strain,  IIIB.  Evidence  of 
enhancing  activity  against  IIIB  was  found  in  serum  samples  obtained  soon  after 
infection with HIV,  on both a CR2+ and an FcyRII+ T cell line.  C’-ADE was seen 
more  frequently than C’-independent ADE.  Therefore, this phenomenon,  as well as 
C’-mediated rescue from neutralisation (C’-RN), was investigated in more detail and 
the  assay  optimised  for  routine  use  and  future  investigation  of C’-ADE  in  clinical 
samples.
3.1 INTRODUCTION
3.1.1 Target cells used in the study of ADE of HIV infection
The  first  accounts  of  ADE  of  HIV-1  were  published  in  the  late  1980s 
(Robinson et al.,  1988a; Takeda et al.,  1988), prompting extensive investigation and 
characterisation of the phenomenon during the 1990s.  Two main types of ADE, FcR- 
ADE  and  C’-ADE,  were  discovered  and  investigated  in detail.  The model  systems 
described for the majority of these studies used the TCLA HIV strain IIIB  (hereafter 
referred to as IIIB), with the cell lines U937 for FcR-ADE studies (Kozlowski et al., 
1995; Laurence et al.,  1990; Subbramanian et al., 2002; Takeda et al., 1992; Takeda et 
al.,  1990; Takeda et al.,  1988) and MT-2 for the C’-ADE studies (Lund et al.,  1995; 
McDougall et al., 1997; Montefiori et al., 1991; Robinson et al.,  1991; Robinson et al., 
1990a;  Robinson  et  al.,  1990b;  Robinson  et  al.,  1989a;  Robinson  et  al.,  1988a; 
Robinson et al.,  1990c; Robinson et al.,  1989b; Subbramanian et al., 2002).  A CR2+ 
cell line with similar characteristics to MT-2 cells, MT-4, was used in the case of one 
group (Banhegyi et al., 2003; Prohaszka et al., 1997; Szabo et al.,  1999).  FcR-ADE of 
primary isolates was also detected in PBMCs and macrophages (Homsy et al.,  1990; 
Homsy et al.,  1989; Jouault et al.,  1991) and C’-ADE in PBMCs (Gras et al.,  1988) 
and  DCs  (Bajtay  et  al.,  2004).  In  this  chapter,  preliminary  C’-ADE  studies  were 
carried  out  in  a  system  similar to  the  MT-2  model  system,  to  enable  comparisons 
between  my  results  and  those  previously  published.  A  related  cell  line,  MT-4,
101expressing FcyRII  (and therefore  different  in phenotype to those used by Banhegyi, 
Prohaszka, Szabo and colleagues mentioned above) was used in parallel for FcR-ADE 
studies.
3.1.2 Features of C’-ADE of HIV
The receptor most frequently reported to mediate C’-ADE was CR2 (Prohaszka 
et al.,  1997; Robinson et al.,  1990c), although CR1 (Delibrias et al.,  1993; Delibrias et 
al.,  1994; Gras et al.,  1993), CR3 (Reisinger et al.,  1990) and later ClqR (Prohaszka et 
al.,  1997) were also shown to mediate enhancement through this mechanism.  Through 
studies  with  monoclonal  antibodies  and  peptide  mapping,  “enhancement  domains” 
were  identified, the most clearly defined being within the primary immunodominant 
region on gp41, aa579-613  (Mitchell et al.,  1998; Robinson et al.,  1991; Robinson et 
al.,  1990a;  Robinson  et  al.,  1990b).  Part  of this  region  is  highly  conserved  and 
incorporates the disulphide loop responsible for interaction with gpl20 (Gnann et al., 
1987;  Helseth  et  al.,  1991;  Maerz  et  al.,  2001;  York  and  Nunberg,  2004).  Other 
regions  on  gp41  and  gpl20  have  also  been  shown  to  elicit  enhancing  antibodies, 
including the V3  loop (Jiang and Neurath,  1992; Jiang et al.,  1991).  The prevalence 
of C’-ADE  antibodies  in  serum  samples  from  infected  individuals  differs  between 
reports, probably due to variations in assay methods.  In some cases C’-ADE is dose- 
dependent  and  most  efficient  at  highest  concentrations  of sera  (Jiang  and Neurath, 
1992; Jiang et al.,  1991) while in others C’-ADE is only seen with extensive dilutions 
of neutralising sera (Montefiori et al.,  1991;  Subbramanian et al.,  2002).  Variation 
also  applies  to  correlation  of C’-ADE  with  disease:  several  studies  have  shown the 
positive  correlation  of C’-ADE  and viral  load  (Szabo et al.,  1999),  or disease  stage 
(Subbramanian et al., 2002), while others have found no correlation when comparing 
C’-ADE antibody titres with disease stage or pace of progression (Montefiori et al., 
1991; Montefiori et al., 1996).
3.1.3 Features of FcR-ADE of HIV
Previous  reports  of FcR-ADE  have  shown  a  role  for  the  receptors  FcyRI 
(Homsy et al.,  1989; Jouault et al.,  1991; Laurence et al.,  1990; Matsuda et al.,  1989; 
Pemo et al.,  1990;  Takeda et al.,  1990), FcyRII (Laurence et al.,  1990),  and FcyRIII 
(Homsy  et  al.,  1989),  and  also  the  IgA  receptor  FcaR  (Kozlowski  et  al.,  1995). 
Enhancing  epitopes  for  FcR-ADE  have  not  been  well  defined,  although  some
102monoclonal antibody studies implicated regions on gpl20 (Takeda et al.,  1992).  FcR- 
ADE is generally associated with higher dilutions of sera (Matsuda et al., 1989), and in 
this respect resembles the classical dengue virus enhancement.  Associations have been 
made between appearance of enhancing antibodies and progression to disease (Homsy 
et al.,  1990).
3.1.4 Studies of enhancing antibodies in seroconvertors
While considerable  investigation  into the occurrence  of enhancing antibodies 
and disease progression had been conducted on samples from late asymptomatic and 
AIDS stages of disease (Homsy et al.,  1990; Montefiori et al.,  1991; Montefiori et al., 
1996; Subbramanian et al., 2002; Szabo et al.,  1999), few researchers have conducted 
studies  of  serum  obtained  during  and  soon  after  seroconversion,  probably  due  to 
difficulty  of obtaining  such  samples.  In  one  study  that  investigated  this,  C’-ADE 
activity to IIIB was detected in seroconversion samples from four individuals (Szabo et 
al.,  1999).  In this chapter the concept is explored further, with early serum samples 
from nine individuals (and later samples in some cases), tested for both C’-ADE and 
FcR-ADE activity.
3.1.5 The effect of complement on neutralisation of HIV in CR2+ cell lines
In  many  studies  of C’-ADE  on CR2+ cells  it was noted that  sera that were 
otherwise  neutralising  became  less  neutralising,  or  even  non-neutralising,  in  the 
presence of complement (Lund et al.,  1995; McDougall et al.,  1997; Robinson et al., 
1988a; Robinson et al.,  1990c; Subbramanian et al., 2002; Szabo et al.,  1999).  While 
this  is  not  enhancement per se,  it  has  been  assumed  that the  mechanisms  of these 
phenomena  are  related.  It  also  has  important  implications  for  vaccine  and 
neutralisation  studies.  On  the  other hand,  it has  been  shown  that  complement can 
increase  the  inactivation  of HIV  seen  with  antibody  alone  when  assayed  on  CR- 
negative cells  (Aasa-Chapman et al., 2004; Aasa-Chapman et al.,  2005).  Therefore, 
the effect of complement on neutralisation of HIV is investigated further in this chapter 
on CR2+ and CR2- T cell lines.
1033.2  RESULTS
3.2.1  Cell lines for studies of ADE
Historically, studies of C’ADE have been carried out on MT-2 cells, therefore 
these were chosen as the target cell for initial studies of C’-ADE.  C’-ADE in MT-2 
cells was attributed to their high-level expression of CR2, since T cells such as H9 and 
CEM that  lacked  CR2  did not support enhanced  infection  (Robinson et al.,  1989a). 
Several reports have indicated that high level CR2 expression on CD4+ T cell lines is 
not unique to MT-2 cells (Delibrias et al., 1992; Fingeroth et al., 1988; Prodinger et al., 
1996;  Sinha et al.,  1993). Therefore six other T cell lines commonly used for in vitro 
studies of HIV (H9,  MT-2,  Molt-4,  SupTl,  SupTl/R5, C8166 and MT-4 cells) were 
tested  for CR2  expression as potential  future target cells  for ADE experiments.  As 
CR1  (Gras  and  Dormont,  1991)  and  CR3  (Reisinger  et  al.,  1990)  have  also  been 
implicated in C’-ADE, cells were also tested for these receptors.  Results are shown in 
Figure 3.1.  High-level expression of CR2 was found on four of the T cell lines:  MT- 
2, Molt-4,  SupTl, and SupTl/R5. C8166 cells expressed a lower but detectable level. 
H9 and MT-4 cells were the only cell lines on which CR2 could not be detected.  H9, 
SupTl and C8166 expressed a low level of CR1, but none of the cells expressed CR3.
The T cell lines were also examined for the expression of FcyRI, -II and -III, in 
order to find a suitable T cell line for the study of FcR-ADE.  Results are shown in 
Figure  3.2.  MT-4  cells  were  found  to  express  high  levels  of FcyRII  and therefore 
deemed appropriate for studies of FcR-ADE.  With the exception of C8166 and MT-2 
cells,  which  expressed  low  levels  of FcyRII,  none  of the  other cell  lines  expressed 
detectable amounts of the FcRs tested.
104Figure 3.1 Expression of CR1, -2 and -3 on seven T cell lines (overleaf, left page)
Cells  were  stained  for  the  cell  surface  expression  of CR1,  -2  and  -3  using  monoclonal 
antibodies  to  the  relevant  antigens  and  a  secondary  antibody  conjugated  to  PE.  Relative 
receptor expression was analysed by flow cytometry.  Appropriate isotype controls are shown 
as  open  peaks  and  receptor  expression  as  closed  peaks.  Ungated  PBMCs  were  used  as 
positive controls for each antibody.
Figure 3.2 Expression of FcyRI, -II and -III on seven T cell lines (overleaf, facing page)
Cells were stained for FcyRI, -II and -III as described for CRs in Figure 3.1.
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106Finally, cells were tested for the expression of the HIV receptors CD4, CXCR4 
and  CCR5.  As  expected,  all  of the  cell  lines  expressed  a  high  level  of CD4  and 
CXCR4, with the exception of MT-4 cells, which expressed a lower level of CXCR4. 
Apart  from  the  Molt-4  cells,  which  expressed  detectable  levels  of CCR5,  only  the 
SupTl/R5 cells expressed a significant amount of CCR5 as these had been artificially 
transduced to stably express it.  Results for expression of all receptors on all seven cell 
lines are summarised in Table 3.1.
CELL
TYPE
RECEPTOR
CD4 CXCR4 CCR5 CR1 CR2 CR3 FcyRI FcyRII FcyRIII
H9 ++ ++ - + - - - - -
MT2 +++ ++ - - +++ - - (+) -
Molt 4 +++ +++ (+) - ++ - - - -
SupTl +++ +++ - + +++ - - - -
SupTl/R5 +++ +++ +++ - +++ - - - -
C8166 ++ + - (+) + - - (+) -
MT4 +++ + - - - - - +++ -
Table 3.1 Summary of CR, FcR and HIV receptor expression on seven T cell lines
Cells  were graded  for expression of each  receptor according to the results  shown  in Figures 
3.1,  3.2  and 3.3.  +++ represents the highest level of expression, followed by ++ and +, with 
(+)  indicating  expression  levels just  above  the  threshold  of detection  and  -   indicating  no 
detectable expression of the relevant receptor.
107Figure 3.3 Expression of CD4, CXCR4 and CCR5 on seven T cell lines
Cells  were  stained  for  the  cell  surface  expression  of  CD4,  CXCR4  and  CCR5  using 
monoclonal antibodies directly conjugated to PE. Relative receptor expression was analysed 
by  flow  cytometry.  Appropriate  isotype  controls  are  shown  as  open  peaks  and  receptor 
expression  as  closed  peaks.  Ungated  PBMCs  were  used  as  positive  controls  for  each 
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1083.2.2  Studies of C’-ADE and FcR-ADE in sera from individuals with acute HIV 
infection
MT-2  cells  were  used  for  preliminary  serum  screening  assays  to  allow  for 
direct comparisons between my results and those  previously published.  MT-4  cells 
were found to express a high level of FcyRII, and as they were the only T cells tested 
that expressed a high level of any of the FcRs, they were used for FcR-ADE screening 
experiments.  This provided the  opportunity to  compare  enhancement  in two T cell 
lines, rather than in cells of unrelated lineage.
Serum samples obtained from individuals recently infected with HIV were used 
as only limited studies of ADE in early infection samples have been reported (Szabo et 
al.,  1999).  The samples from this patient cohort are studied in more detail in Chapter 4 
and described in Chapter 2, Materials and Methods.  Samples from as early as 6 days 
following  the  onset  of PHI  were  tested  for C’-ADE  and  FcR-ADE  activity  against 
IIIB.  Pooled seronegative normal human serum (NHS) was used as a control.
As  discussed  in  section  1.11.3  of the Introduction,  there are  several ways to 
present  results  from  enhancement  assays.  Here  I  have  chosen  to  present  fold 
enhancement values, a measure of the scale of enhancement or neutralisation relative 
to  infection  in  the  absence  of anti-HIV  antibodies.  Multiple  serum  samples  were 
screened  at  one  concentration,  10%,  to  enable  direct  comparisons  and  to  avoid 
excessive dilutions in order to show the dominant antibody activity in the sera. Results 
were normalised to a control culture containing virus, NHS and complement (C’), or 
virus, NHS and heat inactivated complement (HIC’) as appropriate.  HIC’ and C’ were 
also used at a concentration of 10% in the assay.  A value of 1   represents no effect; a 
value  below  0.5  or  0.1  indicates  >50%  or >90%  neutralisation,  respectively;  and  a 
value of 2 represents a 2-fold increase in infection. The dynamics of IIIB infection on 
MT-2 and MT-4 cells differ (Harada et al.,  1985), and see Figure 3.4.  Therefore an 
MOI of 0.001 (100 ffu on 105 cells) was used for the MT-4 cells and 0.003 for the MT- 
2 cells.  At the assayed time points (day 3 for the MT-4 cells and day 5  for the MT2 
cells) RT outputs in the control cultures (i.e. in the presence of NHS and HIC’) were 
250-1000 pg/ml.
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Figure 3.4 Dynamics of IIIB infection of MT-2 and MT- 
4 cells
MT-2 cells were infected with IIIB preincubated with NHS 
and HIC’ for 1   hr at 37°C.  An MOI of 0.003 was used for 
MT-2  cells,  and  0.001  for  MT-4  cells.  Cultures  were 
monitored  for  RT  output  by  RT  ELISA.  RT  output  is 
shown as a function of time.
2-3  serum samples from 9 patients were tested for enhancing activity.  Results 
are shown in Figure 3.5.  On the MT-2 cells sera from 4 out of the 9 patients enhanced 
infection: MM13 days 24 and 31; MM24 days 26 and 44; MM25 day 38; and MM36 
day  6.  All  of the  enhancing  serum  samples were  from  early time points  following 
infection;  when  a  later  sample,  day  464,  was  assayed  from  MM24  it  neutralised 
infection by >90%.  Similarly, day 452 and 848 from MM 13 and MM 14 respectively, 
also neutralised infection.  In the cases of MM24 and MM25, the serum samples that 
enhanced  infection in the presence (C’) of complement reduced viral infection in the 
absence  (HIC’)  of active  complement.  For  several  serum  samples  neutralisation 
exceeded  50%  but  not  90%  in  the  absence  of  C’,  yet  when  assayed  with  C’ 
neutralisation is reduced or completely abrogated:  MM14 days 32 and 40; MM42 days 
22, 29 and 43.  The day 24 and 31  serum samples from MM 13 enhanced infection in 
both the presence and absence of C \
On  the  MT-4  cells,  serum  samples  from  2  out  of the  9  patients  enhanced 
infection:  MM25  day  17  and  MM40  day  11.  Enhancement  occurred  only  in  the 
absence  of C’.  Again,  the  samples  that  enhanced  infection  were  from  early  time 
points,  although  none  of the  samples  that  enhanced  infection  on  the  MT-2  cells 
enhanced  infection  on  the  MT-4  cells.  The  same  samples  that  produced  >90% 
neutralisation on the MT-2 cells, MM14 day 848 and MM24 day 464, did so on the 
MT-4  cells,  with  the  exception  of MM26  days  55  and  62.  In  several  cases  C’ 
increased the inactivation of the virus:  MM26 day 55; MM40 day 39; and MM42 day 
29.
110Figure 3.5 Enhanced  infection of IIIB  by sera isolated from  patients at early time points 
after infection
HIV  IIIB  was  incubated  with  patient  serum  or  seronegative  control  serum  (NHS)  and 
complement (C’) or heat inactivated complement (HIC’) for 1  hour at 37°C, then added to MT-2 
cells  (top  panel)  or MT-4  cells  (bottom  panel).  Levels  of infection  were  determined  by  RT 
ELISA on day 5 after inoculation for MT-2 and day 3 for MT-4.  Fold enhancement is the ratio 
of RT output in the  presence of patient serum to RT output in the presence of NHS.  Patient 
numbers (prefix MM) are shown above each serum set.  The day of serum collection following 
onset  of acute  symptoms  is  shown  below.  Values  above  the  dashed  turquoise  line  indicate 
enhanced  infection.  Values  below  1   indicate  reduced  infection,  and  below  0.1  neutralisation. 
Error bars represent SD from 3 experiments.F
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111Only early serum samples (before day  100) enhanced IIIB  infection of MT-2 
and MT-4 cells, while later samples often neutralised infection.  However, when fold 
enhancement values obtained for each serum sample were plotted against the patient 
viral loads on the day of serum collection, no correlation was seen, as shown in Figure 
3.6.
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Figure 3.6 Lack of correlation  between viral load and fold enhancement on MT-2 and 
MT-4 cells
Fold enhancement values obtained from the assays shown in Figure 3.4 were plotted against 
the patient viral load on the day of serum collection.
In summary,  serum samples obtained at early time points following infection 
with HIV were able to enhance infection of IIIB on two T cell lines; on the MT-2 cells 
the  enhancement  was  C’-dependent  and  on  the  MT-4  cells  it  was  C’-independent. 
Enhancement was seen more frequently and to a greater magnitude on the MT-2 cells. 
In the presence of C’, virus inactivation or neutralisation was often reduced on the MT- 
2 cells and increased on the MT-4 cells.
1123.2.3  Evaluation  of the  use  of percent  infected  cells  and  RT  ELISA  output  as 
experimental parameters
The screening assays presented in Section 3.2.2 showed that enhancing activity 
could be detected in early serum samples from HIV positive individuals.  However, for 
reasons of expense, measuring levels of infection by RT ELISA was not suitable for 
use  in  a  routine  enhancement  assay.  Therefore  the  use  of  intracellular 
immunofluorescent p24 staining, to give infection levels as the percentage of infected 
cells,  was  investigated  as  an  alternative.  Cell  supernatant was collected and  stored 
concurrently  with  each  assay  so  that  RT  output  levels  could  be  determined  as 
confirmation of results.  Comparisons were made between RT output and percentage 
infected  cells  to  ensure  that  both  parameters  gave  a  similar  representation  of 
enhancement and neutralisation, shown in Figure 3.7.  Levels of infection correlated 
for both methods, as shown in Figure 3.8. On the MT-2 cells the R2 value was 0.65; on 
the MT-4 cells the R2 value was 0.87.  Where neutralisation and enhancement occurred 
it was shown in both measurements.  It was therefore deemed acceptable to measure 
the number of infected cells as the endpoint for future assays.
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Figure 3.8 Correlation between infection levels in enhancement assays measured by RT 
output and intracellular p24 staining
Scatter  graphs  comparing  fold  enhancement  levels  measured  by  RT  ELISA  with  fold 
enhancement  levels  measured  by  intracellular  p24  staining,  as  shown  in  Figure  3.6. 
Enhancement assays were performed on MT-2 cells (left) and MT-4 cells (right).
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Figure 3.7 Comparison of infection levels measured by RT output and % infected cells
IIIB  was  incubated  with  patient  serum  or  NHS  and  complement  (C’)  or  heat  inactivated 
complement (HIC’) for 1  hour at 37°C, then added to MT-2 or MT-4 cells.  Levels of infection 
were determined by RT ELISA and intracellular p24 staining on day 5 after inoculation for MT- 
2 and day 3 for MT-4:  (A) fflC’ on MT2 cells, (B) C’ on MT2 cells, (C) HIC’ on MT4 cells, 
and (D) C’ on MT4 cells.  Patient numbers (prefix MM) are shown above each serum set.  RT 
output  is  measured by RT  ELISA  of cell  supernatant  and %  infected  cells  is  measured  by 
intracellular p24 staining of the cells and then flow cytometric analysis.  Fold enhancement is 
calculated relative to infection levels in the presence of seronegative control  serum.  Values 
above the dashed turquoise line indicate enhanced infection.
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4995843.2.4  Neutralisation of IIIB on four T cell lines expressing different levels of CR2
The  phenomenon  of C’-mediated  “rescue”  from  neutralisation  (C’-RN)  was 
observed in the MT2 C’-ADE studies (Figure 3.5: MM 14 days 32 and 40; MM42 day 
22)  and  has  been  observed  by  several  other  investigators  (Lund  et  al.,  1995; 
McDougall et al.,  1997; Robinson et al.,  1988a; Robinson et al.,  1990c; Subbramanian 
et  al.,  2002).  Also,  C’-ADE  has  often  been  associated  with  high  dilutions  of 
neutralising antibody (Montefiori et al.,  1991; Subbramanian et al., 2002).  Therefore, 
in  order to  investigate  both of these  phenomena,  four cell  lines expressing different 
levels  of CR2:  H9  (undetectable  CR2),  MT2  (high  CR2  but  some  FcyRII),  Molt-4 
(relatively  high  CR2)  and  SupTl/R5  (high  CR2)  were  tested  with  IIIB  and  serial 
dilutions  of  three  sera  from  chronically  infected  individuals  with  previously 
characterised neutralising activity (Aasa-Chapman et al., 2004).  QC  sera were used 
due to the limited availability of sera from recently infected individuals used in section 
3.2.2.  On NP2/CD4/X4 cells QC1 was the most potently neutralising serum, followed 
by QC2  and  QC4.  Results  from the T cell  assays are  shown  in Figure  3.9.  While 
enhancement  was  not  detected,  four  different  patterns  of neutralisation  occurred  in 
terms  of differences  in titre  in the  presence  (C’)  and  absence  (HIC’)  of C’.  These 
differences are summarised in Tables 3.2, 3.3 and 3.4.
In the absence of C’, the sera had the same characteristics as those seen on NP2 
cells,  with  neutralising  activity  being  in  the  order QC1>QC2>QC4.  The  IC50  and 
IC90 values for each serum in the absence of C’ were similar on all four cell lines, as 
emphasised in Figure 3.10 and Table 3.4.  In the presence of C’, however, the amount 
of serum required to neutralise IIIB was increased on the three CR2+ cell lines.  This 
increase was greatest on the SupTl/R5 cells, which expressed the highest level of CR2, 
and smallest on the H9 cells, which express no detectable CR2.
115Figure 3.9  Neutralisation of IIIB on four different T cell lines
QC sera 1, 2 and 4 were 3-fold serially diluted in control serum and incubated with HIC’ or C’ and 
IIIB for  1   hour at 37°C, then added to H9 cells (top row), MT2 cells (second row), Molt 4 cells 
(third  row),  and  SupTl/R5  cells  (bottom  row).  Levels  of infection  were  measured  on  day  5 
following infection by intracellular p24 staining and flow cytometry analysis.  % residual infection 
is relative to infection in the presence of control serum and HIC’ or C’ as appropriate.  Red arrows 
show the serum IC50 in the presence of C’ and dotted red arrows in the presence of HIC’.  Error 
bars are SD from 3 experiments.%
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2Figure 3.10 Differences in IIIB  neutralisation curves in the presence of C’  on cells that 
express CR2
The  results  from  Figure  3.9  are  directly  compared  by  superimposing the  IIIB  neutralisation 
curves from all 4 cell types onto each other. H9 (^), MT2 (A), Molt4 (#), and SupTl/R5 (♦). The 
top panel shows QC titration assays carried out in the absence of active C’ (HIC’; open shapes); 
the bottom panel shows the difference that C’ makes to neutralisation (C’; closed shapes).
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117SERUM
IC50 Q < :i QC2 QC4
HIC’ C’ HIC’ C’ HIC’ C’
H9 ND ND 1620 1620 180 180
§ MT-2 4860 1620 1620 540 540 60
N -J
u
Molt-4 1620 180 540 20 180 60
SupTl/R5 4860 60 1620 20 540 <20
Table 3.2 IIIB 50% neutralisation titres (IC50) for three sera on four T cell lines
SERUM
IC90 QC1 QC2 QC4
HIC’ C’ HIC’ C’ HIC’ C’
w ► a r
H9 ND ND 180 180 60 60
l-H MT-2 1620 540 540 180 180 20
-J
W
u
Molt-4 180 20 60 <20 60 <20
SupTl/R5 540 20 180 <20 20 <20
Table 3.3 IIIB 90% neutralisation titres (IC90) for three sera on four T cell lines
HIC’ and C’ 
TITRE FOLD 
DIFFERENCES
SERUM
QC1 QC2 QC4
IC50 IC90 IC50 IC90 IC50 IC90
C
E
L
L
 
L
I
N
E H9 ND ND 1 1 1 1
MT-2 3 3 3 3 9 9
Molt-4 9 9 27 >3 3 >3
SupTl/R5 81 27 81 >9 >27 >1
Table 3.4 Fold differences in IC50 and IC90 values with and without C’
Fold decreases in IC50 and IC90 values in the presence of C’ compared to in the presence of 
HIC’, derived from data in Tables 3.2 and 3.3, are given for each sera on each cell type.
1183.2.5 Evaluation of the use of SupTl/R5 cells for future C’-ADE assays
Due  to their expression  of CCR5  (Figure  3.3),  high-level  expression  of CR2 
(Figure 3.1) and greatest C’-RN (Figures 3.9 and 3.10 and Table 3.4), SupTl/R5 cells 
were considered to be the optimal target cell for future studies of C’-ADE.  Therefore, 
further investigation into the use of SupTl/R5  cells for future assays was conducted. 
First, as QC serum was in greater supply than the seroconversion serum samples, the 
SupTl/R5 cells were evaluated in the context of C’-RN.  Next, neutralising and non­
neutralising monoclonal antibodies were tested with IIIB in the presence and absence 
of  C’.  Finally,  C’-ADE  itself  was  investigated  using  the  seroconversion  serum 
samples that enhanced infection of IIIB on MT-2 cells.
3.2.5.1  Complement concentration
Thus far all assays were carried out with a complement concentration of 10%. 
To  ensure  that  this  was  the  optimal  concentration,  several  concentrations  of 
complement were tested from serum concentrations of 1% to 25%.  Levels of infection 
were determined by both intracellular p24 staining and RT output.  Results are shown 
in Figure 3.11.
At fresh serum concentrations of 1% and 25% levels of C’-RN were reduced. 
5% and  10% give similar levels of C’-RN, therefore a complement concentration of 
10% was considered acceptable for future assays.
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Figure 3.11  Effect of the complement concentration on rescue from neutralisation
Serum  QC4  was  used  at  a  dilution  of  1   in  540  (the  last  dilution  that  caused  >50% 
neutralisation  in the  absence of C’) and incubated with IIIB  and  various concentrations of 
complement (1%, 5%,  10% and 25%) for 1  hour at 37°C.  This was then added to SupTl/R5 
cells, and on Day 5  assayed for the % cells infected (top panel) and the RT output (bottom 
panel).
1203.2.5.2  The  effect of neutralising  and non-neutralising monoclonal antibodies  on 
IIIB replication on MT-2 and SupTl/R5 cells in the presence of C’
Two  monoclonal  antibodies,  known to  neutralise  IIIB,  were tested  on  MT-2 
and  SupTl/R5  cells.  The antibody bl2  is a broadly neutralising human monoclonal 
IgGl  antibody, and recognises an epitope on gpl20 overlapping the CD4 binding site 
(Barbas et al.,  1992; Zwick et al.,  2001a; Zwick et al.,  2003).  447-52D is a human 
monoclonal  IgG3  antibody  that  recognises  the  GPGR  epitope  on  the  V3  loop  and 
neutralises mainly clade B isolates (Conley et al.,  1994; Gomy et al.,  1992).  Results 
are shown in Figure 3.12 and summarised in Tables 3.5 and 3.6.
IC50
447-52D 
(reciprocal dilution)
bl2
(Hg/ml)
CELL TYPE HIC’ C’ DIFF1 HIC’ C’ DIFF2
MT-2 160 40 4 0.08 0.08 1
SupTl/R5 320 <10 >32 <0.0195 0.156 >8
Table 3.5 IIIB IC50 values for two monoclonal antibodies on MT-2 and SupTl/R5 cells
IC90
447-52D 
(reciprocal dilution)
bl2
(ug/ml)
CELL TYPE HIC’ C’ DIFF1 HIC’ C’ DIFF2
MT-2 40 10 4 0.625 0.625 1
SupTl/R5 40 <10 >4 1.25 2.5 2
Table 3.6 IIIB IC90 values for two monoclonal antibodies on MT-2 and SupTl/R5 cells
1  Represents the fold decrease in IC50 or IC90 value in the presence of C’
2  Represents the fold increase in IC50 or IC90 value in the presence of C’
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Figure 3.12  Neutralisation of IIIB  by monoclonal antibodies 447-52D and bl2 on MT-2 
and SupTl/R5 cells
Two known neutralising monoclonal antibodies, 447-52D and bl2, were serially diluted and 
incubated with IIIB and HIC’ or C’  for 1   hr at 37°C then transferred to MT-2 or SupTl/R5 
cells.  Cells were intracellularly stained for p24 on day 5 following infection, and % residual 
infection calculated relative to control cultures (NHS and HIC’  or C’  as appropriate).  Solid 
arrows indicate IC50 values in the presence of C’; dashed arrows in the presence of HIC’.  For 
447-52D the concentration of the antibody was unknown therefore antibody quantity is shown 
as  reciprocal  dilution  of  the  hybridoma  supernatant.  Error  bars  represent  SD  from  3 
experiments.
122As with the QC serum, no enhancement was seen but C’-RN was evident.  C’- 
RN was strongest on the  SupTl/R5  cells, with IC50 values being more than 32-fold 
different in the presence and absence of active complement for 447-52D and more than 
8-fold different for bl2.  447-52D does not neutralise at all in the presence of C’  on 
SupTl/R5  cells.  The  difference  was  less  on  the  MT-2  cells,  with  447-52D  titres 
differing by 4-fold and bl2 titres showing no difference.
As  the  SupTl/R5  cells  supported  considerable  C’-RN,  a  non-neutralising 
antibody reported to enhance IIIB infection, 246-D (Forthal et al.,  1995; Prohaszka et 
al.,  1997)  was tested for its  effect on IIIB  infection of SupTl/R5  cells.  246-D  is  a 
human monoclonal IgGl antibody to the epitope 579-604 of gp41 (Gomy et al., 1989).
Figure  3.13  Enhancement  of  IIIB 
infection  of  SupTl/R5  cells  by 
monoclonal antibody 246D
IIIB was incubated with serial dilutions of 
246-D  in  the  presence  (C’)  and  absence 
(HIC’) of complement for  1   hour at 37°C, 
then  added to  SupTl/R5  cells.  Levels  of 
infection  were  determined  by  intracellular 
p24 staining on day 5 following inoculation. 
The  dashed  turquoise  line  represents  the 
enhancement  threshold.  Error  bars 
represent SD of 3 experiments.
In the absence of C’  246-D had no effect on IIIB infection of SupTl/R5 cells. 
In presence of C’  the highest concentration of antibody enhanced infection,  and this 
effect was rapidly abolished with increased dilution.
Results are shown in Figure 3.13.
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1233.2.5.3  Testing early sera that enhanced IIIB infection on MT-2 cells on SupTl/R5 
cells
Several serum samples that enhanced IIIB infection of MT-2 cells were tested 
on SupTl/R5 cells.  Results are shown in Figure 3.14.  The MM24 days 26 and 44, and 
MM25 day 38 sera enhanced infection of IIIB on both MT-2 and SupTl/R5 cells.  The 
level  of  neutralisation  on  MT-2  and  SupTl/R5  cells  also  corresponded,  with  the 
exception of MM26 day 55.
In conclusion, where enhancement of IIIB infection was seen on MT-2 cells it 
was also shown to occur on SupTl/R5  cells.  C’-RN is more powerful on SupTl/R5 
cells, for both neutralising sera and monoclonal antibodies.
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Figure 3.14 Comparison of C’-ADE of IIIB on MT-2 and SupTl/R5 cells
Enhancement assays were carried out in the presence of C’ on MT-2 and SupTl/R5 cells with 
IIIB  and patient  sera from  MM24,  25  and 26.  Fold enhancement  is  calculated  relative  to 
infection levels in the presence of seronegative control serum.  Values above the dotted blue 
line indicate enhanced infection
1253.3 DISCUSSION
3.3.1 ADE of HIV on T cell lines
3.3.1.1 Magnitude of  ADE
The aim of this chapter was to investigate the occurrence of ADE of the HIV 
strain  IIIB, as reported  in the literature, and to develop a suitable enhancement assay 
for further study of ADE in clinical HIV samples.  From initial screening experiments 
with sera obtained at early stages after HIV infection, ADE was seen more frequently 
on a CR2+ cell line, MT-2, than on an FcyRII+ cell line, MT-4.
Levels of IIIB enhancement seen in the MT-2 system, between 2.08- and 6.4- 
fold,  compared  favourably with those reported previously, with several  investigators 
quoting  fold  enhancement  levels  of  1.5-4  fold  in  similar  experimental  systems 
(Banhegyi et al., 2003; Lund et al.,  1995; Prohaszka et al.,  1997; Szabo et al.,  1999). 
Others  have  reported  higher  enhancement  levels.  However,  difficulties  arise  in 
attempting to directly compare my results with these particular studies, as most present 
enhancement measurements as antibody titres (Montefiori et al., 1991; Robinson et al., 
1988a;  Robinson  et  al.,  1988b)  or percent  increase  in  cell  death  (McDougall  et al., 
1997; Robinson et al.,  1991).  But when quantitative methods, such as % IFA positive 
cells  and  RT  release,  were  reported  in  some  of these  studies the  fold  enhancement 
levels  ranged  from  3.4  to  14-fold  (Robinson  et  al.,  1990a;  Robinson  et  al.,  1990b; 
Robinson  et al.,  1990c;  Robinson et al.,  1989b),  and  in another study levels of HIV 
cDNA  and  integrated  provirus were  increased  8- to  30-fold  (Robinson,  2006).  C’- 
independent ADE was also observed on the MT-2  system  (MM13  days 24  and  31). 
This  resembled  previous  observations  of  C’-independent  ADE  of  HIV  on  FcR- 
negative cell lines, in which monoclonal antibodies were used to show enhancement of 
various  HIV  strains  in  the  range  of 3-10-fold  (Guillon  et al.,  2002;  Schutten  et al., 
1997).
ADE had not previously been investigated in FcyRII+ MT-4 cells.  One group 
reported  the  use  of MT-4  cells  in  enhancement  assays  but  their MT-4  cells  had  a 
different  phenotype  from  the  cells  used  here,  being  CR2+  ClqR+  CD4+  T  cells 
(Banhegyi et al., 2003;  Prohaszka et al.,  1997; Szabo et al.,  1999).  In systems using 
U937 cells, FcR-ADE was reported in the range of 1.5 to 3-fold (Laurence et al.,  1990; 
Takeda et al.,  1990; Takeda et al.,  1988), and my results are in accordance with those.
126Overall,  levels of enhancement of IIIB are much lower than those reported for 
dengue  virus  enhancement,  both  in  published  reports  and  data  presented  in  this 
chapter, with typical levels of dengue virus ADE ranging from 2 to 200 fold (Halstead 
and O'Rourke,  1977b).
3.3.1.2 Correlations of  ADE with disease
Despite using similar methods, my results do not agree with two studies citing 
correlations between fold enhancement and viral loads (Banhegyi et al., 2003; Szabo et 
al.,  1999).  This could be because they studied patients at advanced stages of disease 
whereas my comparisons were made with sera from asymptomatic patients.  At early 
stages of disease viral  loads and antibody titres fluctuate more over a short period of 
time  than  during chronic  and  advanced  stages  of disease,  and this may confuse the 
issue of correlations.  Also, patient numbers were lower in my study although several 
samples  were  taken  sequentially  from  each  patient,  which  may  not  give  the  same 
representation as a cross-sectional study.
3.3.2 CR2 expression is common among T cell lines
CR2 expression was frequently detected on the T cell lines tested, with MT-2, 
Molt-4,  SupTl,  SupTl/R5  and  C8166  cells all expressing detectable  levels.  This  is 
supported  by publications showing high level CR2 expression on other CD4+ T cell 
lines including Jurkat (Braun et al., 1998; Fingeroth et al., 1988; Prodinger et al.,  1996; 
Sinha et al.,  1993), HBP-ALL (Delibrias et al.,  1992; Fingeroth et al.,  1988; Saifuddin 
et al.,  1994),  Molt-3  (Fingeroth et al.,  1988), Molt-4 (Menezes et al.,  1977), C91.PL 
(Prodinger et al.,  1996), and SupTl  (Prodinger et al.,  1996).  Clearly, different clones 
of certain cell lines can exhibit different cell receptor expression patterns. Reports have 
shown an absence of CR2 expression on SupTl cells (Romano et al.,  1997), and MT-4 
cells have been attributed with high-level expression of CR2 (Prohaszka et al.,  1997), 
in  contrast  with  results  presented  here.  CR2  has  also  been  detected  on  human 
peripheral  blood T cells (Fischer et al.,  1991; Fischer et al.,  1999; June et al.,  1992; 
Masilamani  et  al.,  2002;  Sauvageau  et  al.,  1990)  and  thymocytes  (Delibrias  et  al., 
1994;  Fischer et al.,  1999; Tsoukas and Lambris,  1988).  The function of CR2 on T 
cells has yet to be adequately explained.  The fact that CR2 is readily detected on many 
T cell lines and also on primary T cells, however, could indicate an important role for 
this receptor that is yet to be appreciated.
1273.3.3 Complement-mediated rescue of HIV from neutralisation
The concept of complement reducing the power of neutralising antibodies  is 
important, with  implications for neutralisation assays and vaccine design.  It is often 
described  as  a  by-product  of enhancement  and  has  not  been  studied  as  a  separate 
phenomenon.  Here it is shown that the presence of complement can reduce the 50% 
neutralising titre of serum  by up to  81  fold,  and the corresponding 90% neutralising 
titre by at least 27 fold.  In reports where the neutralising titre of serum on MT-2 cells 
is  given  in  both  the  presence  and  absence  of C’,  the  fold  difference  in titre  is  in  a 
similar  range  as  the  results  of my  study:  6-fold  (Robinson  et  al.,  1990c),  2-8-fold 
(Robinson  et  al.,  1988a)  and  3-81-fold  (McDougall  et  al.,  1997),  compared  with  a 
range  of 3-9-fold  difference  for the IC50 and IC90  values for the three neutralising 
sera tested in my assays.  The same phenomenon has not been previously reported for 
Molt-4 or SupTl/R5 cells.
3.3.4 Mechanisms of ADE and C’-RN
3.3.4.1  Mechanism of C’-RN
From results shown in Figures 3.1, 3.2 and 3.9 it may be deduced that the C’- 
mediated rescue from neutralisation is mediated by the presence of CR2, as the only 
cell  line  that  does  not  show  this  activity,  H9,  is  the  only  cell  line  lacking  CR2. 
However,  this  is  not  conclusive  proof  of  the  involvement  of  CR2,  and  will  be 
addressed further in Chapter 6.
On the MT-2 cells the C’-RN was less than on the SupTl/R5 and Molt-4 cells, 
despite the fact that they express a high level of CR2. This could be due to low-level 
expression of FcyRII counteracting the effect of CR2, as in Section 3.2.2 an increase in 
neutralisation in the presence of C’ is seen on the MT-4 cells, in contrast to the C’-RN 
seen  on  the  MT-2  cells.  Alternatively,  receptors  other that those  investigated  may 
contribute to differences seen with and without complement on the four cell lines.  For 
example, Clq receptors or CR4 may be present and may account for the difference in 
C’-mediated  rescue  seen  on  SupTl/R5  compared  with  Molt4  cells  which  have 
apparently the same receptor expression.
It  is  unlikely that the  sole  mechanism  of C’-RN  is masking of neutralisation 
epitopes by complement as previously suggested (Hidvegi et al.,  1993), as, if this were
128the  case  it  would  be  evident  in  the  absence  of CR2.  However,  it  could  be  that 
complement binds to regions close to the neutralisation binding epitopes.  It is possible 
that the mechanism of C’-mediated rescue is the same as that for C’-ADE, and that C’- 
RN is essentially a lower level of C’-ADE.  C’-RN could occur because the balance of 
neutralising and enhancing antibodies results in net neutralisation, yet the presence of 
enhancing antibodies allows rescue from neutralisation in the presence of complement. 
Alternatively, when <90% saturation of the virus by neutralising antibodies occurs, C’- 
RN  may provide the virus with  increased attachment to the target cell and therefore 
greater chance of successful infection, that otherwise was not available in the absence 
of CR2.
If one were to consider C’-RN as a surrogate for assessing assays to measure 
C’-ADE,  then  in  the  direct  comparison  between  H9,  MT-2,  Molt-4  and  SupTl/R5 
cells, the SupTl/R5 cells are the most appropriate cell line for the future studies of C’- 
ADE.  More importantly, they provide the opportunity to study C’-ADE of autologous 
virus using patient virus isolates, most of which are R5-tropic.
3.3.4.2  Monoclonal antibodies
The  fact  that  the  neutralising  activity  of  two  monoclonal  antibodies  with 
different epitopes -  447-52D to the V3 loop and bl2 to the CD4 binding site -  can be 
reduced  on  SupTl/R5  cells  in  the  presence  of C’  indicates  that  the  mechanism  of 
rescue is a general rather than specific one.  It is interesting that the fold rescue from 
neutralisation  is  different  for  the  two  monoclonal  antibodies  -   potentially  the  bl2 
antibody is more potent on an individual molecule basis than the 447-52D antibody.
In  this  chapter,  results  with  monoclonal  antibodies  suggest  that  neutralising 
antibodies have different specificities from enhancing antibodies, as proposed by other 
investigators.  However, examining the effects of three monoclonal antibodies does not 
conclusively show different actions of neutralising and enhancing antibodies -  for this 
to be the case a much greater number of monoclonal antibodies, of various specificities 
and  isotypes,  should be  investigated.  However,  it is possible to say that in this case, 
two  neutralising  antibodies  do  not  enhance,  and  one  enhancing  antibody  does  not 
neutralise, suggesting a difference in neutralisation and enhancement epitopes.
1293.3.4.3  The net effect of complement -  enhancement or inactivation?
Results in this chapter have shown that complement can have various effects on 
viral infection depending on the target cell and serum used.  C’-RN results presented in 
this chapter indicate that viruses assayed here are not irreversibly neutralised at all, nor 
are they  lysed.  As the virus was  incubated with  serum  and complement for  1   hour 
before addition to target cells,  lysis and neutralisation would occur at that stage, and 
addition to cells should make little difference.  However, the fact that the viruses could 
be rescued from neutralisation indicates that they were not irreversibly inactivated by 
complement,  thus  are  not  completely  lysed.  Therefore  I  would  argue  that,  when 
additional  inactivation  is  seen  in the presence of complement (i.e.  in the absence of 
CR2+ cells), this is primarily due to opsonisation and not lysis.
The  IIIB  used  for the experiments shown  in this chapter was produced in H9 
cells,  which  reportedly  have  a  lower  level  of CD55  and  CD59  on  their  surface 
compared  with  primary  cells  (Saifuddin  et  al.,  1995).  Thus  this  particular  virus 
preparation  would  be  expected  to  be  relatively  susceptible  to  lysis.  However,  as 
shown, this is not the case.  Primary isolates grown in PBMCs, therefore, are likely to 
be even  less susceptible to C’-MI and  perhaps even more susceptible to C’-ADE, as 
investigated in Chapter 4.
3.3.5  Concluding remarks
Although results presented here are in agreement with previous reports,  levels 
of enhancement  seen  for IIIB  are  weak and  in many cases variable.  It  became the 
model virus on which to study ADE because most work in the late  1980s focused on 
TCLA strains of HIV as these were easier to grow and characterise.  Also, most T cell 
lines used for in vitro HIV studies express very little, if any, CCR5, and generally do 
not support infection by primary (predominantly R5-tropic) HIV strains, necessitating 
the use of an X4 tropic virus.  Therefore, C’-ADE studies on IIIB set the precedent for 
later work.  However,  several  studies have  questioned  the relevance  of TCLA  HIV 
strains  to  primary  patient  isolates  (Moore  and  Ho,  1995),  particularly  in  terms  of 
neutralisation phenotypes.  The same may be true of enhancement.  In terms of clinical 
relevance it would be more informative to study enhancement of primary HIV isolates, 
particularly those relevant to currently circulating HIV strains.
One viewpoint is that the structure of the virus envelope is more important for 
enhancement than the  epitope  specificity of the antibodies themselves (Davis et al.,
1302001;  Kliks  et  al.,  1993;  Kostrikis  et  al.,  1996)  and  that  some  viruses  are  more 
susceptible to enhancement than others.  These considerations highlight the importance 
of studying enhancement of different HIV strains and, particularly, the enhancement of 
autologous primary isolates.  This is investigated in Chapter 4.
131CHAPTER 4
Longitudinal studies of infection-enhancing antibodies from 
individuals infected with HIV
This chapter investigates the occurrence of antibodies with C’-ADE activity in 
HIV infection using viruses isolated from patient samples and longitudinally collected 
autologous serum samples.
4.1 INTRODUCTION
4.1.1 The need to study C’-ADE soon after infection with HIV
Primary  HIV  infection  is  characterised  by high  levels  of virus  replication,  a 
drop in CD4 cell counts and often concomitant clinical manifestation, PHI.  Viral RNA 
levels  in  the  plasma  can  exceed  107-108   copies  per  ml.  This  usually  precedes  or 
coincides with seroconversion and is followed by a 100-10000 fold drop in viral load 
to  reach  a  stable  level  known  as  the  viral  set  point.  Neutralising  antibodies  are 
generally not detected until several months after infection (Aasa-Chapman et al., 2004; 
Aasa-Chapman et al., 2005; Moog et al.,  1997; Richman et al., 2003; Wei et al., 2003) 
and even then it is doubtful that they neutralise contemporaneous virus.  This leaves a 
time frame  in which non-neutralising antibodies are abundant, and the possibility that 
they are present throughout infection.  Potential activities have been assigned to non­
neutralising antibodies, including ADCC (Forthal et al.,  1995; McDougall et al.,  1997; 
Subbramanian et al., 2002) and FcR-mediated inhibition of viral replication (Forthal et 
al., 2005; Holl et al., 2006).  Using the same patient cohort as the one studied in this 
chapter,  Aasa-Chapman et al  showed that early non-neutralising antibodies produced 
in  response  to  HIV  infection  could  inactivate  autologous  virus  in  the  presence  of 
complement (Aasa-Chapman et al., 2005).  As inactivation was attributed principally 
to opsonisation and not lysis of HIV particles,  it is also possible that these antibodies 
may  enhance  HIV  infection  and  contribute  to  the  initial  burst  of replication  and 
establishment of viral reservoirs seen in early stages of disease.
Studies  have  indicated  that  C’-ADE  can  correlate  with  disease  in  infected 
individuals (Subbramanian et al., 2002; Szabo et al.,  1999).  Other studies have shown 
no correlation (Montefiori et al.,  1991).  However, all of these studies were carried out
132on heterologous virus strains, most commonly IIIB, and concentrated on sera from late 
asymptomatic  disease  stages,  or from  AIDS patients.  C’-ADE of SIV  infection has 
been  shown  by  early  autologous  antibody  and  results  indicated  a  role  for  C’-ADE 
antibodies  in  disease  progression  (Montefiori  et  al.,  1995).  Early  serum  samples 
enhanced  infection  in the presence  of complement,  progressing to  neutralisation  by 
later  samples.  Such  a  study has  not been  done  in  humans,  although  samples  from 
seroconversion  panels have been shown to enhance heterologous virus (Szabo et al., 
1999),  with  results  similar to  those  shown  in  Chapter  3  of this  thesis.  Autologous 
studies  of  enhancement  have  been  carried  out  on  primary  cells  and  showed 
enhancement  to  correlate  with  disease  progression  (Homsy  et  al.,  1990),  but  these 
studies  looked  at  later stages of disease and did not investigate a role for C’  in this 
phenomenon.
Therefore, the focus of this chapter is to address the issue of C’-ADE in early 
sequential serum samples against autologous virus, in order to assess whether there is a 
role  for  C’-ADE  in  early  HIV  infection  and  the  development  of this  response  over 
time.  Using samples  from  a patient cohort, C’-ADE activity is  investigated from  as 
early as  12 days post onset of PHI symptoms to several years after infection.
4.1.2  The enhancement assay
This  chapter  contains  results  from  experiments  using  an  enhancement  assay 
developed from the results in Chapter 3.  SupTl/R5 cells were chosen as the optimal 
target cell  for an  enhancement assay because  (a) they express  a high  level  of CD4, 
CXCR4 and CCR5, allowing for the investigation of both X4 viruses and, importantly, 
R5-using primary isolates from patient samples, (b) they express a high level of CR2 
and therefore provide a system in which to study C’-ADE, and (c) of all the CR2+ T 
cell lines tested in Chapter 3, they showed the most dramatic C’-mediated rescue from 
neutralisation, therefore they are the most sensitive cell line in which to find evidence 
of C’-ADE.
As  in  Chapter  3,  for  the  assays  that  follow,  results  are  shown  as  “fold 
enhancement”,  meaning the ratio of infection  in the presence of autologous serum to 
infection  in  the  presence  of pooled  seronegative  control  serum  (NHS),  calculated 
separately for infection in the presence of HIC’ and C’.  This cancels out the effect of 
non-specific  C’  enhancement  in the assays, which,  for most viruses was 2-fold,  and 
allows the data to be presented only in terms of the additional effect of the antibodies.
133Infectivity  was  measured  by  the  percentage  of cells  infected,  by  intracellular  p24 
staining and flow cytometry 6 days after infection.  A cut-off point of 5 fold was set as 
the  level  of true  enhancement,  as  normal  human  serum  taken  from  7  uninfected 
individuals  enhanced  infection  up  to  3.7  fold  ±  0.57  (compared  to  pooled  control 
serum, NHS) as shown in Figure 4.1.
Figure 4.1  Background enhancement
Virus  was  incubated  with  several  different
seronegative  sera  and  added  to  SupTl/R5
cells.  Serum  number  1   is  the  control  serum
used  for  all  enhancement  assays  and  is
commercially  available  pooled  HIV  antibody
negative  serum  (NHS).  Serum  samples  2-10
were  from  9  HIV  negative  individuals.
Results were standardised to Serum  1.  Results
shown  are  from  MM32  day  10  virus,  but are
representative of viruses from other patients as
no more than  3.7-fold enhancement was  seen 
serum number
in  the  presence  of  HIV  antibody  negative 
serum.  Error bars represent standard deviation 
from 3 experiments.  HIC’ E   C’ ®
The viral  input was set at the low level of 0.1% infected cells (out of 10,000 
cells acquired per replicate in the flow cytometry analysis) because the viruses isolated 
from  patients  were  of  low  titre,  and  also  as  this  leaves  the  greatest  scope  for 
enhancement.  C’,  or the  HIC’  control,  was used  in the  assay at a concentration  of 
10%, as was patient serum or NHS, unless otherwise stated.
4.1.3  The patient cohort
As  shown  in Chapter 3,  serum samples from early time points after infection 
showed  C’-ADE  activity  against  IIIB.  It  was  therefore  decided  to  test  sequential 
serum  sample  sets  from  10  patients  for enhancing activity  against autologous virus. 
Sequential  samples were obtained from  10  individuals  infected with clade B  HIV-1. 
Samples were used from as early as  12 days post onset of symptoms up to  1000 days, 
as  these  were  expected  to  cover  the  time  frame  of  both  non-neutralising  and
I f
134neutralising  antibody  development.  Patient  primary  isolates  were  propagated  from 
patient  PBMCs and the co-receptor tropism determined by titration on NP2/CD4/R5 
and NP2/CD4/X4 cells. All patient primary isolates used in this study were R5 tropic. 
Further details of the patient cohort are given in Materials and Methods section 2.4 and 
Aasa Chapman et al 2005.
4.2  RESULTS
4.2.1 Characterisation of the patient cohort
4.2.1.1 Patient viral loads
Figure  4.2  shows  plasma  viral  loads  for the  10  patients  investigated  in  this 
study  over  the  time  frame  investigated  (data  provided  by  Ian  Williams,  Mortimer 
Market Clinic, UCL).  Peak viral loads coincide with primary symptoms; therefore as 
the time of study is measured in days following the onset of symptoms we expect our 
study to begin during or after the decline in viral load signifying the beginning of the 
asymptomatic disease period.  In some patients this precipitous drop in viral load was 
detectable (MM28, MM32), but in most the viral load was in gradual decline up until 
approximately day  100.  After this the  viral  loads either reach  a steady  level,  as  in 
MM25  and MM33, or continue to fluctuate, as in MM26, MM34 and MM42.  Table
4.1  shows the viral set-point for each patient, taken as the viral load at the time point 
closest to 6 months following onset of symptoms.  Set-points were classified as high, 
medium  or  low  according  to  thresholds  stipulated  by  Mellors  et  al  (Mellors  et  al., 
1997).
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Figure 4.2 Patient viral loads
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Viral  loads  were  determined  for  each  patient 
throughout the period of study.  RNA was  amplified 
from plasma by RT-PCR and subsequently quantified 
by ELISA.  Results are shown as HTV RNA copies per 
ml.  Data,  provided by Ian  Williams  and  his team  at 
the Mortimer Market Centre, were determined using a 
Chiron 3.0 viral load test (California, USA).
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136PATIENT SET-POINT
(copies/ml)
GROUP PATIENT SET-POINT
(copies/ml)
GROUP
MM24 170,200 High MM32 N/A
MM25 71,100 High MM33 80,000 High
MM26 44,600 High MM34 9,600 Low
MM27 28,800 Medium MM38 N/A
MM28 5,600 Low MM42 115,100 High
Table 4.1  Patient viral load set-points
The  viral  set-point  for each patient is determined by the viral  load at the time closest to 6 
months.  Patients  are classified  into 3  groups  according to their set-points:  low (<10,000), 
medium (10,000-30,000) and high (>30,000) according to thresholds determined by Mellors et 
al (Mellors et al., 1997).  N/A: viral load data were not available.
4.2.1.2  The development of anti-HIV Env antibody responses
The  development of an  anti-HIV antibody response was  investigated  in each 
patient by ELISA.  Antibodies to monomeric gpl20 from IIIB were detected in plasma 
samples collected  sequentially throughout the period of study.  Results are shown  in 
Figure  4.3.  Background  antibody binding  (measured  in the  absence  of gpl20)  was 
subtracted for each sample therefore any value above 0 indicates the presence of anti- 
gpl20 antibody.  With the exception of MM38, all patients had detectable antibodies to 
HIV-1  gpl20  from  the  earliest time point available,  allowing the  potential  for ADE 
activity  from  the  earliest  samples  used  in the experiments that  follow.  The  ELISA 
detects  antibodies to  monomeric  HIV  IIIB  gpl20,  therefore  it  is  possible that early 
antibodies to autologous native envelope were present but below the limit of detection 
of the  assay.  The  assay  also  fails  to  detect  antibodies  to  the  gp41  portion  of the 
envelope and possibly lower affinity antibodies such as IgM isotypes, so these should 
also be taken into account.
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Figure 4.3 Anti-gpl20 antibody development
Antibodies to HIV monomeric gpl20 were detected in 
sequential  patient  plasma  samples  by  ELISA. 
Background  is  subtracted  from  all  results,  so  any 
positive  value  represents  the  presence  of anti-gpl20 
antibodies.  Patient ID numbers are shown above each 
graph.  Error bars represent SD from 3 replicates.
MM25 MM26 MM27
15
10
5
0
10 100 1000
15
10
5
0
10 100 1000
15
10
5
0
10 100 1000
MM28 MM32
15
10
5
0
100 1000 10 1000
15
10
5
100
MM33
15
10
5
0
100  10 100 1000
MM34
15
10
5
0
MM38
10  100  1000
Days following onset of symptoms
138
MM42
15
10
5
0
10 100  1000 
  ►4.2.2  C’- ADE of early virus isolates by autologous sera
4.2.2.1  Strong C'-ADE activity is observed in early serum samples
Viruses isolated from early time points, between 6 and 62 days following onset 
of symptoms,  were  assayed  in the presence of sequential autologous serum  samples 
and C’ or HIC’.  Results from the autologous enhancement assays are shown in Figure 
4.4.  With the  exception of MM27,  all  patients  showed evidence of strong C’-ADE 
activity,  with  enhancement  levels as high as 236-fold.  The patients can be grouped 
according to the patterns of C’-ADE activity development over time:
Group 1: MM24, MM25 and MM26
C’-ADE was  strongest at earliest time points then  subsided to neutralisation. 
In both the presence (C’) and absence (HIC’) of active complement, greater than 90% 
neutralisation was seen at similar times for all three patients:  on day 208 for MM24; 
day  185  for MM25  and day 253 for MM26.  The phenomenon of C’-mediated rescue 
from  neutralisation  did not occur in these samples.  Neutralisation  is investigated  in 
more detail in section 4.2.3.
While neutralisation occurred at a similar time and to the same degree in these 
patients,  enhancement differed.  The overall magnitude of enhancement was highest 
for MM24, peaking at 236-fold on day 44; then for MM26 at 35-fold on day 139; and 
lowest for MM25 at 8-fold on day 31.  The peak enhancement was seen with sera from 
time points close to the day from which the virus was isolated (MM24 day 26 virus; 
MM26 day 31  virus; MM25 day 62 virus).
Group 2: MM27
C’-ADE was below the enhancement threshold and within 1   SD of infection in 
the presence of HIC’. It was highly variable, as shown by the large error bars seen in 
Figure 4.4.  Neutralisation was not detected in this assay.
Group 3: MM28, MM33, MM34 and MM42
C’-ADE activity was weaker at earlier time points then steadily increased from 
day  100 onwards.  In each patient there was a smaller early peak before the late peak 
of enhancement:  for MM28 there was 29-fold enhancement on day 34 then 86-fold on
139day 782; for MM33 41-fold on day 26 then 115-fold on day 719; for MM34 11-fold on 
day 45 then 28-fold on day 353; and for MM42 6-fold on day 36 then  19-fold on day 
238.  As with those seen in Group  1, the patterns in Group 3 were similar whilst the 
magnitudes differ.  For all 4 patients in this group the second peak of enhancement was 
approximately 3 times greater than the first, yet peak enhancement ranges from 19-fold 
to  115-fold within patients and the length of time between the first and second peaks 
differed in all 4 patients.  The first peak resembled that seen in the Group  1   patterns, 
occurring between days 26 and 45 with a magnitude of between 6- and 41-fold. It is 
the second,  larger peak and the failure to neutralise the early virus that distinguishes 
the  Group  3  patterns  from  those  of Group  1.  For  MM33,  the  last  of the  samples 
assayed showed the greatest enhancement.  For MM28, MM34 and MM42 the level of 
enhancement declined in the last sample; in the case of MM34 and MM42 this dropped 
to below the level seen in the early time points.
MM32  and  MM38  were  excluded  from  classification  as  the  sample  sets  for 
these patients were incomplete: MM32 was lost to follow-up and MM38 commenced 
antiretroviral treatment.  However, the time points assayed showed C’-ADE activity, 
with MM32 enhancement reaching 58-fold on day 21 and MM38 46-fold on day 93.
In all patients except MM27, the serum samples taken from the same time point 
that  the  virus  was  isolated  enhanced  infection.  In  several  patients  C’-independent 
ADE was detectable (MM24, MM26 and MM28), a phenomenon previously observed 
by Schutten and colleagues on SupTl cells with monoclonal antibodies (Guillon et al., 
2002;  Schutten  et  al.,  1997).  However,  the  C’-independent  ADE  was  of  limited 
magnitude compared to the C’-ADE.
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Figure 4.4  C’-ADE of early viruses from 10 patients by autologous sequential sera
Serum sets from  10 patients were tested against autologous virus for C’-ADE activity. 
Virus was incubated with patient or control (NHS) serum in the presence of HIC’ (□)  or 
C’ (■ ) for  1   hour at 37°C and then inoculated onto SupTl/R5 cells.  After 6 days the 
percentage of cells infected is measured by intracellular p24 staining.  Fold enhancement 
is  calculated  relative  to  infection  levels  in  the  presence  of NHS,  and  HIC’  or  C’  as 
appropriate.  Patient numbers are given above each chart.  Arrows indicate the time point 
from which virus was isolated.  Error bars represent SD from 3 experiments.
1424.2.2.2  C’-ADE increases the number of cells infected, the RT output and cell death 
To further characterise the C’-ADE observed in Figure 4.4, several parameters 
of infection were measured: the percentage of cells infected, cell viability, RT output 
and  change  in  RT  output  over  the  course  of the  assay,  using  day  26  virus  and 
autologous  serum  samples  from  MM24.  The  fold  enhancement  of the  number of 
infected  cells  and  RT output closely correlated,  as  shown  in Figure 4.5  (A) and (B) 
overleaf,  although  the  net  fold  enhancement  in  the  presence  of complement  was 
approximately 2-fold higher in the measurement of infected cells, as shown in Figure
4.6  below.  This  could  be  because  there  was  a  lag  between  cell  infection  and  RT 
production.  This is supported by Figure 4.5 (D) which shows a more rapid progression 
of infection in the enhanced cultures compared with the NHS + C’ control resulting in 
a greater fold enhancement as a function of time.  It could also be that cells that formed 
syncytia  were  inefficient  at  releasing  virus.  Figure  4.7  shows  the  extent  of the 
cytopathic effect with microscope images and flow cytometry plots from experiments 
done  in  the  presence  of  NHS  and  complement  and  autologous  day  44  sera  and 
complement.  Figures 4.5 and 4.7 show that the enhancement seen for patient MM24 
is  the  difference  between  a  low  level,  barely  detectable  infection,  and  a  highly 
cytopathic one.  In the presence of C’, day 44 serum enhanced RT output by 92-fold, 
the number of cells infected by 236-fold and increased the percentage cell loss to 80% 
compared  to  0%  in  the  presence  of  control  serum  and  C’.  These  findings  are 
summarised in Table 4.2.
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Figure 4.5  RT output, % infected cells and % viable cells in enhanced infection
Enhanced  infection of virus isolated at day 26 following onset of symptoms from patient 
MM24.  Assays  were  performed  on  SupTl/R5  cells  with  autologous  sequential  patient 
serum  samples  or an NHS  control  in the presence of HIC’  (open  squares) or C’  (closed 
squares)  .  Levels  of infection  are  shown  as  (A)  %  infected  cells  measured  by  flow 
cytometry,  (B) %  cell  loss measure by MTT assay,  and  (C) RT output  measured  by RT 
ELISA.  Panel (D) shows the assay time course from (C).  Fold enhancement and % viable 
cell  loss  are  calculated  relative  to  infection  in the  presence  of NHS  and  HIC’  or C’  as 
appropriate.  Error bars represent SD from 3 experiments.
144A   1000
10"  10'  102   103   104  
p24 antigen expression
Figure 4.7  Microscopy images and flow cytometry plots from an enhancement assay
Images show enhanced infection of virus isolated on day 26 (following onset of symptoms) 
from  patient MM24.  Assays were performed on  SupTl/R5  cells with  autologous virus  in 
the presence of NHS and C’  (top images) or day 44 serum and C’  (bottom  images)  .  The 
left panels show microscopy images from Day 5 of the enhancement assay.  Arrows in the 
top left image point to syncytia.  On the same day the cells were intracellularly stained for 
p24 and analysed by flow cytometry (right panels).  The fold enhancement seen for day 44 
serum  is calculated relative to  infection in the presence of NHS  and C’  and  in this case  is 
236-fold.
145PARAMETER ASSAY
NHS + 
HIC’
NHS + C’
d44 + 
HIC’
d44 + C’
% infected cells
Intracellular 
p24 stain
0.09 0.195 1.45 46.1
% viable cells MTT 101.3 100.7 84.0 20.1
RT production 
(pg/ml)
RT ELISA 147.9 221.8 662.1 20494.8
Table 4.2 Parameters of enhanced infection
To characterise the nature of enhanced infection, three different measurements were used.  A 
virus  isolate derived from patient MM24 26 days following onset of symptoms was incubated 
with  control  serum  or  day  44  autologous  serum  in  the  presence  (C’)  or  absence  (HIC’)  of 
active complement for 1   hour at 37°C and then transferred onto SupTl/R5 cells.  Determinants 
of  infectivity  were  examined  5  days  after  infection.  The  number  of  infected  cells  was 
determined by intracellular staining for p24 antigen and subsequent flow cytometric analysis. 
The  percentage  of viable  cells  was  determined  by  MTT  assay,  with  100%  representing the 
level of viable cells in the absence of virus.  RT production was measured in supernatant from 
infected cells using a commercial RT ELISA.
4.2.3  C’-ADE of viruses isolated from later time points following infection
Viruses  isolated  early  after  infection  were  enhanced  by  autologous  sera 
therefore it was decided to investigate enhanced infection of later virus isolates.  This 
provided  the  opportunity  to  study  enhancement  in  contemporary  virus-serum  pairs 
from two different time points.  Also, the effect of serum time points taken before the 
virus  was  isolated  could  be  examined  to  give  information  about  the  antibody 
environment  in  which  the  virus  evolved.  Representative  patients  from  each  of the 
patterns described in section 4.2.2 were used.  Results are shown in Figure 4.8.
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147Figure 4.8  C’-ADE of early and late viruses by autologous sera
Viruses isolated at early and late time points following onset of symptoms were assayed on 
SupTl/R5 cells in the presence of C’ and sequential autologous sera.  Fold enhancement of 
infection of early viruses by autologous sera are shown as turquoise squares (■), and late 
virus as dark blue squares (Q).  The time at which the early virus was isolated is indicated 
with a turquoise arrow, and the late virus with a dark blue arrow.  Error bars represent SD 
from 3 experiments.
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148For all patients except MM24, enhancement of later virus was seen to an equal 
or greater degree than with  early virus.  Again, the patients  fall  into the same three 
groups:
Group 1: MM24 and MM26
Sera  that  neutralised  early  virus  enhanced  later  virus.  Thus,  virus  that  had 
escaped neutralisation maintained the capacity to be enhanced.  For MM24 the peak of 
enhancement for the day 26 virus is 236-fold on day 44 and the peak for day 464 virus 
is 356-fold on day  124.  The day 26 virus was neutralised at day 208,  164 days after 
the enhancement peak and  182 days after the virus was isolated.  The day 464 virus 
was neutralised at day 660,  536 days after the enhancement peak and  196 days after 
the virus was isolated.  For MM26 the peak of enhancement for the day 62 virus was 
35-fold on day  139 and the peak for the day 384 virus was 30-fold on day 384.  The 
day 62 virus was neutralised on day 253, 114 days after the enhancement peak and 191 
days after the virus was isolated.  The day 384 virus was not neutralised, but this may 
be because later time points were not available, and as the enhancement was beginning 
to fall in the last sample assayed it may occur later.
For  the  early  and  later  Group  1   viruses  that  were  neutralised,  neutralisation 
occurs between 154 and  196 days after the virus was isolated
Group 2: MM27
The day 28 virus was not enhanced but dramatic enhancement of the day 585 
virus was seen: 286-fold peaking on day 299.  This is interesting as it shows that it was 
not  the  MM27  serum  that  lacked  C’-ADE  activity,  but that the  early virus was not 
susceptible to enhancement.
Group 3: MM34 and MM42
The same pattern of enhancement seen for the early virus was maintained for 
the  late  virus,  but  overall  enhancement  levels  were  higher.  Interestingly,  peak 
enhancement  levels fell on the same days for the late viruses as for the early viruses, 
yet  with  a  greater  magnitude  of enhancement:  day  353  for  MM34,  with  28-fold 
enhancement for the day 32 virus and 78-fold for the day 443  virus; and day 238 for 
MM42, with  19-fold for the day 28 virus and 30-fold for the day 238 virus.  The same 
minor and major peaks occurred with the late viruses from each patient.  For MM34,
149the  first  peak  occurred  on  day  45  with  a  26-fold  enhancement,  with  the  second 
occurring  on  day  353  with  a  78-fold  enhancement -  again,  the  second  peak was  3 
times greater than the first, as with the early virus.  For MM42 the difference between 
the peaks was not 3-fold, but a minor and major peak could still be distinguished:  20- 
fold  on  day  43  and  30-fold  on  day 238.  These  findings,  along with  data  from  the 
Group 3 early virus enhancement assays described in Section 4.2.2, are summarised in 
Table 4.3 below.
PATIENT
DAY OF 
VIRUS 
ISOLATION
1S1 (MINOR) PEAK 2nu (MAJOR) PEAK
Day
Magnitude
(fold)
Day
Magnitude
(fold)
MM28 6 34 29 782 86
MM33 12 26 41 719 115
MM34 32 45 11 353 28
MM34 443 45 26 353 78
MM42 28 36 6 238 19
MM42 238 43 20 238 30
Table 4.3 Details of the fold enhancement patterns found in Group 3
With  the  exception  of  MM24,  for  all  of  the  late  viruses  the  peak  of 
enhancement  fell  on  or  the  time  point  before  the  day the  virus  was  isolated.  For 
MM24  the  peak  of enhancement  for the  late (day 464) virus was on day  124.  The 
enhancement levels for the early and late viruses with contemporaneous sera is shown 
in Table 4.4.  In all patients, except MM24, enhancement seen with contemporaneous 
virus-serum pairs was significantly greater for the later viruses.
150PATIENT
DAY OF VIRUS 
ISOLATION
CONTEMPORANEOUS
SERUM
ENHANCEMENT1
P VALUE*
MM24
26 143
N/A
464 76
MM26
62 8
0.02
384 32
MM27
28 4
0.008
585 50
MM34
32 7
<0.001
443 78
MM42
29 6
<0.001
238 30
Table 4.4 Comparison of C’-ADE levels in contemporaneous virus-serum pairs for early 
and late viruses
'Fold enhancement (in the presence of C’) is shown for contemporaneous serum with early and 
late viruses.  *P values are derived from a two-tailed Student’s T test assuming equal variance, 
based on the null hypothesis that the two means are equal.
4.2.4  The relationship between C’-ADE and neutralisation
While  studies  of neutralisation  were  possible  in  the  enhancement  assays,  these 
assays were specifically developed to study enhancement and so the initial viral input 
was  low.  Therefore  it  was  appropriate  to  confirm  neutralisation  data  from  the 
enhancement  assay  with  a  separate  neutralisation  assay  routinely  used  in  our 
laboratory.  The  neutralisation  assay  is  described  fully  in  Materials  and  Methods. 
Briefly,  patient  plasma,  at  a  concentration  of  10%,  was  incubated  with  autologous 
virus for  1   hour at 37°C, then inoculated onto NP2/CD4/R5 cells.  After 2 hours cells 
were washed,  then  incubated for 2 days before fixing,  staining for p24 and counting 
foci of infection.
Neutralisation  in  the  enhancement  assay  was  determined  by  the  RT  ELISA 
readings, as these are more sensitive at a low level of infection than the % infected cell 
measurements.  As cells were left for 2 days after infection in the neutralisation assays, 
data  were  taken  from  the  day  3  RT ELISA  time  points  in  the  enhancement  assay.
151Figure  4.9  shows  a  comparison  of  neutralisation  data  taken  from  day  3  of  an 
enhancement  assay  compared  with  data  from  a  neutralisation  assay.  Results  from 
other patients are comparable.  Levels and timing of neutralisation were the same for 
data  derived  from  both  assays.  This  is  important  as  it  shows  that the  neutralising 
activity  of the  patient  samples,  whether derived  from  sera or plasma,  was the  same 
when assayed on different cell types as long as assays were carried out in the absence 
of active complement.
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Figure  4.9  Comparison  of  neutralisation 
seen  in  enhancement  and  neutralisation 
assays.
Assays were performed using MM24 virus from 
day  26.  Enhancement  assays  (triangles)  were 
performed  on  SupTl/R5  cells  with  patient 
serum  in the absence of C’,  and neutralisation 
assays  (squares)  on  NP2/CD4/R5  cells  with 
patient  plasma.  Error  bars  represent  standard 
deviation from three experiments.
Some  C’-independent  ADE  was  detected  in  the  enhancement  assays,  as 
described  in  Section  4.2.2.  Whilst  samples  giving  greater than  50%  neutralisation 
remained comparable in the neutralisation and HIC’ results of the enhancement assays, 
early non-neutralising samples enhanced infection even in the absence of complement 
on day 6 of the enhancing assay.
Figure 4.10 compares neutralisation by plasma on NP2/CD4/R5 cells with C’- 
ADE  by  serum  on  SupTl/R5  cells  for viruses  from  6  different patients.  Unlike  in 
previous  neutralisation  results  shown  in  this  thesis,  graphs  here  are  shown  as  % 
neutralisation rather than % residual infection in order to emphasise the divergence of 
neutralisation and enhancement levels.  Figure 4.10 shows that after the appearance of 
antibodies capable of neutralising infection by greater than 90% a drop in enhancement 
levels was seen.  Broken lines on the graphs show both the 90% neutralisation and the 
5-fold  enhancement  thresholds.  For  patients  MM24,  MM25,  MM26  and  MM34, 
enhancement levels either dropped dramatically or disappeared completely at the point
152when  neutralisation  exceeded  90%.  In  samples that neutralised to a  level  less than 
90%,  enhancement  appeared  to  parallel the  neutralisation pattern.  This was  shown 
most clearly for MM28, MM33  and MM34.  In MM28 and MM33 neutralisation did 
not  exceed  90%  and  the  change  in  enhancement  levels  closely mirrored that of the 
neutralisation.  For MM34, neutralisation and enhancement levels paralleled, until day 
759 when >90% neutralisation occurred and enhancement dropped to just above the 5- 
fold threshold.
Table  4.5  below  summarises the enhancement data for early viruses and the 
occurrence of neutralisation for all patient sera tested.  The peak levels of enhancement 
obtained for each patient did not appear to correlate with the classification of the viral 
set-point shown in Table 4.1.
PATIENT
NUMBER
VIRAL
SET
POINT
VIRUS1
PEAK
(FOLD)2
DAY OF 
PEAK3
90% NEUT4 
(50%)
MM24 high 26 236 44 124  (51)
MM25 high 31 8 31 185  (66)
MM26 high 62 35 139 253  (76)
MM27 medium 28 3 299 -  (46)
MM28 low 6 86 782 -  (503)
MM32 N/A 10 58 21 -  (-)
MM33 high 12 115 719 -  (69)
MM34 low 32 28 353 759  (443)
MM38 N/A 29 46 93 N/D
MM42 high 28 19 238 N/D
Table 4.5  Peak C’-ADE and appearance of neutralisation
Summary of the magnitude and timing of the peak fold enhancement for each patient shown in 
Figure 4.5 and the appearance of neutralising antibodies shown in Figure 4.10.  1  The time, in 
days, following onset of symptoms at which the virus used in the assay was isolated.  2  The 
peak fold enhancement seen within a given serum set for each virus and 3  the sample day on 
which this occurs.  4  The day, following onset of symptoms, on which >90% neutralisation is 
seen and, in parentheses, >50% neutralisation is seen.  N/A = not applicable; N/D = not done.
153Figure  4.10  Neutralisation  and  enhancement  of  HIV  infectivity  by  autologous 
sequential plasma and serum samples.
Neutralisation  assays  (yellow  squares)  were  performed  on NP2/CD4/R5  cells  with  heat 
inactivated  patient  plasma.  Results  are  shown  as  %  neutralisation  relative  to  control 
plasma. Enhancement assays (turquoise squares) were performed on SupTl/R5 cells in the 
presence  of patient  sera  and  complement.  Results  are  shown  as  fold  enhancement  of 
infection  relative  to  control  serum.  Autologous  early  virus  isolates  are  used  for  all 
experiments.  The  dashed  yellow  line  indicates  the  90%  neutralisation  threshold.  The 
dashed  turquoise  line  represents the  5-fold  enhancement threshold.  Error bars represent 
standard deviations from 3 experiments.Fold enhancement  ■
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2 ts>4.2.5  Characterisation of neutralising and enhancing antibodies
4.2.5.1  Purified IgG and IgM
Thus far experiments were performed using whole serum or plasma samples. 
To confirm  that the  enhancement seen by patient serum was mediated by antibodies 
and  not  another  serum  factor,  IgG  and  IgM  were  purified  from  patient  plasma. 
Column elution fractions were adjusted to the volume of plasma applied to the column 
in order to maintain the original plasma antibody concentration as far as possible.
Both IgG and IgM enhanced infection of early autologous virus when purified 
from  an  early  time  point,  day  26  (Figure  4.11).  IgG  and  IgM  purified  from 
seronegative human plasma (NHP) were used as controls.
□  IgG
□  IgM
□  IgG + IgM
■ Whole serum
26  292
days following onset of symptoms
Figure  4.11  C’-ADE  activity  of purified  IgG 
and IgM
IgG and IgM were purified from MM24 day 26 
and  292  plasma  using  commercial  kits  and 
tested  against  MM24  day  26  virus  in  the 
presence  of  C’  on  SupTl/R5  cells.  Fold 
enhancement was calculated relative to infection 
in the  IgG  or  IgM  purified  from NHP  and  C’. 
Error bars represent SD from 3 experiments.
Levels of enhancement seen for purified IgG and IgM from day 26 were lower 
than  for  serum.  This  could  be  because  significant  levels  of antibody  were  lost  or 
denatured  during  the  purification  process.  However,  as  shown  in  Figure  4.12  the 
enhancement was still powerful enough to produce a visible rise in infected cells.
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Figure  4.12  Flow  cytometry  plots  of MM24  day 26 virus  infection  in  the  presence  and 
absence of day 26 IgM
SupTl/R5 cells were infected with MM24 day 26 virus, preincubated with IgM from NHP and 
C’ (control infection; left), or IgM from MM24 day 26 plasma and C’ (right).  Cells were gated 
for infected cells (p24 positive) against uninfected cells incubated with C’.
The level of enhancement by day 26 IgM was lower than that for day 26 IgG, 
yet when both were combined the enhancement reached an intermediate between the 
two.  The day 292 IgG neutralised the day 26 virus, whilst the IgM enhanced, albeit at 
a lower level than the day 26 IgM.  When combined, however, the effect of the IgG 
dominated and the virus was neutralised.  This supports data presented in Section 4.2.4 
showing  that  when  neutralising  antibodies  capable  of  achieving  >90%  virus 
neutralisation were present a co-existing enhancing response was suppressed.
156Due to limited availability of material, IgG was later purified from MM24 day 
44 and day 464 plasma for further investigation and assayed only in the presence of C \ 
In the serum enhancement experiments shown in section 4.2.3, day 44 serum enhanced 
infection of both the early (day 26) and later (day 464) autologous virus, whilst day 
464 serum neutralised the day 26 virus and enhanced the day 464 virus (Figure 4.13A). 
Figure 4.13B  shows  10-fold serial dilutions of the IgG assayed against day 26 virus. 
The enhancing effect of day 44 IgG titrated out, whereas the neutralising day 464 IgG 
became  enhancing  with  increasing  dilution.  At  a  dilution  of  1:100  the  fold 
enhancement seen with day 44 and 464 IgG was comparable, and at  1:1000 the day 
464  IgG  was  still  enhancing  while  the  day  44  IgG  had  dropped  below  the  5-fold 
enhancement threshold.  Figure 4.13C shows serial 2-fold dilutions of the day 464 IgG 
to  focus  in  on the point at which neutralisation became enhancement.  This process 
was gradual rather than occurring at a critical dilution point.
The  IgG  was  then  tested against the day 464  virus at  10-fold serial  dilutions 
(Figure 4.13D).  As expected, both the day 44 and 464 IgG enhanced the later virus 
and this effect could be diluted out in the same way as against the early virus.
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Figure  4.13  Titration  of  purified 
antibodies  from  enhancing  and 
neutralising serum time points
IgG  was  purified  by  Protein  (G)  affinity 
column  from  patient  plasma  taken  on  the 
same  day  as  sera  that  enhanced  and 
neutralised early patient virus, days 44 and 
464 respectively.  (A):  early (day 26) and 
later  (day  464)  viruses  assayed  with 
sequential  sera.  Light  and  dark green
squares  show  the  time  points, days 44 and 464 respectively,  from which IgG was 
isolated. (B):  10-fold serial dilutions of IgG tested against day 26 virus.  (C):  Further 2- 
fold  dilutions  of day 464  IgG  tested  against day  26  virus to  show the  point at which 
neutralisation becomes enhancement.  (D):  10-fold serial dilutions of IgG tested against 
day 464 virus.
1584.2.5.2  Competition studies between neutralising and enhancing IgG
Against MM24 day 26 virus,  IgG from day 44 enhanced while IgG from day 
464 neutralised infection in the presence of C \ Therefore, it was decided to test which 
of these activities was dominant when present together.  Various ratios (1:15, 2:14, 1:3, 
1:1, 3:1,  14:2,  15:1) of the d44 and d464 IgGs were prepared with each other and with 
NHP IgG as a control, and assayed at a constant overall IgG level of 10%.  Mixtures of 
day 44 and 464 IgG were tested against virus from day 26 (Figure 4.14A) and day 464 
as a control  (Figure 4.14B).  Strikingly, equal amounts of neutralising and enhancing 
IgG  had no effect on virus infection i.e. neither enhanced nor neutralised and gave a 
fold enhancement value of exactly 1.  It appears from Figure 4.14A that neutralisation 
was the dominant effect, as small amounts of enhancing antibody had  little effect on 
the  ability  of  day  464  IgG  to  neutralise  infection,  whereas  small  amounts  of 
neutralising IgG reduced the amount of enhancement seen by day 44 IgG.  A ratio of 
15:1  day 44:464 antibody reduced enhancement from 23-fold to  13-fold, and 3:1 to 4- 
fold, thus below the enhancement threshold.
For  comparison,  day 44  and  464  IgG were  prepared  in  the  same ratios with 
NHP IgG and tested against day 26 virus.  As shown in Figure 4.14 C, when diluted 
1:1  with  NHP  IgG,  the  day  464  IgG  was  neutralising,  indicating  that  it  was  the 
presence  of the  day  44  enhancing  IgG  that  abrogated  this  neutralisation  in  Figure 
4.14A,  and  not the  fact that the  antibody had  been  diluted.  Conversely,  only slight 
losses in enhancement levels were seen in the 1:1 ratio of Figure 4.14D, showing that it 
was the  presence  of neutralising IgG that caused the  loss of enhancement  in Figure 
4.14A.  Interestingly, whilst the  1:15 and 2:14 ratios of day 464 to NHP IgG resulted 
in enhanced  infection,  the presence of that much day 464 IgG with the d44 IgG still 
reduced the enhancement seen compared to day 44 IgG alone.
As a further control, the mixtures of day 44 and 464 IgG were tested against 
day 464 virus, as shown in Figure 4.14B.  If the different effects of the day 44 and 464 
IgG on day 26 virus infection could be attributed to a difference in the quantity of IgG 
present (i.e. day 44 IgG is the same as d464 IgG but at sub-neutralising concentrations) 
then this would become apparent when tested against day 464 virus.  However, both 
day 44 and 464 IgG enhanced day 464 virus to a high level, and mixing various ratios 
of the two antibody preparations had no effect.
159KEY
Q   d44 IgG ^   d464 IgG Q   NHP IgG
Figure 4.14 (overleaf)
Neutralising and enhancing antibody competition experiments
MM24 day 44 and 464 IgG were mixed in various ratios (15:1,  14:2, 3:1,  1:1,  1:3, 2:14, 
1:15) with each other and with IgG purified from NHP.  These were incubated at a total 
IgG concentration of 10% ,with  10% C’ and day 26 or 464 autologous virus for 1   hour at 
37°C  then  added  to  SupTl/R5  cells,  as  in  the  standard  enhancement  assay.  Fold 
enhancement was calculated relative to infection in the presence of NHP IgG and C\  Pie 
charts below each bar represent the relative amounts of IgG in each sample, as detailed in 
the key on the adjacent page. A: mixtures of d44 and d464 IgG tested against day 26 virus; 
B:  mixtures of d44 and d464 IgG tested against day 464 virus; C:  mixtures of d464 and 
NHP IgG tested against day 26 virus; D: mixtures of d44 and NHP IgG tested against day 
26 virus. Error bars represent SD from three replicates.
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1614.2.6  C’-ADE of heterologous viruses
Results  presented  so  far  addressed  C’-ADE  in  an  autologous  system.  This 
section  investigates  whether  these  sera  have  C’-ADE  activity  against  heterologous 
viruses.  Three patient serum sets with known C’-ADE patterns -  one from each of the 
patterns  described  in  section  4.2.2  -   were  tested  against  early  viruses  from  each 
patient.  Results are shown in Figure 4.15.  The data show that the pattern of C’-ADE 
over time was a property of the serum whilst the magnitude of the enhancement was a 
property of the virus.  The representative serum sets from the Group  1   and 3 patterns, 
MM25  and  MM33  respectively,  maintained  their  patterns  on  all  3  viruses  tested; 
MM27  serum  failed to  fit into either of the other patterns,  as before.  The Group  1  
pattern  was  perhaps  the  most  striking  of all:  for all  3  viruses tested  against MM25 
serum,  peak  enhancement  occurred  on  day  31  or  38  and  then  declined  with  time. 
Importantly, the day  185  serum that neutralised MM25  virus did not neutralise virus 
from  MM27  or  MM33,  showing  that  the  enhancing  activity  was  transferable  to 
heterologous  virus  but  neutralisation  was  not.  The  Group  3  serum,  MM33,  also 
maintained a distinctive pattern on all 3 viruses tested, with a minor peak on day 26 or 
33  and  a  major  peak  a  later time  point:  day  523,  621  and  719  for viruses  MM25, 
MM27 and MM33 respectively.
In terms of magnitude of enhancement, virus from MM33 was enhanced to a 
greater degree than the other 2 viruses.  This was true of autologous serum, with a peak 
of 115-fold, as well as heterologous serum.  In both cases MM33 virus was enhanced 
more than the autologous virus for each serum set, with peaks of 36- and 25-fold for 
MM25 and MM27 serum sets respectively.
The  MM27  virus  was  an  interesting case  as this  virus  was  not enhanced by 
autologous  sera.  However,  MM27 virus was  enhanced by MM25  and MM33  sera, 
albeit at the low levels of 9- and  10-fold respectively.  Conversely, MM27 sera could 
enhance other viruses, with peaks of 33-fold for MM33  and  10-fold for MM25.  For 
the  latter  this  was  higher  than  with  MM25  autologous  sera.  This  implies  that 
characteristics  of  both  MM27  virus  and  sera,  rather  than  either  alone,  limited 
enhancement.
The  data  discussed  above  are  summarised  in  Table  4.6,  clearly  showing the 
different magnitudes of enhancement associated with each virus and the tendency for 
peak levels of enhancement to occur at similar times for a given set of sera.
162□  HIC’  ■  C’
Figure 4.15  (overleaf)
C’-ADE by heterologous serum sets
Early  virus  and  sequential  serum  sets  from  3  patients  were tested  against each  other to 
investigate heterologous C’-ADE.  Representatives were chosen from each of the 3 groups 
described in Section 4.2.2. Virus was incubated with patient serum or NHS in the presence 
of HIC’ (white squares) or C’ (black squares) for 1  hour then transferred to SupTl/R5 cells 
and  incubated  for  6  days.  Fold  enhancement  is  calculated  relative  to  infection  in  the 
presence of NHS. The patient from which virus was derived is indicated on the far left in 
yellow, and serum is indicated at the top in red. Results from autologous virus-serum sets 
are edged in green.  Error bars represent SD from 3 experiments.
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164SERUM
MM25 MM27 MM33
Peak1 Day5 Peak Day Peak Day
C Z 5
MM25 8 31 10 755
16 523
£
5
MM27 9 38 4 299 10 621
MM33 36 38 25 299 115 719
Table 4.6  C’-ADE in heterologous virus-serum sets
Enhancement  assays  on  SupTl/R5  cells were carried out with  combinations  of viruses and 
serum sets to investigate C’-ADE by heterologous sera.  Results were summarised from Figure 
4.15.  Serum sets from 3 patients, MM25, MM27 and MM33, were tested against early viruses 
from each patient.  Results are shown as ‘the peak fold enhancement seen for a given serum set 
and 2the serum sample day on which this peak occurs.  Numbers in bold type are the results for 
autologous virus-serum sets.
4.3  DISCUSSION
4.3.1  C’-ADE of early viruses in comparison to previous reports
The frequency and magnitude of C’-ADE shown in this chapter are surprising. 
Recent  literature  on  C’-ADE of HIV  showed  levels  of enhancement to  be  closer to 
those  shown  in Chapter 3, with 2- or 3-fold increases in infection routinely reported 
(Banhegyi et al., 2003; Lund et al.,  1995; Prohaszka et al.,  1997;  Szabo et al.,  1999). 
As HIV is a chronic infection, proceeding over several years, these enhancement levels 
are  considered  important  as  a  2-3-fold  increase  in  infection  carried  over  numerous 
cycles  of  infection  would  have  a  significant  effect  on  overall  virus  production. 
Therefore it had previously been accepted that levels of HIV enhancement were not as 
dramatic  as  those  of dengue.  Here  this  is  challenged,  with  levels  of enhancement 
reaching almost 350-fold, well within the range of dengue virus enhancement, which is 
commonly  reported  to  increase  levels  of  infection  by  2-200  fold.  (Halstead  and 
O'Rourke,  1977a;  Halstead  and  O'Rourke,  1977b)  The  high  levels  of enhancement
165were consistent when measured as the percentage of cells infected, the percentage of 
remaining viable cells, and the level of RT production.
The  use  of a  CR2+ T  cell  line  expressing  CCR5  may  account  for the  high 
enhancement  level.  As  other T cell  lines  used  for  studies  of C’-ADE  lack  CCR5, 
investigation has been limited to X4 tropic viruses such as the TCLA strain IIIB. As 
shown  in  Chapter  3,  in  my  experience  enhancement  of this  virus  is  weak,  often 
variable,  and  observed  far  less  frequently  than  for  the  patient-derived  R5  tropic 
viruses.  To exclude the possibility that the high enhancement levels were artefacts of 
using SupTl/R5 cells, NP2/CD4/R5 cells transduced to stably express CR2 were used 
for enhancement assays in Chapter 6.
Aspects of my study reflect results from SIV infection of macaques presented 
by Montefiori and colleagues (Montefiori et al.,  1995).  In their study, macaques were 
inoculated with the pathogenic SIVmac25i, and sequential early serum samples tested for 
C’-ADE against the inoculum virus.  Peak powers of enhancement were seen in early 
sera,  most  commonly  at  the  lowest  serum  dilution  tested.  Powers  of enhancement 
decreased over time as neutralisation emerged.  These results resemble my results from 
the Group  1   patient early virus experiments (Section 4.2.2).  However, the power of 
enhancement decreased over time as neutralisation emerged, yet no studies were made 
of later  virus  isolated  from  the  macaques.  As  later viruses  isolated  from  Group  1  
patients in my study were enhanced by sera that neutralised early virus, the same may 
occur in the macaques if later isolates were  investigated.  Therefore their results are 
realistically  only  semi-autologous,  and  are  only  likely  to  represent  the  very  early 
events following infection with SIVm aC 25i  before significant diversification of the virus 
has occurred.  To a certain extent my results have the same limitations, as each serum 
sample tested was not matched by a contemporaneous virus isolate, but tested against 
an isolate from a fixed early or late time point.
4.3.2  Reconciliation of current neutralisation models with C’-ADE results
No evidence of neutralisation of autologous virus by contemporaneous sera 
was  found.  It  is  therefore  possible  that  enhancing  antibodies  are  the  dominant 
antibody response throughout infection, due to rapid virus escape from neutralisation. 
Competition  studies  showed  that,  when  present,  neutralisation  is  a  more  powerful 
response than enhancement.
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bind to functional Env spikes and inhibit viral entry via steric hindrance at a critical 
level  of occupancy.  Meanwhile,  non-functional  Env  spikes  elicit  non-neutralising 
antibodies,  constituting  an  immunogenic  “decoy”  to  direct  the  immune  response 
towards epitopes considered non-essential  for virus  infection.  Linking my results in 
with this model, there are two interpretations of the enhancement data:
1.  Neutralising antibodies bind functional spikes while enhancing antibodies bind 
non-functional spikes, such as gp41 stumps.
2.  Enhancing antibodies are NAbs at sub-neutralising concentrations.
I favour the first interpretation, for several reasons.  Firstly, neutralisation can often be 
observed  in  the  absence  of C’,  yet when  complement  is  added the  neutralisation  is 
abrogated.  This indicates that the virus is coated by antibody, and therefore it is not a 
question of low levels of neutralising antibodies binding to virus to enhance infection. 
Model  1   fits my data and previous literature of C’-ADE better.  It would explain the 
discovery of a gp41  “enhancing domain”, which happens to overlap the gp41-gpl20 
interacting region and therefore would only be exposed after shedding of gpl20.
4.3.3  The  nature  of enhancing  antibodies  -   clues  from  studies  of heterologous 
virus and sera.
Further  clues  about  the  differences  between  enhancing  and  neutralising 
antibodies  are  provided  by  data  on  heterologous  enhancement.  The  fact  that 
heterologous sera can enhance viruses shows that there is cross-reactivity, yet only in 
terms  of enhancement  and  not  neutralisation.  This  could  suggest  that  neutralising 
antibodies  must  bind  specific  epitopes  in  order  to  neutralise,  whereas  enhancing 
antibodies must simply be able bind to the virus.  Alternatively,  it could be that the 
enhancing antibodies recognise a more conserved epitope, such as in gp41, whilst the 
neutralising antibodies  recognise more  variable  epitopes,  probably as  a result of the 
fact  that  these  regions  are  targeted  by  neutralising  antibodies  and  are  constantly 
evolving.
4.3.4 C’-ADE and C’-ML -  is there scope for both to occur?
As  discussed  in  Chapter  3,  the  producing  cell  type  can  have  an  effect  on 
whether or not virus  is susceptible to  lysis by complement.  Perhaps the preparation 
differences between the  IIIB  used  in Chapter 3  and the primary isolates used  in this
167chapter contributes to the different levels of enhancement seen.  Yet, as production of 
virus  in  PBMCs  is more  physiologically relevant than  in the T cell  line H9,  results 
presented  in this  chapter  are  more  representative  of what  might  occur  in vivo  than 
those in Chapter 3.
Other studies have reported that inactivation (C’-MI) of early autologous virus 
occurs in the presence of early autologous sera and complement (Aasa-Chapman et al., 
2005; Huber et al., 2006).  There may be several explanations for the differences seen 
between  these  and  my  studies.  Firstly,  it  is  possible that C’-ADE  occurs on  CR2+ 
cellular  targets,  while  C’-MI  occurs  on  CR2-  cellular targets  as  reported  by  Aasa- 
Chapman and colleagues (Aasa-Chapman et al., 2005).  This  is investigated in more 
detail  in  Chapter  5.  Therefore  the  cell  type  first  encountered  by  the  virus  might 
determine the  outcome of the opsonisation,  provided that lysis does not occur in the 
majority  of viruses.  This  interpretation  does  not  agree  with  results  presented  by 
(Huber et al.,  2006),  who  used a freeze-thaw assay system to  show lysis of primary 
patient HIV isolates by early autologous sera and complement.  However, while lysis 
is inferred, the involvement of the MAC was not formally demonstrated.  In addition, 
the  proportion  of  lysis  in  each  virus  preparation  was  not  directly  correlated  with 
infectivity of each strain following opsonisation, so it is possible that a proportion of 
the viruses are lysed, yet these viruses are in the portion that appear uninfectious.  In 
theory, if a given viral stock has an infectious particle-to-particle ratio of 1:1000, then 
50% of these virions could be lysed while the remaining particles could account for a 
maximum of 500-fold enhancement.  Alternatively, increased lysis in the freeze-thaw 
assay may be a measure of complement-opsonisation of the virus rather than MAC- 
mediated  lysis.  Virions  with  higher  membrane  protein  contents  may  be  more 
susceptible  to  rupture  by  freeze-thaw cycles than those with  less  surface-associated 
protein.  Another  possibility  is  that  lysis  does  occur  in  the  enhanced  viruses,  but 
instead of rendering the viruses uninfectious it facilitates virus-cell fusion.  This could 
be  investigated  using  C5-deficient  serum  as  a  complement  source  for enhancement 
assays.  To investigate the occurrence of both C’-mediated lysis and C’-ADE, parallel 
assays  on  autologous  virus-serum pairs should be undertaken and compared directly 
with the infectivity of the autologous virus.
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Unlike  in Chapter 3, where the same virus, IIIB, was tested with each serum 
sample,  drawing direct correlations  between  C’-ADE  and viral  loads  in this chapter 
was  complicated  by  the  fact  that  different  viruses  were  used  for each  patient,  and 
sometimes two different viruses, early and late, were used per patient.  As mentioned 
in section 4.3.1, the most representative method of comparing C’-ADE longitudinally 
with  viral  load  would  be  to  analyse  sequential  contemporaneous  virus-serum  pairs. 
This approach was not feasible due to the labour-intensive and technically demanding 
method  of virus propagation, therefore only early and  late viruses from each patient 
were studied.  Neutralising antibodies from later sera therefore interfere with the C’- 
ADE profile by neutralising early virus.
However, conclusions may be drawn from the fact that all viruses tested were 
enhanced by contemporary autologous serum, meaning that enhancement is possible in 
vivo.  With the exception of MM24, later isolates were enhanced significantly more by 
autologous  contemporary sera than early  isolates.  Therefore,  later viruses that have 
escaped  neutralisation maintained their capacity for enhancement, and in most cases 
were enhanced to a greater magnitude than early isolates, suggesting an evolutionary 
advantage  of increasing the  capacity to  be  enhanced.  The  peak  enhancement time 
points  for all  late viruses tested occurred on or before the virus isolation day, adding 
weight  to  the  suggestion  that  these  viruses  have  evolved  due  to  their  capacity  for 
enhancement.
Several studies have shown the existence of CR2+ CD4+ T cells in peripheral 
blood, which provides the possibility that C’-ADE could occur in vivo (Fischer et al., 
1991;  Fischer  et  al.,  1999;  June  et  al.,  1992;  Masilamani  et  al.,  2002).  One  study 
showed  that  the  proportion  of  CR2+  CD4+  T  cells  was  lower  in  HIV-infected 
individuals compared with uninfected individuals,  implying destruction of these cells 
by  HIV  (June  et  al.,  1992).  Alternatively,  C’-ADE  could  be  an  in  vitro  surrogate 
marker  for the  important  process  of FDC  trapping of opsonised  virus.  This  would 
represent an equally important pathogenic activity of C’-ADE antibodies, and ought to 
be  investigated  in  more  detail,  perhaps  using  an  in vitro  germinal  centre  model  as 
previously described (Heath et al.,  1995).
1694.3.6  Concluding remarks
This  chapter  shows  the  successful  application  of  the  enhancement  assay 
developed in Chapter 3 to the investigation of C’-ADE in natural infection with HIV. 
For the first time, sequential serum samples from early to chronic infection were tested 
with autologous early virus and produced levels of enhancement up to 236-fold.  When 
later virus isolates from the same individuals were tested with the same serum samples, 
enhancement levels were equivalent to or greater than those seen with early virus, with 
enhancement levels reaching 356-fold.
The  importance of C’-ADE in natural  infection remains to be seen.  The high 
levels of C’-ADE, the fact that C’-ADE occurs in contemporaneous virus-serum pairs, 
and the  fact that  later isolates from the same patients were enhanced to an equal  or 
greater degree than early isolates, sometimes having escaped neutralisation, all suggest 
that C’-ADE may play a role in HIV infection and should be further investigated.
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Infection-enhancing antibodies from individuals vaccinated 
with an envelope subunit vaccine
This  chapter  investigates the appearance  of antibodies with  C’-ADE and C’- 
mediated  inactivation (C’-MI) activity after immunisation with a HIV gpl20 subunit 
vaccine.  Sequentially  collected  serum  samples  taken  from  individuals  following 
vaccination  were  tested  against  the  TCLA  strain  MN  and  the  vaccine  virus  strain 
W61D for enhancement, neutralisation and C’-MI.  Finally, to investigate the potential 
for antibodies elicited by vaccination to enhance infection of currently circulating virus 
strains,  sera  were  tested  against  a  primary  virus  isolate  from  the  patient  cohort 
investigated in Chapter 4.
5.1 INTRODUCTION
5.1.1 The importance of studying enhancement in the context of vaccination
Elicitation  of enhancing antibodies by vaccination could  lead to an  increased 
risk of infection or exacerbated disease symptoms.  There have been several cases of 
increased disease severity in human vaccine recipients (Morens,  1994).  Whether this 
is  linked  to  enhancing  antibodies  has  not  been  conclusively  proven  due  to  the 
possibility  of  alternative  mechanisms  of  immunopathology.  In  animal  studies, 
however,  the  evidence  linking  enhancing  antibodies  and  vaccine-related  disease 
exacerbation  is  more  convincing.  This  is  mainly  due  to  results  from  experimental 
infections  following  vaccination  or  passive  antibody  transfer  of the  target  animals. 
Studies of feline infectious peritonitis virus (FIPV), a coronavirus infection of cats that 
is predominantly subclinical, have shown that experimental infection of cats passively 
immunised with antibodies to FIPV resulted in a rapid and exacerbated disease state 
compared  to  seronegative  cats  (Weiss  and  Scott,  1981).  Likewise,  attempted 
immunisation  with  an  avirulent FIPV  strain  increased  the  chances of infection with 
challenge virus (Pedersen and Black,  1983).
Disease  enhancement  occurred  in  ponies  upon  challenge  after  an  EIAV 
envelope  subunit  vaccination,  with  vaccinated  ponies  developing  higher  plasma 
viraemia  and  succumbing  earlier  to  a  more  severe  form  of  acute  disease  than
171unvaccinated  ponies  (Raabe  et  al.,  1998;  Wang  et  al.,  1994).  Nonetheless,  EIAV 
enhancement assays tested to date are not conclusively predictive of vaccine outcome, 
suggesting the disease enhancement has an added level of complexity (Raabe et al., 
1999).  Enhanced FIV disease has been observed in cats upon challenge following FIV 
immunisations  of  various  strategies:  DNA  vaccination  (Richardson  et  al.,  1997), 
envelope  subunit  vaccination  (Siebelink  et  al.,  1995)  and  cell-based  vaccination 
(Giannecchini et al., 2002).
Of  the  above  examples,  EIAV  and  FIV  are  lentiviruses,  making  the 
investigation of HIV vaccine-related disease exacerbation particularly pertinent.  SIV 
vaccine studies in macaques, developed as a model for HIV vaccination and challenge, 
have also produced enhancing antibodies.  In a thorough study of C’-ADE following 
immunisation of macaques with SIV rgpl60, no clear relationship was found between 
titres  and  power  of C’-ADE  and  vaccine  outcome;  despite  high  levels  of C’-ADE 
antibodies some animals were protected and some infected following challenge with a 
homologous virus strain (Montefiori et al.,  1995). However, it should be borne in mind 
that  these  studies  were  conducted  with  challenge  viruses  identical  or  closely 
resembling  the  vaccine  strain,  therefore  in  many  cases  a  degree  of protection  was 
observed -  a situation that is unlikely to occur in field settings of HIV vaccine trials. 
In  a  study  in  which  macaques  were  not  protected  from  virulent  virus  challenge 
following DNA vaccination, C’-ADE was implicated in vaccine failure, but again, no 
clear relationship between enhancing antibodies and vaccine outcome was determined 
(Lu et al.,  1996).
A  recent  VZV/SIV  vaccine  trial  in  macaques  resulted  in  enhanced  disease 
severity,  with  vaccinated  macaques  exhibiting  higher viral  loads  and progressing to 
AIDS dramatically faster than the unvaccinated control animals (Staprans et al., 2004). 
Enhancing antibodies were not detected and the accelerated disease progression was 
attributed  to  CD4  cell  priming  and  increased  activation  of CD4  T cells  upon  virus 
challenge  (Staprans  et  al.,  2004).  A  lack of enhancing  antibodies  in  one  particular 
assay,  however,  does not rule out their involvement entirely, and the examples cited 
above highlight the difficulties involved in linking cause and effect of vaccine-related 
disease enhancement.
A  prophylactic  vaccine against HIV  infection  remains an elusive target and 
vaccine  trials  in  various  stages  are  being  undertaken  throughout  the  world.  It  is 
accepted that a neutralising antibody response will form an important component of an
172effective  vaccine  (Moore  and  Burton,  2004).  Many  initial  attempts  at  eliciting 
protective antibody responses through vaccination focused on the use of recombinant 
HIV  envelope  proteins:  gpl60  or  gpl20.  A  high-profile  vaccine  trial  involving  a 
recombinant envelope  subunit vaccine (VaxGen/AIDSVAX) was conducted recently 
(Billich, 2004).  This trial attracted controversy due to the belief of many researchers 
that this  strategy had been previously tested and proven  ineffective (Johnston, 2003; 
Watanabe,  2003).  Yet,  to  date  it  is  the  only  vaccine  candidate  to  reach  phase  III 
clinical  trials.  Disease  enhancement  has  not  been  seen  following  HIV  vaccination 
trials in humans.  But the risk remains, as many HIV vaccine trials are in their infancy 
and it is possible that ADE may still occur.  Particular concerns have been raised about 
the  use  of  envelope  subunit  vaccines  against  HIV  (Weiss,  2001)  as  monomeric 
envelope  subunits  are  known  to  elicit  non-neutralising  antibodies,  and  have  yet  to 
show any evidence  of inducing a protective neutralising response.  These antibodies 
may therefore be enhancing in certain situations.
It  is unclear from  in vitro  studies whether HIV vaccines can elicit enhancing 
antibodies.  One study that investigated FcR-ADE found no evidence of enhancement 
following  vaccination  with  an  rgpl60  subunit vaccine  derived  from NL4-3,  a strain 
similar  to  IIIB  (Haubrich  et  al.,  1992).  Another  study,  investigating  C’-ADE  in 
samples from a similar vaccine trial, found antibodies with C’-ADE activity in 6 out of 
24 subjects tested; neutralising activity was found in only 5 of the 24 subjects (Dolin et 
al.,  1991).  Both of these studies were conducted using IIIB.  To date, no studies of C’- 
ADE  have  been  conducted  on  vaccinee  sera using clinically relevant HIV strains or 
HIV vaccine strains other than IIIB.
Given the evidence of in vitro ADE of HIV, combined with reports of disease 
enhancement in vaccine trials of other lentiviruses, further information on the risks and 
mechanisms of HIV ADE is warranted.  On the other hand, it is possible that vaccine- 
elicited non-neutralising antibodies could have a protective effect through mechanisms 
such as C’-MI.  The aims of this chapter, therefore, are to investigate the functional 
activities of the antibodies produced following vaccination with an envelope subunit 
vaccine.  This also provides the opportunity to investigate the co-existence of C’-MI, 
using  the  assay  presented  by Aasa-Chapman  and  colleagues  (Aasa-Chapman  et al., 
2005)  and  C’-ADE,  using the  enhancement assay described  in  Chapter 4,  in  serum 
samples  that  have  been  previously  thoroughly  characterised  for  neutralising  and 
binding antibody activity (Beddows et al.,  1999; McCormack et al., 2000).  This will
173allow  direct  comparisons  between  these  two  different  C’-mediated  activities  of 
antibodies.  The use of the enhancement assay allows the investigation of a range of 
viruses, to add to the limited repertoire of post-vaccination ADE studies.
5.1.2  The vaccine trial
The  serum  samples  used  in  this  chapter  are  from  participants  of a  Phase  I 
clinical  trial,  MRC  V001  (McCormack  et  al.,  2000).  Healthy  HIV  seronegative 
volunteers  were  immunised  with  monomeric  recombinant  gpl20  (rgpl20)  derived 
from  a R5X4  subtype  B  HIV-1  strain,  W61D.  W61D  is  derived  from a molecular 
clone of a Dutch clinical isolate (Groenink et al.,  1991).  Individuals were vaccinated 
on weeks 0, 4 and 28; serum samples were obtained on weeks 0, 2, 6, 12 or 16, 28, 30, 
40, 52, 68 and 84, as shown in the vaccine regime diagram in Figure 5.1.
Immunisations
60- 0— 0 -0 -------------------0  0  0  0-----------------0
2  6  12 16  30  40  52  68  84
Sample time (weeks)------------------------------------ ►
Figure 5.1  Timeline of the vaccine regime
Red arrows indicate immunisations, carried out on weeks 0, 4 and 28.  Sample time points are 
shown as diamonds with the time in weeks below.  Note that in the case of some individuals, 
samples were taken on week 16 instead of week 12, and week 32 instead of week 30.
5.1.3  Overview  of the  virus  strains,  serum  samples  and  assays  used  for  the 
characterisation of the antibody response in vaccinees
Three  virus  strains  were  used  to  characterise  the  antibody  response  to  the 
vaccine:  MN, a well characterised X4 TCLA HIV strain susceptible to neutralisation 
by a wide range of sera and used for initial characterisation of the neutralising response 
following vaccination  (McCormack et al.,  2000);  W61D,  an R5X4  dual tropic  virus 
strain  from  which  the  vaccine  was  derived;  and  MM32  dlO  virus,  an  R5  primary 
isolate from the recent patient cohort investigated in Chapter 4.  Enhancement and C’- 
MI assays were used to investigate the nature of the antibodies elicited by vaccination.
174The  C’-MI  assay,  using  NP2/CD4/X4  or  -R5  cells,  is  essentially  an  NP2-based 
neutralisation  assay  adapted to  assess the  additional  effect  of complement on  virus 
inactivation,  as  published  previously  (Aasa-Chapman  et  al.,  2005).  Note  that 
neutralisation  refers  to  the  inactivation  of virus  by  antibody  alone,  as  seen  in  the 
absence  of  active  complement  (HIC’),  whereas  C’-MI  refers  to  any  additional 
inactivation  by antibody seen  in the presence of C’.  Results from C’-MI assays are 
shown  in yellow and orange throughout this chapter.  The enhancement assay, using 
SupTl/R5 cells, was described in section 4.1.2.  Results from enhancement assays are 
shown in blue and white throughout this chapter, as in Chapter 4.  All serum samples 
were tested at 10% in the enhancement and C’-MI assays to enable direct comparisons 
between and within assays.
5.2  RESULTS
5.2.1  Characterisation of the neutralising antibody responses in vaccine recipients
According to previous reports characterising the antibody response in recipients 
of this  vaccine,  neutralising  antibody  responses  were  weak  (Beddows  et  al.,  1999; 
McCormack  et  al.,  2000).  Of several  viruses  tested,  MN  was  most  susceptible  to 
neutralisation by vaccinee sera (McCormack et al., 2000), therefore it was used as a 
reference  strain  for neutralisation  assays presented  in this  chapter.  Throughout this 
chapter, the twelve vaccine recipient sera sets are divided into two groups according to 
neutralisation  and  antibody  binding  data  presented  by  McCormack  and  colleagues 
(McCormack et al., 2000) and personal communication from Sheena McCormack, as 
summarised in Table 5.1.  JUL008, JUJ009, JUX011, JUF061, JUB063  and JUX065 
showed  highest  50%  neutralising  antibody  titres  against  MN  and  overall  highest 
binding  antibody  titres  by  ELISA,  therefore  these  will  be  referred  to  as  Group  A. 
JUA001,  JUV012,  JUR014,  JUZ064,  JUV066  and  JUT067  showed  lower  or  no 
neutralising  antibody  titres  to  MN  and  lowest  antibody  binding  titres  by  ELISA, 
therefore these will be referred to as Group B.  JUZ064 is the exception to this rule, as 
week 30 samples from this vaccinee showed high MN 50% neutralisation and MN V3 
loop  binding antibody titres,  yet had  low  W61D gpl20 and  W61D V3  loop binding 
antibody titres.  On the basis of this finding, and MN neutralisation data presented in 
section 5.2.1.1, this subject was placed in Group B.
175GROUP MN MN W61D W61D GROUP MN MN W61D W61D
A 50%1 V32 V33 gpl204 B 50%* V32 V33 gpl204
JUL008y 160 800 1600 25600 JUA001X 20 400 200 6400
JUJ0092 320 6400 6400 102400 JUV012y 40 400 400 12800
JUX011Z 160 1600 3200 102400 JUR014y 40 200 200 6400
JUF061Z 320 1600 3200 102400 JUZ064X 320 1600 800 12800
JUB063y 160 1600 1600 51200 JUV066y 40 400 400 12800
JUX065y 320 6400 1600 51200 JUT0672 80 400 800 12800
MEAN 240 3067 2933 64000 MEAN 97 567 467 10667
RANGE 160- 800- 1600- 25600- RANGE 20- 200- 200- 6400-
320 6400 6400 102400 320 1600 800 12800
Table 5.1 Characteristics of the twelve week 30* vaccinee serum samples.
For comparison,  values  were  used  from  the  week  30  samples  (2  weeks  following the third 
immunisation)  from  each  individual  (*week  32  results  are  shown  for  JUV066).  1   MN
neutralisation  data,  shown  as  the  reciprocal  of  the  last  serum  dilution  at  which  50% 
neutralisation  occurs.  2  MN  V3  loop  peptide,  3  W61D  V3  loop  peptide,  and 4  recombinant 
W61D gpl20 binding antibody titres, determined by ELISA and shown as the last reciprocal 
dilutions showing positive substrate binding.  Adjuvants used are indicated x Alum, y SBAS-1, 
z SBAS-2.  Data were kindly provided by Sheena McCormack.
Due to the  limited volume of sera available,  a selection  of vaccine recipient 
sera  were  tested  in  each  assay;  only  in  the  enhancing  assays  presented  in  section
5.2.2.2  were all twelve sets tested.  Certain time points were unavailable for two of the 
individuals: day 30 or 32 serum was not available for JUX065, and samples after day 
30 were not available for JUB063.  In the case of JUV066 a week 32 sample was used 
instead of week 30.
5.2.1.1  Neutralisation of the TCLA strain MN
Sequential  serum  samples  from  nine  immunised  individuals  were  tested  for 
neutralisation and C’-MI activity against MN.  Results are shown in Figure 5.2.  As no 
sera attained more than 90% neutralisation, the level of 50% neutralisation is marked 
on  each  graph  as a broken red  line.  At time points immediately following the third 
immunisation (in most cases week 30), those from Group A neutralised MN by up to
17681%.  Sera from all individuals from this group neutralised MN by at least 50%.  None 
of the  sera  from  Group  B  subjects  showed  more  than  50%  neutralisation,  yet  the 
sequential samples show a similar, but weaker, pattern as the Group A subjects, with 
peaks of neutralisation activity occurring on week 30.  The neutralisation assay used in 
our laboratory is known to be more stringent than others, in that IC50 and IC90 values 
are  lower  for  a  given  serum  than  results  from  other  assays  (Aasa-Chapman  et  al., 
2004),  therefore  overall  levels  of neutralisation  are  lower  than  those  published  by 
McCormack and colleagues (McCormack et al., 2000).  However, relative levels of 
neutralising  antibodies  agree  with published  levels,  with  Group  A  subjects  showing 
highest levels of neutralisation against MN, whereas Group B subjects showed lowest 
levels of neutralisation.  For clarity, a comparison between my MN neutralisation data 
and those presented in McCormack 2000 is shown in Figure 5.3.
Figure  5.3  Comparison  of  MN 
neutralisation
Data  from  McCormack  2000,  shown  as 
50%  neutralising  titres,  were  plotted 
against data from my assays in Figure 5.2, 
shown  as  percent  neutralisation.  Results 
from  week  30  sera  from  the  nine 
individuals were used for the comparisons. 
One  outlier,  JUZ064,  ringed  in  red,  was 
excluded from the correlation.
C’MI  is  detectable  in both groups.  For Group  A,  due to  the  relatively high 
level of neutralisation seen for day 30 samples, C’-MI is not significant for any of the 
day  30  samples.  However,  several  samples  taken before  and  after  day  30  for  each 
subject show weak or no neutralising activity augmented by C’-MI.  Significant C’-MI 
is seen for JUL008 week 68; JUJ009 weeks 6 and 52; and JUF061  week 6 (p < 0.05 
using a two-tailed student’s T test assuming equal variance).
For Group B,  in which neutralisation levels are lower overall,  C’-MI is more 
frequent,  again  with  post-week  30  samples  showing  the  greatest  difference  in  the 
presence of C’.  Significant C’-MI is seen for JUZ064 weeks 2, 30, 40 and 68; JUV066 
week 40; and JUT067 weeks 6,40 and 68.
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Figure 5.2  Neutralisation and C’-MI of MN by sequential serum samples from 
nine vaccinated individuals
C’-MI  assays  were  carried  out  on  NP2/CD4/X4  cells  with  MN  and  sequential 
vaccinee  serum  samples.  % residual  infection  is calculated relative to the  Week 0 
control samples for each individual, in the presence (C’) and absence (HIC’) of active 
complement as appropriate.  Points that fall below the dashed red line indicate >50% 
inactivation.  Error bars represent SD from 3 experiments.
179In summary, vaccinee sample sets fall into two groups according to their peak 
levels  of neutralisation  against MN,  and  these  groups  agree  with  data  published  by 
McCormack  2000,  except  for  results  from  subject  JUZ064.  Peak  levels  of 
neutralisation occur in samples taken two weeks after the third immunisation, week 30. 
C’-MI is evident in many samples that show weak or no neutralisation, but only in one 
case does  it account for greater than  50% inactivation  in the absence of pre-existing 
neutralisation:  JUJ009 week 52.
5.2.1.2  Neutralisation of the vaccine virus strain W61D
According to data published previously, PBMC-grown W61D is not neutralised by 
the  vaccinee  sera  (Beddows  et al.,  1999;  McCormack  et al.,  2000).  However,  it  is 
possible that antibodies produced  in response to vaccination  have C’-MI activity for 
this virus.  Four serum sets, from Group A vaccinees JUL008 and JUB063, and Group 
B vaccinees JUZ064 and JUT067, were tested for neutralisation and C’-MI of W61D. 
Results are shown in Figure 5.4.  No neutralisation is seen for any of the subjects in 
either group.  The  presence  of C’  significantly  increases the  amount of inactivation 
seen  in  several  serum  samples:  JUL008  week  40;  JUB063  week  30;  and  JUZ064 
weeks  12,  30  and  68  {p < 0.05  using  a two-tailed  student’s  T  test  assuming  equal 
variance).  Of these, only for JUB063 week 30 does the inactivation exceed 50%.
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Figure  5.4  Neutralisation  and  C’-MI  of  W61D  on  NP2/CD4/R5  cells  by 
sequential serum samples from four vaccinated individuals
C’-MI  assays  were  carried  out  on  NP2/CD4/R5  cells  with  W61D  and  sequential 
vaccinee serum samples.  % residual  infection  is calculated relative to the  Week 0 
control samples for each individual, in the presence (C’) and absence (HIC’) of active 
complement as appropriate.  Points that fall below the dashed red line indicate >50% 
inactivation.  Error bars represent SD from 3 experiments.
1815.2.2 Characterisation of the enhancing antibody responses in vaccine recipients
Vaccinee samples were next tested for C’-ADE activity using the enhancement 
assay described in Chapter 4.  The threshold of enhancement for MN was set at 2-fold, 
as  10 different seronegative sera tested did not exceed a level of 1.14 ± 0.5  increase in 
infection.  The threshold of enhancement of W61D was  set at 3-fold,  as  10 different 
seronegative  sera tested  failed to exceed  a  level  of 1.8±0.24.  Also,  in the  following 
experiments the fold enhancement is calculated relative to the day 0 serum sample for 
each  subject,  thereby eliminating natural variations  in serum that may occur between 
individuals.
5.2.2.1  Enhancing antibodies to MN
Four  serum  sets,  from  Group  A  subjects  JUX011  and  JUF061,  and  Group  B 
JUA001  and JUT067, were tested for C’-ADE activity against MN.  Results are shown 
in  Figure  5.5.  Enhancement  of MN  was  not  detected  in  any  of the  samples tested. 
However, for week 30 samples from JUX011, JUF061  and JUT067 significant C’-RN 
is evident (p <  0.05  using a two-tailed student’s T test assuming equal variance).  As 
the JUA001  sera did not neutralise MN by greater than 50% in the absence of C’, C’- 
RN  was  not observed  for this subject.  Greater than  50%  inactivation  is not detected 
for  any  of the  samples  when  assayed  in  the  presence  of C’,  showing  that  C’-RN 
completely eliminates any neutralising activity that was present in the absence of C’.
182GROUP A
JUX011 JUF061
2
1
0
100 0 50
2
0
100 0 50
JUA001
GROUP B
JUT067
s
E
V  C J s
C Q
-=
s
< w
2 "o
2
1
0
100 0 50
2
1
0
0 50 100
Serum time point (weeks)
□  HIC’  □  C’
Figure 5.5  Lack of C’-ADE of MN on SupTl/R5 cells by sequential vaccinee 
serum samples
Enhancement assays were carried out on  SupTl/R5  cells with MN and sequential 
vaccinee serum samples.  Fold enhancement was calculated relative to infection in 
the presence of pre-vaccination (Day 0) serum for each individual, in the presence 
(C’) and absence (HIC’) of active complement. The enhancement threshold for MN 
is 2-fold.  Error bars represent SD from 3 experiments.
1835.2.2.2  Enhancing antibodies to W61D
The presence  of C’-ADE activity  in  vaccinee  sera was  next  investigated with 
the  virus  strain  from  which  the  vaccine  was derived:  W61D.  Results  are  shown  in 
Figure  5.6.  With the exception of JUV066,  all  subjects showed evidence of C’-ADE 
activity,  with  peak  enhancement  levels  ranging  from  4.32  to  11.97.  In  all  cases the 
peak enhancing activity occurs on week 30,  or the closest available  sample after this 
time  point.  Smaller peaks of enhancement are also  seen  on the weeks  following the 
week  4  inoculation.  Group  A  subjects  showed  the  highest  week  30  enhancement 
levels,  averaging  7.3-fold,  whereas  Group  B  showed  the  lowest  enhancement  level, 
with the group peak fold enhancement averaging 4.7-fold.
In  most  subjects  the  levels  of enhancement  decline  with  time  following  the 
week 30 samples,  falling below the 3-fold enhancement threshold by the final sample 
tested.  However,  in the cases of JUL008, JUJ009, JUX011, JUZ064 and JUT067, the 
most recent  serum  samples  tested  continue  to  enhance  infection,  although  the  levels 
appear to be declining.
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Figure 5.6  (overleaf)
C’-ADE of W61D on SupTl/R5 cells by sequential vaccinee serum samples
Enhancement  assays  were  carried  out  on  SupTl/R5  cells  with  the  vaccine  virus  strain 
W61D and sequential vaccinee serum samples.  Fold enhancement was calculated relative 
to infection in the presence of pre-vaccination (Day 0) serum for each  individual,  in the 
presence (C’) and absence (HIC’) of active complement.  Volunteers were vaccinated on 
weeks  0,  4  and 28.  Points that  fall  above the  dashed  turquoise  line  indicate enhanced 
infection.  Error bars represent SD from 3 experiments.
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186The  fact  that  the  antibodies  in  these  individuals  were  elicited  by  the  same 
immunogen,  W61D  gpl20,  and  that  none  of these  individuals  produced  detectable 
neutralising antibodies to W61D, provides the opportunity to compare the level of non­
neutralising  antibodies  with  the  level  of enhancement  between  individuals.  Peak 
enhancement  values  (week  30;  week  32  for JUV066)  were  compared with  titres  of 
antibodies  to  W61D  gpl20  and  the  W61D  V3  loop  peptide,  as  reported  by 
McCormack et al 2000.  Correlation data are shown in Figure 5.7.  Individuals with the 
highest antibody binding titres to  W61D gpl20  and  W61D V3  loop peptide had the 
highest enhancement levels, whereas antibody titres to the MN V3 loop peptide did not 
correlate  with  enhancement.  A tentative  linear relationship  is  shown  on the  graphs, 
with  R2  values  of  0.70  and  0.90  for  the  gpl20  and  V3  loop  peptide  correlates 
respectively,  yet may only demonstrate that there  is a relationship between antibody 
binding titres and levels of enhancement -  the mechanics of enhancement are unknown 
so  a  linear  relationship  cannot  be  assumed.  The  exclusion  of the  outliers  can  be 
justified on the grounds that the same two samples, JUJ009 and JUF061, are outliers 
on  both  the  W61D  gpl20  and  V3  loop  correlations,  suggesting  that  the  observed 
enhancement levels of these individuals were lower than expected.  One further point 
of speculation is the fact that, when extrapolated, the trend lines pass through 3.5-fold 
enhancement  when  the  antibody  titre  is  0  on  both  the  gpl20  and  V3  loop  peptide 
graphs.  This  may  be  coincidence,  but  does  in  fact  cross  the  Y-axis  close  to  the 
enhancement threshold set for this virus (3-fold).
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Figure  5.7  Correlations  between  peak 
antibody  binding  titres  and  peak  fold 
enhancement levels
Fold  enhancement  values  from  week  30  samples 
(or week 32  in the case of JUV066) were plotted 
against the reciprocal antibody binding titres from 
the  same  samples  for  each  vaccinee.  Antibody 
binding titres to A) monomeric recombinant W61D 
gpl20, B) W61D V3 loop peptide, and C) MN V3 
loop  peptide  as  a  control,  were  determined  by 
ELISA  (data  kindly  provided  by  Sheena 
McCormack).  Obvious  outliers,  ringed  in  red, 
were  eliminated  from  the  correlation.  These 
outliers were samples from JUJ009 and JUF061.
1885.2.2.3  Enhancing antibodies to a primary clinical isolate
Week 30  sera from the subjects that showed the highest (JUX011) and  lowest 
(JUV066) fold enhancement of W61D infection were tested against a primary isolate, 
MM32 dlO virus,  characterised  in Chapter 4.  This virus was enhanced up to 58-fold 
by autologous serum and complement (Chapter 4,  Section 4.2.2).  Therefore, this is a 
virus  known  to  have  high  enhancement  potential,  and  is  also  relevant  to  viruses 
currently circulating in the UK.  Results are shown in Figure 5.8.  In terms of the C’- 
ADE cut-off threshold for this virus determined in Chapter 4 (5-fold), no enhancement 
is detected.  However,  in the presence of JUX011   serum,  a clear peak of infection  is 
discernable at week 30, resembling the enhancement patterns seen with W61D virus in 
section 5.2.2.2.  In the presence of JUV066 sera no such pattern is detected.
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Figure  5.8  Lack  of C’-ADE  activity  in  serum  samples  from  two  vaccinees 
against the primary patient isolate MM32 dlO.
A clinical primary isolate, MM32 dlO, was tested in an enhancement assay with 
sequential  serum  samples  from  vaccinees  JUX011  and  JUV066.  Enhancement 
thresholds are not shown as these were pre-determined for MM32 dlO virus at 5- 
fold, which  falls  outside the  scale  used for the  graphs.  Error bars represent  SD 
from 2 experiments.
1905.2.3  Summary of antibody activity found in vaccinee samples
Data  presented  in  this  chapter,  with  the  exception  of those  shown  in  section 
5.2.2.3,  are  summarised  in  Figure  5.9  using week 30 or 32  sample  results from  each 
volunteer as these showed peak neutralisation and enhancement levels in all sequential 
serum  sets tested.  Infection  levels on each chart,  including those from C’-MI assays, 
are  shown  as  “fold enhancement”  for ease of comparison between assays.  The  50% 
inactivation thresholds, and enhancement thresholds (2-fold for MN, 3-fold for W61D) 
are  also  indicated.  The  data  shown  in  this  way  highlight the  fact that the  Group  A 
subjects have the strongest neutralizing activity against MN, and also the strongest C’- 
ADE  activity  against  W61D.  C’-RN  of MN  and  C’-MI  of W61D  also  seem  to  be 
stronger in this group.  Data from  subject JUX011   show that  it is possible to have co­
existing  antibodies with  neutralising,  C’-RN and  C’-ADE activity  in the  same serum 
sample, with each activity revealed according to the test virus strain and cell type used. 
Likewise,  data  from  subject  JUZ064  show  that  C’-MI  and  C’-ADE  can  exist  in  the 
same  serum  sample.  Importantly,  strong C’-MI activity detected against  W61D with 
JUB063  serum  on NP2/CD4/R5  cells  is  in  contrast to the  strong C’-ADE activity of 
the same serum against W6ID when assayed on SupTl/R5 cells.  Overall, the different 
patterns of antibody activity obtained for the same serum samples assayed by different 
methods are  striking,  and support a need for caution when drawing conclusions from 
vaccine samples assayed by one method alone.
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Figure 5.9 (overleaf)
Summary of the antibody activities elicited by vaccination
Results  from  week  30  samples  from  each  vaccinee  for each  assay  performed  (C’-MI 
assays  performed  on  NP2/CD4/R5  and -X4  cells;  enhancement  assays  performed  on 
SupTl/R5  cells)  with  each  virus tested  (MN  and  W61D)  are  summarised.  Data  are 
derived from results presented in Figures 5.2, 5.4, 5.5 and 5.6.  A fold enhancement scale 
is used in order to directly compare results. Dashed turquoise lines indicate the 2-fold and 
3-fold  enhancement  threshold  for  MN  and  W61D  enhancement  assays  respectively; 
dashed red lines indicate the  50%  inactivation threshold; therefore,  samples above the 
dashed turquoise line indicate enhanced infection while samples below the dashed red 
line indicate inactivation.  Error bars represent SD for 3 experiments.
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1935.3  DISCUSSION
5.3.1  Different antibody activities can be detected after immunisation
The comparisons shown in Figure 5.9 reveal important information about the 
nature  of  the  antibodies  elicited  following  vaccination,  and  the  actions  of these 
antibodies in different assay situations.  Firstly, in Group A subjects, neutralisation of 
MN is seen on NP2 cells in the presence and absence of C’.  Neutralisation is increased 
slightly, but not significantly, in the presence of C’ for week 30 samples.  In contrast, 
on the SupTl/R5 cells, comparable levels of MN neutralisation are seen in the absence 
of C’,  but  C’-RN  occurs  in  the  presence  of complement.  However,  in  Group  B 
subjects,  neutralisation of MN does not occur in the absence of C’  on the NP2 cells, 
yet significant C’-MI  is evident in the presence of C’  for JUZ064 week 30.  On the 
basis of these data alone, the elicitation of non-neutralising antibodies by vaccination 
could be considered a worthwhile vaccine strategy, as in combination with C’ in vivo, 
virus inactivation is predicted to occur in the majority of cases.  Indeed, assays carried 
out on NP2 cells with  W61D, which is not neutralised by any of the sera tested, also 
show that inactivation can occur in the presence of non-neutralising antibodies and C’. 
However,  and  most  importantly,  assays  carried  out  with  W61D  on  SupTl/R5  cells 
show that the same non-neutralising sera that inactivated virus in the presence of C’ on 
NP2  cells  can  actually enhance  infection  in the  presence  of C’  on  SupTl/R5  cells. 
This is an aspect of vaccination evaluation that few researchers address.  This shows, 
for the  first time,  that the  same  sera that appear to have  inactivating activity  in the 
presence of C’  in one situation, can have enhancing activity in another situation -  in 
this case when assayed on cells expressing CR2.  Essentially,  C’-MI  antibodies can 
have C’-ADE activity.
5.3.2  Nature of the enhancing antibodies produced by vaccination
Overall,  the  W61D  rgpl20  vaccine  elicited  a  poor  neutralising  antibody 
response to the viruses tested, yet produced a strong and persistent C’-ADE response. 
Firstly, this shows that vaccines classed as “ineffective” may prove to be dangerous if 
C’-ADE assays presented here translate to enhancing antibodies in vivo.  Secondly, it 
shows that gp41 antibodies are not the only type of antibody capable of enhancing HIV 
infection.  Thirdly,  it  shows  that  enhancement  of HIV  infection  is  not  necessarily 
caused by sub-neutralising concentrations of neutralising antibodies, as proposed in the
194“classical” dengue enhancement model, but by high concentrations of non-neutralising 
antibodies, as suggested in Chapter 4.
As a result of HIV enhancement studies published in the early 1990s showing 
that  regions on  gp41  contained the major enhancing epitopes (Mitchell  et al.,  1995; 
Robinson et al.,  1991; Robinson et al.,  1990a; Robinson et al.,  1990b) and that gpl20 
was the major target for neutralising antibodies,  subsequent envelope-based vaccines 
focused on the use of gpl20.  As the only characterised enhancement epitopes reside 
on  gp41  of HIV,  the  results presented  in this  chapter suggest that,  either enhancing 
epitopes  exist  on  gpl20,  or  specific  epitopes  are  unimportant  for  enhancement. 
However, levels of enhancement presented in this chapter are lower than those seen in 
Chapter  4,  and  the  lack  of gp41  antibodies  may  account  for this.  Interestingly,  a 
formally protective vaccine, derived from SIV recombinant vaccinia virus expressing 
SIV  gpl60  (VVrpgl60),  was  rendered  ineffective  after  boosting  with  a  peptide 
fragment corresponding to the immunodominant (i.e.  infection-enhancing) domain of 
gp41  (Mitchell et al.,  1995), implying contribution of these antibodies to an enhancing 
effect.  High  titres  of  C’-ADE  antibodies  were  detected  in  those  macaques  that 
progressed  rapidly to  disease,  whereas macaques  boosted with  an  irrelevant peptide 
were protected and produced low titres of C’-ADE antibodies (Mitchell et al.,  1995). 
Alternatively, low levels of enhancement in my results could also be explained by the 
virus  used  for  the  enhancement  assays,  W61D,  which  may  be  less  susceptible  to 
enhancement than the primary isolates tested in Chapter 4, or the overall titre of HIV- 
binding antibodies  produced,  which  is  lower than those  seen  in  infected individuals 
(Beddows et al.,  1999; McCormack et al., 2000).
C’-ADE is strongest at peak binding antibody titres, which may translate to a 
specific risk period for vaccinated individuals.  The duration of the C’-ADE response 
against W61D appears to be  longer than the neutralising response against MN -  the 
only other definite antibody activity observed in these samples.  As shown in section 
5.2.2.2, final samples from JUL008, JUJ009, JUZ064, JUX011  and JUT067 continue 
to enhance W61D infection, indicating the existence of this response past the time of 
follow-up.  Not only do enhancement levels correlate with peak antibody titres within 
individuals,  but  enhancement  levels  also  correlate  with  antibody  binding  titres 
compared  between  individuals.  Those individuals that produced the highest level of 
antibodies  capable  of binding  to  W61D  gpl20  or  V3  peptide  showed  the  highest 
enhancement.
195On  no  occasion  is  MN enhanced by the sera tested,  despite the  fact that the 
majority  of these  sera enhanced  infection of W61D.  This  supports the  suggestions 
made in Chapter 3, that C’-ADE could be a property of the virus, and that C’-RN is a 
phenomenon that occurs  in the  absence  of true  enhancement,  perhaps  reflecting the 
balance between enhancement and neutralisation.
Results of enhancement assays carried out with MM32 dlO virus indicated that 
antibodies produced by vaccination may not be capable of enhancing the infection of 
clinically relevant primary isolates.  This may be because the antibodies elicited by the 
W61D gpl20 vaccine do not have a high affinity for the gpl20 of MM32 dlO virus. 
Perhaps vaccination with a strain more closely related to MM32 dlO, or use of other 
primary isolates in the assay, would result in enhanced infection.  In assays presented 
in this chapter the fold enhancement is calculated relative to the Week 0 samples for 
each  subject,  therefore the  serum donor variation that exists when comparing serum 
from patient viruses with NHS should not exist.  It is therefore possible that the peak of 
infection seen in the presence of week 30 serum from JUX01 land C’ represents a very 
low  level  of  enhancement.  Further  investigation  ought  to  be  carried  out  on  the 
capacity  for  vaccine-induced  antibodies  to  enhance  infection  of  other  clinically 
relevant primary isolates.
5.3.3  Do enhancing antibodies put vaccinated individuals at risk?
With  regards  to  HIV,  vaccine-induced  enhancement  of disease  could  reveal 
itself in  several  forms.  The  most  obvious  is  an  increased  rate  of infection  among 
vaccine recipients.  While this is the main indicator of vaccine success or failure, there 
may also be more subtle outcomes.  The time period between infection and onset of 
AIDS  may be  reduced  in the  presence of enhancing antibodies.  This would be the 
equivalent of an exacerbated disease state of other viruses,  such as atypical measles. 
Alternatively,  the  vaccine  may  have  different  risks  according  to  an  individual’s 
genotype for certain cellular receptors, for example, Fc polymorphisms or CR density 
may vary among individuals.
Many of these “adverse” effects would only become apparent after the period 
of follow-up.  This becomes important for recent vaccine trials, which, relative to the 
long course of HIV infection, are still in their infancy.  Take, for example, the case of 
dengue  disease  enhancement  in  infants  born  to  immune  mothers:  peak  age  risk  for 
ADE-induced  DSS  or  DHF  occurs  at  approximately  6  months,  and  this  is  for
196maternally-acquired  antibodies  which  are  passively  acquired.  Vaccination  induces 
active  antibody  production  and  these  antibodies  can  still  be  detected  years  after 
vaccination.  Also,  as mentioned  in section  5.3.2, there may be specific risk periods 
following  vaccination  during  which  infection  becomes  more  likely.  Re-analysis  of 
breakthrough  infections  from  larger clinical trials of HIV envelope  subunit vaccines 
may reveal such patterns.
5.3.4 Concluding remarks
Overall,  given that this vaccination strategy failed to elicit antibodies capable 
of greater  than  90%  neutralisation  of any  of the  viruses  tested  in  the  presence  or 
absence of complement, even at the peak of antibody production, it is unlikely that this 
vaccine would be protective against circulating clinical HIV strains.  Indeed, this was 
the  conclusion  of the  researchers  involved  in the trial  (Beddows et al.,  1999).  This 
argument is further strengthened by the detection of enhancing antibodies against the 
vaccine  strain,  providing the  potential  for this  vaccine to  have  harmful,  rather than 
beneficial,  effects on  its recipients if infected with HIV.  However,  as suggested by 
SIV studies in macaques (Montefiori et al.,  1995) and animal models for other viruses 
(Raabe et al.,  1999), detection of enhancing antibodies may not correlate directly with 
vaccine  outcome,  therefore  further  study  is  warranted.  This  may  only  be  possible 
through  studies  of breakthrough  infection  following  subunit vaccination.  As results 
presented here are from a phase I clinical trial, the recipients are unlikely to become 
infected with HIV and are therefore followed-up for a limited period.  A similar trial 
that reached phase III clinical trials, the Vaxgen trial, did result in infected individuals. 
Retrospective studies of the antibody profiles in individuals that did become infected 
with  HIV,  compared with those that did not,  would provide valuable information on 
the relevance of enhancing antibodies to vaccine outcome.
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Further investigations into antibody-dependent enhancement 
mechanisms and proposals for future work
This chapter details  investigation into the mechanism of the C’-ADE and C’- 
RN seen in Chapters 3, 4 and 5.  Co-receptor usage, infectious virus to particle ratios, 
the  involvement of CR2  and the requirement of the CR2 signalling domain were all 
investigated.  Finally,  in the context of results presented in this chapter, directions for 
future work are proposed.
6.1  INTRODUCTION
This chapter further investigates aspects of C’-ADE of HIV seen in Chapters 
3, 4 and 5.  Separate experiments, involving the investigation of co-receptor usage in 
enhancement,  the  bearing  of infectious  particle-to-particle  ratios  of individual  virus 
isolates  on  capacity  for  enhanced  infection,  and  the  involvement  of  CR2  in 
experiments  presented  so  far,  are  presented.  Together they provide  insight  into the 
mechanism of C’-ADE in terms of receptor involvement and viral characteristics.
As  high  levels  of enhancement  shown  in  this thesis  were  obtained with R5- 
using primary  isolates (Chapter 4) and an R5X4-using strain W61D (Chapter 5), but 
not with two X4-using TCLA strains, MN and IIIB  (Chapters 3  and 5),  it is possible 
that  the  co-receptor  usage  of these  viruses  has  some  influence  on  the  capacity  to 
become  enhanced  and  that  enhancement  is  inefficient  through  the  X4  route  of 
infection.  Alternatively,  it  is  possible  that  certain  virus  strains  are  not  efficiently 
enhanced, regardless of co-receptor usage, by the sera tested thus far in this thesis.  To 
determine whether enhancement can occur through the X4 route of infection, the R5X4 
vaccine strain  W61D,  investigated  in Chapter 5, was assayed on SupTl  cells lacking 
the CCR5 co-receptor but naturally expressing CXCR4.  Levels of enhancement were 
compared with those seen on SupTl/R5 cells.
To gain further information about the nature of viruses enhanced by antibody 
and complement, the relative infectivity levels of nine HIV primary isolates studied in 
Chapter 4 were determined. Virus produced in vivo and virus preparations produced in 
vitro are known to consist of a high proportion of apparently noninfectious or defective
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Env trimers on the viral surface and to a certain extent due to the shedding of gpl20 
leaving behind non-functional spikes (McKeating et al.,  1991).  Infectious particle-to- 
particle ratios have been estimated to be as high as  1:100 to  1:60,000 (Layne et al., 
1992; Piatak et al.,  1993), and can vary according to viral strain and culture conditions 
(McKeating et al.,  1991).  Given the high level of enhancement seen for the primary 
isolates  investigated  in Chapter 4,  it is possible that increased infection seen through 
C’-ADE  draws  on  this  so-called  “noninfectious” pool  of virions,  allowing  infection 
that  otherwise  would  not  be  seen  in  the  absence  of  enhancing  antibody  and 
complement,  as  opposed  to  increasing  the  infectivity  or  replication  of  already 
infectious  virions.  Therefore,  ratios  of  infectious  titre  to  total  viral  content  were 
calculated and compared with peak fold enhancement levels observed for eight of the 
primary isolates studied in Chapter 4.
Limited  investigation  has  been  carried  out  on  the  mechanisms  of C’-ADE 
occurring through CR2, and the ability of CR2 to mediate these effects on various cell 
types.  Potential ways in which C’-ADE could occur through CR2 are:
1.  Increased  attachment  of the  virus  to  the  target  cell,  resulting  in  increased 
efficiency of entry.
2.  Signalling  through  the  receptor  resulting  in  endocytosis  of  the  virus  and 
subsequent infection via an alternative pathway.
3.  Signalling through the receptor to suppress intracellular antiviral activity.
4.  Signalling through the receptor to increase viral replication.
5.  Partial  lysis  of  the  virion  resulting  in  increased  efficiency  of  virus-cell 
membrane fusion.
The  mechanism  of C’-ADE  of HIV  has yet to  be  formally  shown.  Several 
papers have proposed that increased attachment to the target cell, resulting in enhanced 
viral  entry,  is the principal mechanism through mathematical modelling (Lund et al., 
1995) and quantitative PCR (Robinson, 2006).  Furthermore, the involvement of CR2 
in C’-ADE on T cell lines has been shown using blocking antibodies (Prohaszka et al., 
1997; Robinson et al.,  1990c), but never using a molecular approach.  It has not been 
shown if expression of CR2 in a cell type other than a T cell line confers the ability to 
support enhanced infection on the target cell.
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presentation  on  B  cells  has  been  proposed.  Studies  have  shown  CR2-dependent 
endocytosis  of C3dg-coated  antigens  by  antigen-non-specific  B  cells  (Hess  et  al.,
2000).  Efficiency  of B  cell  receptor  (BCR)-mediated  antigen  internalisation  and 
presentation  is  enhanced  when  cross-linked to  CR2,  but not when  cross-linked to a 
CR2  mutant  lacking  a  cytoplasmic  tail  (Barrault  and  Knight,  2004).  Furthermore, 
while the  cytoplasmic tail of CR2  is not required  for binding of C3dg or EBV,  it is 
required for internalisation of C3dg and for EBV infection (Carel et al.,  1990).  CR2 
has also been shown to signal independently of the BCR and B cell co-receptor (CD 19 
and CD81) complex through two different pathways.  In the first, ligation of CR2 leads 
to  the  activation  of the  Src  tyrosine  kinase  pp60src.  This  in  turn  phosphorylates 
tyrosine on nucleolin, which then interacts with SH2 domains of phosphatidyl inositol 
3’-kinase (PI 3-kinase).  The activated PI 3-kinase subsequently phosphorylates Akt on 
serine and threonine residues, activating Akt and inducing the serine phosphorylation 
of GSK-3,  resulting  in  the  down-regulation  of GSK-3  activity  (Barel  et  al.,  2003; 
Baribaud et al., 2001).  While the events downstream of this pathway await resolution, 
one  potential  outcome  of  the  down-regulation  of  GSK3  activity  is  inhibition  of 
apoptosis  (Franke  et  al.,  1995).  In  a  second  elucidated  pathway,  tyrosine 
phosphorylation of Cbl under control of c-Src kinase lead to, among other signalling 
events,  the  release  of  Vav  from  Cbl.  Vav  proteins  represent  a  group  of  signal 
transduction molecules that may play a role in oncogenesis and development (Bustelo,
2001).
Overall,  the  potential  for  ligand-bound  CR2  to  interact  with  and  activate 
signalling  proteins  independently  of the  B  cell  receptor  complex  means  that  CR2- 
triggered  signalling cascades could occur in any cell type,  and have the potential to 
mediate the signalling-induced C’-ADE mechanisms outlined above.  In this chapter, 
cloned full-length and cytoplasmic tail-truncated CR2 molecules are expressed in NP2 
cells to  investigate,  firstly,  whether CR2 mediates the C’-ADE  shown  in this thesis, 
and  secondly,  whether  CR2-activated  intracellular  signalling  is  required  for  this 
process.
Given time restraints, the results presented in this chapter are not intended to 
represent a full investigation into the mechanism of C’-ADE, but contribute interesting 
insights into the process.  Therefore, they could form the basis of further investigation
200into  the  mechanism  of C’-ADE  of HIV,  and as  such  proposals  for future  work are 
incorporated into the discussion.
2016.2 RESULTS
6.2.1  C’-ADE can occur via the CXCR4 route of infection.
As  shown  in  Section  3.2.1,  SupTl  cells  do  not  express  detectable  levels  of 
CCR5,  and  are  not  infected  by  R5-only  using  isolates.  Therefore  virus  infection  of 
these cells is most likely to occur via the CXCR4 co-receptor.  The vaccine virus strain 
studied  in  Chapter 5,  W61D,  is dual tropic and therefore provides the opportunity to 
investigate C’-ADE  in  both  SupTl  and  SupTl/R5  cells.  If C’-ADE via CCR5  were 
more efficient, then this would be apparent upon comparison of enhanced infection of 
SupTl  and SupTl/R5 cells.
Parallel  enhancement assays were carried out on  SupTl  and  SupTl/R5  cells 
using W61D virus and week 0 and 30 sera from JUL008 and JUX011   in the presence 
(C’)  and  absence  (HIC’)  of active  complement.  As  with  the  results  presented  in 
Chapter 5, fold enhancement was calculated relative to infection levels in the presence 
of week  0  serum  for each  subject.  Results are  shown  in Figure  6.1.  There was no 
significant difference between enhancement levels seen on SupTl  and SupTl/R5 cells 
for JUX011  (p >  0.05  using a two-tailed  student’s T test assuming equal variance), 
although  the  enhancement  seen with  JUL008  serum  was  significantly higher on the 
SupTl/R5 cells, 9-fold, compared with 5-fold on the SupTl cells (p < 0.05).
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Figure 6.1  C’-ADE of W61D on SupTl/R5 and SupTl cells
The R5X4-tropic vaccine virus strain,  W61D, was tested with known  enhancing sera 
from two vaccine recipients on SupTl/R5 and SupTl  cells.  Virus was incubated with 
week 0 or 30 sera and HIC’ or C’ for 1  hour at 37°C and transferred to either SupTl/R5 
or SupTl cells.  Levels of infection were determined by intracellular p24 staining on day 
6  following  inoculation.  Fold  enhancement  was  calculated  relative  to  the  week  0 
control cultures.  The top panel shows experiments using JUL008 week 30 serum, and 
the bottom panel JUX011  week 30 serum.  Error bars represent SD from 3 experiments.
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Cell type6.2.2 Ratios of infectious particles to particles in virus preparations susceptible to 
enhancement
I decided to measure the infectious titres compared to overall RT level of eight 
of the primary isolates studied in chapter 4, given the possibility that the derived ratio 
may vary among viruses with different observed enhancement susceptibilities.  Viral 
stocks from MM24 d26, MM24 d464, MM25  d31, MM26 d62, MM26 d834, MM27 
d28,  MM28  d6,  MM32  dlO  and  MM34  d32  were  tested.  All  nine  viruses  were 
produced  by the  same  method:  co-cultivation  of patient PBMCs with  fresh PBMCs 
from seronegative donors, detailed in Materials and Methods. Therefore it was deemed 
appropriate to measure overall RT levels and infectious titres of the viral stocks as a 
relative comparison of infectivity.  Infectious titres were determined on NP2/CD4/R5 
cells  using  a  standard  procedure  described  in  Materials  and  Methods.  Overall  RT 
activity,  representative  of the total  amount of virus present,  were determined by RT 
ELISA of the virus stocks.  The ratio of pg RT per ml to infectious units per ml (pg 
RT:infectious  units)  was plotted against the observed peak fold enhancement values 
obtained for each virus with autologous sera and complement derived from the results 
presented  in  Figures  4.4  and  4.8.  Results  are  shown  in  Figure  6.2.  A  positive 
correlation, with R2 value of 0.89, is seen between the pgRT: infectious units ratio and 
the  peak  observed  fold  enhancement,  indicating that virus  isolates with the greatest 
discrepancies between total  virus particles and  infectious particles were enhanced to 
the greatest degree.
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Figure  6.2  Inverse  correlation  between  viral 
infectivity levels and fold enhancement
Concentrations of RT in virus stocks of MM24 d26, MM24 
d464, MM25  d31, MM26 d62, MM26 d384, MM27 d28, 
MM28  d6, MM32 dlO and MM34  d32, were determined 
by RT ELISA.  Infectious viral titres were determined by 
titration  on  NP2/CD4/R5  cells.  Ratios  of  pg  RT  to 
infectious units were determined as a relative measure of 
the  proportions  of infectious  viral  particles  in  each  virus 
preparation.  These  values  were  plotted  against the  peak 
fold  enhancement  seen  with  autologous  serum  for  each 
virus.
2046.2.4 Mechanism of CR2-mediated C’-RN and C’-ADE
6.2.4.1  Construction of cell lines expressing CR2, mutant CR2 and FcyRIIa
Although a role for CR2 in the C’-ADE and C’-RN results presented so far in 
this thesis has been presumed due to the use of a CR2+ T cell line (lacking other CRs 
and  FcRs)  and  deductions  from  previous  reports  in  the  literature,  it  has  not  been 
formally proven.  Also, the exceptionally high levels of enhancement of clinical HIV 
isolates could be  SupTl/R5-cell type specific.  To address both of these issues, CR2 
was cloned from SupTl  cells and stably expressed in NP2/CD4/R5 and NP2/CD4/X4 
cells.
To further probe the mechanism of C’-ADE, a mutant form of CR2, lacking all 
but  3  amino  acids  of the  cytoplasmic  tail,  was  constructed.  The  cytoplasmic  tail 
mutant,  based  on  constructs  used  in  previous  reports  investigating  a  role  for  the 
cytoplasmic  tail  in  CR2  function  (Barrault  and  Knight,  2004;  Carel  et  al.,  1990), 
consisted of the entire extracellular and transmembrane portions of CR2, but only the 
amino acids K,  H and R of the cytoplasmic tail, and is therefore referred to as KHR. 
The  C3dg  binding  site  is  located  in  the  two  most  membrane-distal  SCRs  of CR2 
(Lowell et al.,  1989); therefore removal of the majority of the cytoplasmic tail was not 
expected to affect ligand binding.  A schematic diagram of CR2 and the mutant KHR 
are shown in Figure 6.3.  Further details of the CR2 and KHR constructs are given in 
Materials  and  Methods.  CR2  and  KHR constructs were  subcloned  into a  lentiviral 
vector  system  for  stable  expression  in  NP2/CD4/R5  and  -X4  cells.  For  further 
investigation of the C’-RN results presented in Chapter 3, NP2/CD4/X4 cells were also 
transduced to stably express FcyRIIa (kindly provided by Dr.  Francesca Gennari and 
Prof. Mary Collins).  Cell surface expression of CR2, KHR and FcyRIIa are shown in 
Figure 6.4.  NP2 cells were negative for the expression of other complement and Fc 
receptors, and CD 19.
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Figure 6.3  Schematic diagram of full-length CR2 and the KHR mutant
Full-length CR2 consists of a 34 aa cytoplasmic tail, a 28 aa transmembrane region and 
a long extracellular domain of consisting of 15 or 16 short consensus repeats (SCRs) of 
60-70  aa  each.  These  are  divided  into  four  homology  domains,  designated  I-IV  as 
shown, each consisting of four SCRs. In the short CR2 isoform homology domain III 
contains  only  3  SCRs.  The  C3dg  binding  region  is  located  in  SCRs  1   and  2  of 
homology domain I.  A cytoplasmic tail mutant was produced by inserting a stop codon 
after the first three amino acids of the cytoplasmic tail, and is consequently referred to as 
KHR.
206Figure 6.4  Expression of CR2, KHR and FcyRH on NP2 cells
FcyRIIa  was  stably  expressed  on  NP2/CD4/X4  cells  (top  row).  CR2  and  the 
cytoplasmic tail  mutant CR2,  KHR,  were  stably expressed on NP2/CD4/R5  cells (2nd 
and 3rd row respectively).  NP2/CD4/R5 and -/X4 cells were tested for CR2 and FcyRII 
expression as controls.  NP2/CD4/X4/CR2 and -/KHR cells expressed equivalent levels 
of CR2 and KHR to the NP2/CD4/R5/CR2 and -/KHR cells, data not shown.CR2 FcyRII
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2076.2.4.2  The effect of CR2, KHR and FcyRIIa on neutralisation of  IIIB
Chapter 3 showed evidence of C’-RN on T cell lines expressing high levels of 
CR2.  C’-RN was not seen on the CR2-negative T cell line H9, and lower levels of C’- 
RN was seen on MT-2 cells expressing a high level of CR2 and a low level of FcyRII. 
To  formally  attribute  these  effects to high-level  CR2  expression,  IIIB  neutralisation 
assays  were  carried  out  on  CR2+,  KHR+,  FcyRIIa+  and  control  NP2/CD4/X4  cells 
with  QC2  serum.  Results  are  shown  in Figure  6.5A  and  summarised  in Table  6.1. 
Figure  6.5B  demonstrates,  as with  Figure  3.9,  the  striking effect of complement on 
neutralisation of IIIB on CR2+ cells.
Up to 27 times more QC2 serum was required to neutralise IIIB to greater than 
50% on NP2/CD4/X4/CR2 cells  in the presence of complement, and at least 9 times 
more  to  achieve  greater  than  90%  neutralisation.  This  was  slightly  lower  on 
NP2/CD4/X4/KHR  cells,  with  9-fold  more  QC2  required  for  both  50%  and  90% 
neutralisation  in  the  presence  of complement.  The  CR2  and  KHR  cells  therefore 
demonstrate that C’-RN occurs via the CR2 receptors, and that this is possible on cells 
from unrelated lineages: T cells and glioma cells.  No difference was seen for 50% or 
90%  neutralisation  titres  in the presence and absence  of complement on the control 
NP2/CD4/X4 cells.
Interestingly, the presence of FcyRIIa slightly alters the IC50 values, but in this 
instance  less  QC2  serum  is  required  for  50%  neutralisation  in  the  presence  of 
complement.  Significant differences are seen for neutralisation of IIIB in the presence 
of HIC’ and C’ at QC2 serum dilutions of 540 and 1620 (p < 0.05).
QC2
IC50 IC90
HIC’ C’ DIFF1 HIC’ C’ DIFF1
NP2/CD4/X4 540 540 1 180 180 1
NP2/CD4/X4/CR2 1620 60 27 180 <20 >9
NP2/CD4/X4/KHR 540 60 9 180 <20 >9
NP2/CD4/X4/F  cyRIIa 540 1620 3 180 180 1
Table 6.1  IIIB 50% (IC50) and 90% (IC90) neutralisation titres for QC2 on NP2/CD4/X4 
cells expressing CR2, KHR or FcyRIIa
IC50 and IC90 values, derived from Figure 6.5, are summarised.  ‘Fold differences between 
IC50 and IC90 values in the presence and absence of active complement.
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Figure  6.5  Neutralisation  of IIIB  on  NP2/CD4/X4  cells  expressing  CR2,  KHR  or 
FcyRIIa
(A)  Neutralisation  of  IIIB  by  QC2  serum  was  assayed  on  NP2/CD4/X4  cells,  and 
NP2/CD4/X4/CR2, -/KHR and -/FcyRIIa cells in the presence (C’) and absence (HIC’) 
of active complement.  IIIB was incubated with serial dilutions of QC2 diluted in NHS, 
or NHS  as  a  control,  and  HIC’  or  C’  for  1   hr at  37°C  then  added  to  each  of the  4 
different cell lines.  Cells were incubated for 2 hrs at 37°C then washed and fresh media 
added.  After a further incubation of 48 hrs at 37°C cells were fixed and stained for p24 
expression.  Ffu  per  well  were  counted,  and  %  residual  infection  levels  determined 
relative to the NHS control.  Solid and dashed red arrows  indicate IC50 values  in the 
presence  (C’)  and  absence  (HIC’)  of  active  complement  respectively.  Error  bars 
represent SD from 3 experiments.
(B)  Results from  Figure 6.6A  from all 4 cell  lines shown as  infection  in the presence 
(right)  and  absence  (left)  of  C \  to  emphasise  the  effect  that  complement  has  on 
neutralisation on cell lines with and without CR2.NP2/CD4/X4 NP2/CD4/X4/FcyRII
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2096.2.4.3  The ability of CR2 and KHR to mediate enhancement of early patient viruses 
by autologous sera
Chapter 4 showed high-level enhancement of patient primary isolates, obtained 
soon after infection with HIV, by autologous sera and complement on SupTl/R5 cells. 
Two  primary  isolates  were  tested  with  known  autologous  enhancing  sera,  in  the 
presence  (C’) and absence (HIC’) of active complement, to investigate whether these 
results can be re-created on NP2/CD4/R5 cells expressing CR2 or KHR.  Viruses from 
two patients were used:  MM33 dl2 virus, which was enhanced on SupTl/R5 cells by 
late autologous sera (peak d719, 115-fold), and MM32 dlO virus, which was enhanced 
on  SupTl/R5  cells by early autologous sera (peak d21,  58-fold).  Autologous serum 
from d719 was used with the MM33 virus, which enhanced to a level of 115-fold, and 
d 15 autologous serum was used with MM32, which enhanced to a level of 24-fold on 
SupTl/R5 cells in the presence of C \
Results  are  shown  in  Figure 6.6.  Fold enhancement is calculated relative to 
infection in the presence of NHS and HIC’ or C’, as appropriate, on each cell type in 
exactly the same way as experiments carried out on SupTl/R5 cells in Chapter 4.  On 
the NP2/CD4/R5  control cells,  no enhancement of infection  is seen for either of the 
viruses.  In  contrast,  on  the  NP2/CD4/R5/CR2  and  -KHR  cells,  C’-ADE  of both 
viruses is detected.  For the MM33 d 12 virus, d719 serum enhanced infection 42-fold 
on  the  NP2/CD4/R5/CR2  cells  and  20-fold  on  the  NP2/CD4/KHR  cells.  For  the 
MM32 dlO virus, d l5 serum enhanced infection 9-fold on the NP2/CD4/R5/CR2 cells 
and  7-fold  on  the NP2/CD4/KHR cells.  No enhancement  is  seen  in the absence of 
complement.
Two  inputs  of each  virus  were  used,  but  only the  lower  input  was  used  to 
calculate fold enhancement as the higher input resulted in too many ffu to count in the 
enhanced wells.  Pictures from the higher input enhanced wells for MM33 are shown 
in Figure 6.7, highlighting the dramatic effect of enhancing antibodies and complement 
on  the  infectivity  of these  primary  isolates.  The  only  difference  between  the  two 
assays  in  the  photo  is  the  presence  of NHS  (top  panel)  or  d719  autologous  serum 
(bottom panel).
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Figure  6.6  C’-ADE  of  primary  patient  isolates  with  autologous  sera  on 
NP2/CD4/R5 cells expressing CR2 and KHR
Autologous  patient  sera,  shown  to  enhance  infection  of primary  patient  isolates  in 
enhancement  assays  detailed  in  Chapter  4,  were  tested  for  enhancement  on 
NP2/CD4/R5/CR2  and  -/KHR  cells,  and  control  NP2/CD4/R5  cells.  Virus  was 
incubated with autologous patient serum, or NHS as a control, and C’ or HIC’ for 1  hour 
at 37°C, then transferred to NP2/CD4/R5 (control), NP2/CD4/R5/CR2 (CR2) or -/KHR 
(KHR) cells.  After incubation for 48 hrs at 37°C cells were fixed and stained for HIV 
infection.  Fold enhancement was calculated relative to the NHS + C’ control on each 
cell type.
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Figure 6.7  C’-ADE of MM33 dl2 virus by autologous serum on 
NP2/CD4/R5/CR2 cells
Photographs of infected NP2/CD4/R5/CR2 cells.  MM33 dl2 virus was incubated with 
NHS or MM33  d719 serum , and C’  for  1   hour at 37°C then added to cells. After 2 
hours virus was removed and cells washed, then incubated for 48 hours at 37°C.  After 
fixing, cells were stained for HIV infection with anti-p24 primary antibody, followed by 
P-gal substrate, resulting in blue staining of infected cells and syncytia.  The top panel 
shows  infection  in the  presence  of C’  and  control  serum, NHS.  The  bottom  panel 
shows enhanced infection, in the presence of C’ and d719 autologous serum.
2126.3 DISCUSSION
6.3.1 Infectious units and the nature of the viral envelope
Laboratory  preparations  of  HIV  typically  have  low  infectious  particle-to- 
particle ratios (Burton, 2006; Finzi et al., 2006; Layne et al.,  1992; Piatak et al.,  1993), 
making  growth  of  and  experimentation  with  primary  isolates  troublesome. 
Furthermore, in the absence of appropriate target cells, infectious particles rapidly lose 
infectivity due  to the  disintegration of the  envelope  spike  (McKeating et al.,  1991). 
C’-ADE  has  the  potential  to  alter this  situation,  both  by retaining the  infectivity of 
infectious particles for prolonged periods and by rendering previously uninfectious or 
inefficient virions infectious, for example due to receptors with lower affinity for CD4, 
or due to lower numbers of Env spikes on the viral surface.  A result important in this 
context  is the  observation that viruses that had the greatest discrepancy between RT 
content and infectivity also showed the greatest enhancement, indicating that the least 
infectious viruses were most enhanced.  At this stage it is impossible to say whether 
the correlation is because the viruses with fewer infectious particles are enhanced more 
because  C’-ADE  is a strategy used by these viruses for  infectivity,  or if the viruses 
with  the  most  infectious  particles  are  enhanced  less  because  there  are  insufficient 
residual viral particles to allow greater enhancement.  Future work stemming from this 
observation would be to compare the nature of the envelopes.  Do the most enhanced 
viruses  have  fewer  or  more  envelope  spikes?  Are  they  more  susceptible  to  gpl20 
shedding?  Do their affinities for CD4 or co-receptor differ?
6.3.2 Co-receptor usage in C’-ADE
Equivalent levels of C’-ADE of the R5X4 tropic virus strain W61D were seen 
on SupTl  cells in both the presence and absence of CCR5.  This implies that C’-ADE 
can occur both through the CCR5  and CXCR4 routes of infection.  For the JUL008 
serum, however, the fold enhancement level on the SupTl/R5 cells was almost twice 
as  high  as  that  seen  on  the  SupTl  cells.  It  is  possible  that  the  co-receptor  usage 
accounts  for  this  difference.  To  investigate  this  further,  enhancement  experiments 
using  a  wide  range  of X4-,  R5-  and  R5X4  viruses  should  be  carried  out  on  the 
NP2/CD4/R5/CR2 and NP2/CD4/X4/CR2 cells.  It would be interesting to determine 
whether R5  viruses are generally more  susceptible to enhancement than X4 viruses, 
and whether X4 TCLA strains such as IIIB and MN are poorly adapted for high-level
213enhancement.  An  interesting  investigation  in  this  context  would  be  to  isolate  X4 
viruses  from  individuals  at  late-stage  of HIV  infection,  following  the  co-receptor 
switch,  and investigate their potential for enhancement compared to R5 viruses from 
the same individual.
6.3.3  Mechanisms of CR2-mediated C’-ADE
Here  it  is  shown  for  the  first time  that  HIV-permissive  cells  transduced  to 
express CR2 are able to support enhanced infection.  Previously, the involvement of 
CR2  in C’-ADE had only been shown through blocking antibody experiments on the 
MT-2  and  MT-4  cell  lines  (Prohaszka  et  al.,  1997;  Robinson  et  al.,  1990c).  This 
finding  eliminates  the  possibility  that  C’-ADE  is  a  unique  feature  of  SupTl  and 
SupTl/R5 cells, or T cell lines in general, as NP2 cells are a glioma cell line conferred 
with susceptibility to HIV infection through the artificial expression of CD4 and CCR5 
or CXCR4.  Results with the CR2+ NP2 cells also confirm that C’-ADE and C’-RN 
are  mediated  through  the  same  mechanism,  as  both  phenomena  were  observed  on 
CR2+ and KHR+ NP2 cells.
The results presented in this chapter strongly suggest that increased attachment 
of  the  virus  to  the  target  cell  surface  is  the  primary  mechanism  of C’-ADE,  as 
enhancement is achieved with a CR2 receptor lacking a cytoplasmic tail and therefore 
lacking signalling ability.  However, while increased attachment may account for the 
majority  of  enhancement  seen,  results  from  the  MM33  dl2  virus  suggest  that 
enhancement is approximately two-fold more efficient on the cells with CR2 compared 
with cells with KHR.  This is only seen for MM33 dl2 virus, which is enhanced 40- 
fold on the CR2+ cells compared with 20-fold on the KHR+ cells, whereas MM32 dlO 
virus  is  enhanced  9-fold  on  the  CR2+  cells  and  7-fold  on  the  KHR+  cells.  It  is 
possible that the discrepancy seen in the higher-level enhancement of MM33 dl2 virus 
is accounted for by signalling-dependent mechanisms, and this warrants further work. 
The use of molecules that block certain signalling pathways may reveal the nature of 
the difference in enhancement on the two cell lines -  specifically blocking a signalling 
pathway on the CR2+ cells may reduce the level of enhancement to that seen on the 
KHR+ cells.  Alternatively, the difference could be accounted for by the nature of the 
expression of CR2 on the cell surface.  For example, cytoplasmic tail truncation may 
affect localisation of the receptor in the membrane.
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the mechanism of C’-ADE, by increasing the efficiency of fusion between virus and 
CR2+  cells,  could  be  investigated  by  using  C5-deficient  serum  as  the  complement 
source  in  enhancement assays.  However,  the  fact that C’-MI  does  not occur in the 
presence  of complement  on  the  CR2-negative  cells  (see  Figure  6.6,  control  cells) 
suggests that this  is not the case,  as the occurrence of C’-ML would be expected to 
result in decreased infectivity of the viruses on CR2-negative cells.
The contribution of the CD4 and CCR5 receptors to enhancement should also 
be  investigated.  Can  CR2-mediated  C’-ADE  permit  infection  through  CD4- 
independent mechanisms?  Can higher levels of CR2 compensate for lower levels of 
CD4  or  CCR5  expressed  on  the  cells?  To  extend  the  results  further,  probing  the 
abilities  of  other  complement  receptors,  and  potentially  Fc  receptors,  to  support 
enhanced  infection  could  be  investigated,  and this  would  have  further  relevance  to 
enhanced infection of HIV cellular targets in vivo.
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DISCUSSION
7.1  SUMMARY OF RESULTS
In Chapter 3, MT-2 and MT-4 cells were used to investigate ADE of the TCLA 
virus  strain  IIIB,  as  previously  performed  by  others.  Low-level  C’-ADE  and ADE 
activity were seen in serum samples obtained at early time points following infection 
with HIV.  Later serum samples neutralised IIIB infection.  C’-ADE on the MT-2 cells 
was seen more frequently and to a greater magnitude than ADE on the MT-4 cells.  C’- 
ADE was therefore investigated further.  Studies of neutralisation in the presence and 
absence of complement were undertaken on T cell  lines expressing various levels of 
CR2.  Complement-mediated rescue from neutralisation (C’-RN) was observed on T 
cells expressing CR2, but not on H9 cells that were CR2-negative.  C’-ADE, however, 
was not observed with neutralising sera from chronically-infected individuals.  C’-RN 
was used as a surrogate for C’-ADE in order to optimise the enhancement assay for the 
future  investigation  of C’-ADE  of clinical  primary  isolates.  SupTl/R5  cells  were 
chosen  as  the  target  cell  for  future  enhancement  assays  due  to  their  high-level 
expression  of CR2,  CD4,  CXCR4  and  CCR5,  allowing  for the  study of C’-ADE of 
both  primary  isolates  and  TCLA  virus  strains,  and  due  to  the  fact that  C’-RN  was 
greatest on the SupTl/R5 cells.
In  Chapter  4,  the  enhancement  assay  developed  in  Chapter  3  was  used  to 
investigate  C’-ADE  of primary virus  isolates  by  autologous  sequential  sera.  Using 
viruses  isolated at early time points following infection, C’-ADE was seen to a high 
level,  up to 236-fold,  in 9 out of 10 patients investigated.  When  later virus isolates 
were investigated from 5 of these patients, including the one that failed to produce C’- 
ADE  activity against the early  isolate,  C’-ADE was also seen to a high  level,  up to 
356-fold.  Furthermore,  sera  that  neutralised  early  viruses  enhanced  later  viruses. 
When neutralising and enhancing sera were tested in competition studies against early 
virus,  neutralisation  was  the  dominant  activity.  C’-ADE  was  detected  against 
heterologous primary isolates, but neutralisation was not.
In  Chapter  5,  the  enhancement assay was  used to  investigate  serum  samples 
obtained  from  individuals participating in a monomeric HIV gpl20 vaccine trial.  A 
C’-MI  assay was used  in  parallel to  investigate C’-MI activity  in the same vaccinee
216serum  samples on CR2-negative NP2 cells.  Some neutralisation was detected in the 
vaccinee samples, but only against the TCLA strain MN.  No neutralising activity was 
detected against the vaccine virus strain, W61D.  C’-ADE activity against W61D was 
detected in all vaccinees, and in some could still be detected in the last sample taken, 
indicating that this reponse may endure past the period of follow-up.  Individuals that 
showed  the  strongest neutralising response to MN  showed the highest levels of C’- 
ADE of W61D.  C’-MI was also detected against W61D, and this was often seen in 
serum samples that enhanced W61D infection of SupTl/R5 cells.  It was demonstrated 
that, depending on the virus strain and assay system used, C’-MI, C’-ADE, C’-RN and 
neutralisation could be detected in the same serum samples.
In Chapter 6, the mechanism of the C’-ADE and C’-RN reported in Chapters 3, 
4 and 5 was investigated.  It was shown that the viruses enhanced to the greater degree 
by autologous sera in Chapter 4 had the greatest discrepancies between infectious titres 
and  overall  level  of virus particles present in the virus  stocks.  C’-RN and C’-ADE 
were shown to be mediated by CR2, as demonstrated by the stable expression of CR2 
in NP2 cells.  A cytoplasmic tail mutant of CR2, KHR, was also able to mediate C’- 
ADE, indicating that the principle mechanism of C’-ADE was increased attachment of 
opsonised viruses to the target cell.
7.2  CONCLUDING REMARKS
The  interplay  between  HIV,  antibodies,  complement  and  target  cells  is 
complex,  and the outcome of such  interactions varies according to the assay system 
used:  neutralisation  and  lysis,  as well  as opsonisation  leading to viral  inhibition or 
clearance  mechanisms,  /ra^s-infection  and  enhancement  of infection  have  all  been 
reported.  The  overall  balance  of the  antibody  effector  mechanisms  involved  will 
determine  which  outcomes  dominate  in vivo,  and whether the  virus  or the  immune 
system  wins  the  final  battle.  The  results  presented  in  this  thesis  point  towards  a 
favourable effect of antibodies and complement on HIV  infection; at least when the 
target cells express CR2.  CR2 expression has been detected on CD4+ T cells in vivo 
(Fischer et al.,  1991; Fischer et al.,  1999; June et al.,  1992; Masilamani et al., 2002), 
with some studies placing the proportion of normal peripheral blood T cells expressing 
CR2 as high as 40% (Fischer et al.,  1991).  Further investigation and characterisation 
of CR2+ T cells may reveal a role for them in HIV infection.
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CR2, yet it is possible that other forms of ADE may be relevant to HIV infection.  This 
is  touched  upon  briefly  in  Chapter  3,  where  enhancement  of IIIB  by  certain  serum 
samples seen on the CR2+ T cell line MT-2, was not seen by the same serum samples 
on the  FcyRII+ T cell  line MT-4.  There  is a possibility that even where C’-ADE is 
undetectable,  other forms of ADE are active.  C’-ADE has been shown to occur via 
CR1  and CR3 (Delibrias et al., 1993; Delibrias et al., 1994; Gras et al., 1993; Reisinger 
et  al.,  1990),  and  in  one  study  CR3-mediated  C’-ADE  occurred  in  primary  DCs 
(Bajtay et al.,  2004).  The  use  of CR1  as  a binding receptor for HIV  dissemination 
throughout the body has also been proposed (Stoiber et al., 2005).  CR2 has also been 
shown to mediate /ram-infection (Doepper et al., 2000; Dopper et al., 2003; Jakubik et 
al.,  1999),  and other CRs and FcRs may play a similar role.  As shown in Table 7.1, 
FcRs and CRs are commonplace on cells infected by HIV. Furthermore, in the absence 
of CR+ or FcR+ target cells, other cells in the vicinity of infection are almost certain to 
express at  least one type of CR or FcR.  Overall, this provides the potential for C’- 
ME,  C’-ADE,  FcR-ADE,  rram-infection,  or a combination  of all  of these,  to  occur 
throughout the course of HIV infection.
CELL TYPE
COMPLEMENT
RECEPTOR
Fc RECEPTORS
CD4+ T lymphocytes CR1, CR2 FcaR, FcpRI
Monocytes/macrophages CR1, CR3, CR4
FcyRI, FcyRII, FcyRIII, 
FcaR
Dendritic cells CR1, CR3 FcyRI, FcyRII
Table  7.1  The  potential  for HIV target cells  to  express  complement  and  Fc  receptors.
Note  that  not  all  subsets  of the  listed  cell  types  express  all  receptors  listed.  Adapted  from 
Speth  1997 and Sullivan 2001 (Speth et al., 1997; Sullivan, 2001).
The influence of C’ on neutralisation or inactivation of HIV is often ignored in 
favour  of  simplified,  high-throughput  assays  designed  to  screen  a  wide  range  of 
antibodies against a wide range of viral variants.  The target cells used for these studies 
are uniform and are engineered to express only the receptors essential for HIV entry -
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absence  of complement  in  vitro,  yet,  in  vivo,  the  majority  of virus  is  likely  to  be 
opsonised  with  antibodies  and  complement.  Therefore,  while  these  systems  are 
invaluable for studies of HIV neutralisation, they are not always fully representative of 
the  situation  in vivo.  Results presented  in Chapter 5  highlight the fact that a single 
serum  sample  can  cause  C’-ADE,  C’-MI,  and C’-RN  depending on the virus  strain 
tested and the target cell used.
Aside from  investigations of receptor expression patterns of HIV target cells, 
one  might  look  to  the  virus  for  clues  about  its  interactions  with  antibodies  and 
complement.  Features of gpl20 ensure protection of conserved receptor-binding sites 
from  neutralisation  while  maintaining  high  levels  of sequence  variability  to  enable 
rapid escape  from neutralising antibodies.  The disassembly of functional spikes and 
the presence of non-functional spikes on the viral surface ensure the production of a 
barrage of non-neutralising antibodies by the host immune system.  Regions of gp41, 
for  example,  that  are  only  exposed  on  non-functional,  disassembled  or  post-fusion 
spikes are immunodominant.  In addition, intact Env spikes on the viral surface are few 
in number and arranged in clusters (Zhu et al., 2006), and the efficiency of interaction 
with  CD4  for  primary  isolates  is  low  (Ugolini  et  al.,  1999).  Mechanisms  such  as 
increased  binding  to  the  target  cell  via  C-type  lectin  receptors  (Geijtenbeek  et  al., 
2000;  Lee  et al.,  2001),  heparin  sulphate proteoglycans (Mondor et al.,  1998), GalC 
(Kensinger et al., 2004) and host proteins incorporated into the viral membrane, such 
as ICAM-1  (Fortin et al.,  1997) may all contribute to increasing the efficiency of HIV 
interaction  with  the  target  cell.  It  is  unknown  how  efficient  these  attachment 
mechanisms are in the presence of antibody and complement.  Strategies such as cell- 
to-cell transfer at the viral synapse (Piguet and Sattentau, 2004) and trans infection by 
B cells, DCs, FDCs and RBCs (Banki et al., 2005a; Stoiber et al., 2005) also serve to 
protect the virus  from neutralisation while promoting infection.  C’-ADE may be as 
efficient  as,  if not more  efficient than,  these mechanisms  at promoting  infection  of 
CD4+ target cells.  ADE would work particularly well as it combines a decoy strategy 
- directing the immune response towards non-functional spikes or enhancing domains - 
with an attachment strategy.  Indeed, in Chapter 4, autologous viruses that had evolved 
to evade a neutralising response maintained the capacity for enhanced infection, to a 
level  equal to or greater than earlier viruses.  This suggests that,  not only do viruses
219evolve  to  escape  a  neutralising  response,  they  may  also  evolve  to  maintain  an 
enhancing response.
The role of ADE  in HIV transmission and establishment of infection has not 
been thoroughly investigated.  A shift in focus from blood to mucosae due to recent 
reports  of high-level  destructive  infection  of the  MALT provides the opportunity to 
study  a  new  set  of  cellular  targets,  albeit  difficult  to  access,  for  CR  and  FcR 
expression.  IgA  may  be  more  efficient  at  mediating  ADE  than  IgG  or  IgM,  as 
proposed by Kozlowski and colleagues (Kozlowski et al.,  1995). Therefore studies of 
FcaR and CRs on T cells of the MALT may prove particularly interesting.
To take the data presented  in this thesis to their final conclusions, one might 
propose that antibodies and complement in HIV infection are harmful.  Yet, numerous 
situations suggest otherwise, not least the fact that the virus rapidly evolves to evade 
neutralisation  (Frost  et  al.,  2005;  Richman  et al.,  2003;  Wei  et  al.,  2003),  and that 
cobra-venom  treated  (Schmitz et al.,  1999) and B-cell depleted (Miller et al.,  2007) 
monkeys with  SIV have higher viral  loads and progress rapidly to disease and death, 
compared  to  monkeys  with  intact  complement  and  antibody  responses.  Therefore, 
involvement of C’-ADE may serve only to select for certain viral variants,  i.e. those 
that are resistant to neutralisation and enhanced to the greatest degree, or C’-ADE may 
only function to establish virus reservoirs on FDCs, for example.  Alternatively, ADE 
described in this thesis may correlate with other phenomena occurring in vivo, such as 
increased viral clearance.
While the role of C’-ADE in natural infection is likely to be complicated and 
determined by many different factors, the role of C’-ADE following vaccination may 
be more straightforward for the major reason that most subunit vaccines fail to produce 
neutralising  antibodies.  Thorough  analyses  of  breakthrough  infections  following 
vaccine  trials  ought to  be  undertaken  from  the  perspective  of potentially  enhanced 
infection.  If it emerges that there is a timeframe in which vaccinated individuals are 
more likely to become infected than placebo controls, or if individuals with detectable 
enhancing  antibodies  at the  time  of infection  have  higher viral  load  set  points than 
those without enhancing antibodies, then there might be cause to be concerned about 
enhancing antibodies.
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